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Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world 
with poor prognosis associated with tumor invasion and metastasis. Our previous 
microarray analysis had revealed two metastasis related genes – Cyr61 and Lasp1, 
which have aberrant expression of being down-regulated and up-regulated, 
respectively in HCC by comparing matched HCC tumor and non-tumor liver samples 
(Neo et al. 2004). Here we report the functional characterization of Cyr61 and Lasp1, 
and the results indicate that these genes may play important roles in the growth and 
metastasis of human HCC.  
The effect on cell growth was investigated using Gateway constructs of these 
two genes for over-expression and specific siRNA for gene knockdown. After 
transfection with either expression construct or siRNA, the WST-1 cell proliferation 
assay and soft agar assay were performed to examine the anchorage dependent and 
independent growth, respectively. As a potential tumor suppressor in HCC, over-
expression of Cyr61 inhibited HCC cell growth both in monolayer and in soft agar, 
whereas knockdown of endogenous Cyr61 by siRNA promoted cell proliferation rate. 
In contrast, knockdown of Lasp1 by siRNA significantly inhibited HCC cell growth, 
while further over-expression of Lasp1 enhanced cell proliferation, supporting the 
potential role of Lasp1 as an oncogene in HCC. These results suggest that aberrant 
expression of Cyr61 and Lasp1 might contribute to the growth advantage of HCC 
tumors.  
Next, the cell adhesion ability to ECM proteins plus the cell migratory and 
invasive activities were explored. Over-expression of Cyr61 exerted an inhibitory 





integrin signaling pathways, as suggested by the enhanced cell adhesion to ECM 
proteins. Interestingly, both siRNA knockdown and over-expression of Lasp1 in HCC 
cells suppressed cell migration and invasion ability, suggesting that Lasp1 functions 
within a certain optimal concentration. Confocal microscopy studies indicated that 
Lasp1 may inhibit HCC invasion and metastasis through recruiting and/or 
sequestering focal adhesion associated proteins, such as zyxin, VASP, and paxillin, 
and thus influencing F-actin dynamics. 
A surprising finding was that both Cyr61 and Lasp1 were found to be linked to 
the central master regulator p53. Cell cycle analysis showed that over-expression of 
Cyr61 induced G2/M arrest with concomitant up-regulation of p53 protein in HepG2 
cells carrying wild-type p53, suggesting that Cyr61 may act as an upstream molecule 
of p53 and suppress HCC cell growth through both p53 dependent and alternative 
pathways. Lasp1, on the other hand, was identified as a p53 downstream target. We 
have provided a series of biochemical and biological evidences showing that Lasp1 is 
a bona fide p53 target gene, which is transcriptionally suppressed by p53. 
In conclusion, this study provides insights into the roles of two interesting 
genes which are involved in tumor metastasis and growth. The data also strengthens 
the understanding of the effect of p53 on cellular processes in the molecular 
pathogenesis of HCC and may present additional targets as diagnostic markers and 
therapeutics to control the progression and metastasis of human HCC.  
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1.1. Hepatocellular carcinoma (HCC) 
1.1.1. Epidemiology of HCC 
Liver cancer comprises histologically distinct primary hepatic neoplasms, 
including hepatocellular carcinoma, intrahepatic bile duct carcinoma 
(cholangiocarcinoma), hepatoblastoma, bile duct cystadenocarcinoma, 
hemangiosarcoma and epitheliod hemangioendothelioma (Anthony 2002). American 
Cancer Society estimated that over 667,000 new cases of liver cancer occurred 
worldwide in 2005. Among these, HCC, which represents 83% of all cases, is the most 
frequent type of liver cancer (Farazi and DePinho 2006).  
HCC is the fifth most common neoplasm in the world, with more than 500,000 
new cases emerging annually, and an age-adjusted incidence of 5.5-14.0 per 100,000 
populations (Parkin et al. 2001; Llovet et al. 2003). The incidence of HCC is 
geographically variable, with the highest frequency observed in Southeast Asia and sub-
Saharan Africa (Thomas and Zhu 2005). HCC is also predominantly male associated, 
with an overall M:F ratio of about 3:1. The male predominance is more obvious in 
relatively young age ranges in high risk regions but in older age ranges in low incidence 
countries (Kew 2002).   
HCC is rapidly fatal, with an average life expectancy of 6 months from time of 
diagnosis, and a less than 3% survival rate for untreated cancer over 5 years. Death is 
often due to severe liver failure associated with cirrhosis and/or rapid outgrowth of 
multilobular HCC (Feitelson et al. 2002). Although early HCC is cured by surgical 
resection, most HCC patients are diagnosed at advanced stages that preclude the 
optimum surgical treatment, and for those 20-30% resectable tumors, 5-year recurrence 
rates approach as high as 75% to 100%, mainly due to invasion and metastasis (Tung-
Ping Poon et al. 2000; Llovet et al. 2003). 
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1.1.2. Etiology of HCC 
The various causes of HCC are perhaps better understood than those of any 
other cancers in human. The major etiological factors of HCC, including the chronic 
infections with hepatitis B virus (HBV) or hepatitis C virus (HCV) and prolonged 
dietary exposure to aflatoxin B1, are responsible for about 80% of human HCCs (Bosch 
et al. 1999; Thorgeirsson and Grisham 2002).  
HCC is frequently the long-term result of chronic viral infections. In developing 
countries, it affects young patients with chronic hepatitis B virus infection. 
Approximately 2 billion individuals worldwide have HBV infection, and in endemic 
areas, the carrier rate is up to 10-20% of the population. The chronic HBV carriers have 
a 100-fold relative risk of developing HCC compared with non-carriers. HBV causes an 
estimated 320,000 deaths annually, in which approximately 30-50% is attributable to 
HCC (Llovet et al. 2003; Farazi and DePinho 2006). Numerous evidences support the 
direct involvement of HBV in the transformation process through HBV genome 
integration (Wang et al. 1990; Tokino et al. 1991; Gozuacik et al. 2001; Murakami et al. 
2005), HBxAg transactivation activity (Nijhara et al. 2001; Tarn et al. 2001) or direct 
binding of HBxAg to inactivate the tumor suppressor p53 (Ueda et al. 1995). Despite 
the high incidence of HBV infection, the development of an effective vaccine for HBV, 
combined with its universal administration in endemic regions, will significantly reduce 
the incidence of HCC within the next generation (Feitelson et al. 2002) . 
While HCC is highly prevalent in developing regions where HBV infections are 
prevalent, the incidence has been continuously rising in economically developed 
countries, including Japan, Western Europe, and the United States for the last two 
decades, mostly due to an increasing rate of HCV infection (El-Serag and Mason 1999; 
Thomas and Zhu 2005). In these countries, HCC appears in relatively older patients 
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with cirrhosis related to hepatitis C virus infection. About 20% of chronic HCV cases 
develop liver cirrhosis, and 2.5% develop HCC (Bowen and Walker 2005). According 
to a report by WHO (1997), around 170 million people in the world are infected with 
hepatitis C virus, but unfortunately, specific vaccination is not yet available (Forns et al. 
2002; Farazi and DePinho 2006) . 
Besides virus infections, prolonged exposure to the fungal toxin, aflatoxin B1, 
also poses an elevated risk for the development of HCC. Aflatoxin B1 is produced as a 
secondary metabolite by the fungus Aspergillus flavus, which is found on many food 
products such as nuts, spices and oilseeds. This toxin seems to function as a mutagen, 
and is associated with a specific p53 mutation at codon Ser249 (Bressac et al. 1991; 
Hussain and Harris 1998), and with cooperating mutational activation of oncogenes 
such as HRAS (Riley et al. 1997). In addition, it is noteworthy that aflatoxin B1 intake, 
often co-exists with HBV infection, will cause a 5~10 fold increased risk of developing 
HCC in such individuals compared with exposure to only one of these factors (Kew 
2003) . 
Alcohol abuse is another important HCC risk factor. Alcohol can damage the 
liver through oxidative-stress mechanisms, which might contribute to 
hepatocarcinogenesis in several aspects, such as promoting the development of fibrosis 
and cirrhosis (Campbell et al. 2005), affecting HCC-relevant signaling pathways (Osna 
et al. 2005) and causing the accumulation of oncogenic mutations (Marrogi et al. 2001).  
Furthermore, other etiological factors associated with HCC include long-term 
oral contraceptive use in women, certain metabolic disorders, diabetes, non-alcoholic 
fatty liver disorders and non-alcoholic steatohepatitis. All these factors are believed to 
lead to the development of fibrosis or cirrhosis, which therefore might further contribute 
to HCC development (Farazi and DePinho 2006). 
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1.1.3. Molecular pathogenesis of HCC 
HCC commonly develops in an order of liver cell injury, which leads to 
inflammation, hepatocyte regeneration, liver matrix remodeling, fibrosis, cirrhosis, and 
ultimately HCC (Thomas and Zhu 2005). In the slow process of hepatocarcinogenesis, 
genomic changes progressively alter the hepatocellular phenotype to produce cellular 
intermediates that evolve into HCC (Thorgeirsson and Grisham 2002). Nearly every 
carcinogenic pathway is altered to some degree in HCC. In hepatic inflammation and 
chronic hepatitis, alterations in hepatocyte growth factor expression, somatic mutations, 
protease and matrix metalloproteinase over-expression and oncogene expression are 
frequently seen, and as the liver injury progresses through fibrosis, cirrhosis, dysplastic 
foci to HCC, these changes become more extensive (Thomas and Zhu 2005).  
As reviewed by Thorgeirsson and Grisham (2002), during the long pre-
neoplastic stage, at which the liver is often the sites of chronic hepatitis virus infection 
and/or cirrhosis, hepatocyte proliferation is enhanced by up-regulated mitogenic 
pathways. Increased expression of transforming growth factor-α (TGF-α) and insulin-
like growth factor-2 (IGF-2), mostly through epigenetic mechanisms, is believed to 
account for accelerated hepatocyte cycling. Aberrant methylation also modifies CpG 
groups of genes and chromosomal segments, with DNA methyltransferases being 
greatly up-regulated in HCC (Lin et al. 2001; Saito et al. 2001). With altered gene 
expressions and signal pathways, hepatocytes proliferate repeatedly, which initiates the 
development of monoclonal populations of aberrant and dysplastic hepatocytes.  
A number of molecular changes that likely represent early changes in the 
development of HCC tumor occur in high frequency within cirrhotic tissue and small 
tumor nodules. During chronic HBV infection, HBxAg has been shown to bind to and 
functionally inactivate the tumor suppressor p53 and the negative growth regulator p55 
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by cytoplasmic sequestration (Wang et al. 1994; Ueda et al. 1995; Huo et al. 2001; 
Feitelson et al. 2002). HBxAg relieves the p53 suppression of the alpha-fetoprotein 
(AFP) gene, which may provide a reasonable explanation for the up-regulation of AFP 
in up to 80% of HCCs (Ogden et al. 2000). HBxAg has also been shown to 
transcriptionally suppress the expression of the translation initiation factor, sui1, as well 
as the cyclin dependent kinase inhibitor, p21, both of which function to inhibit 
hepatocellular growth (Feitelson 1999). In addition, the activation of expression of 
insulin-like growth factor 2 (IGF2) (d'Arville et al. 1991) and insulin-like growth factor 
receptor 1 (IGFR1) by HBxAg supports the growth of cells independent of other serum 
growth factors (Kim et al. 1996). HBxAg stimulated cell growth also appears to be 
associated with constitutive activation of the Ras–Raf–MAPK and NFκB signal 
transduction pathways (Lucito and Schneider 1992; Benn and Schneider 1994).  
Another important early event in hepatocarcinogenesis involves the mutation of 
β-catenin.  β-catenin is a component of the Wnt signal pathway, which targets a number 
of genes such as c-myc, cyclin D1, fibronectin, the connective tissue growth factor 
WISP, and matrix metalloproteinases (MMPs). The findings of mutated β-catenin in 
early stages of HCC and the stimulated expression of extracellular matrix (ECM) 
protein genes by constitutively active β-catenin in the nuclei suggests that β-catenin 
mutations may result in alterations in normal cell-cell interactions and play a significant 
role in the development of fibrosis and cirrhosis (Calvisi et al. 2001). 
Genome-wide structural alterations, such as amplifications, mutations, deletions 
and transpositions, which develop slowly in a few genes and chromosomal loci during 
the pre-neoplastic stage, increase markedly in dyplastic hepatocytes and HCCs 
(Thorgeirsson and Grisham 2002). Loss of heterozygocity (LOH) at chromosome 1p, 
4q, 6q and 8q (Konishi et al. 1993; De Souza et al. 1995; Kuroki et al. 1995; Kishimoto 
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et al. 1996; Niketeghad et al. 2001; Yeh et al. 2001) occur sporadically in pre-
neoplastic liver or in small differentiated tumors (Huang et al. 1999). Majority of these 
losses have been mapped to tumor suppressor genes that normally limit hepatocellular 
growth and survival, and genes involved in other functions like DNA repair, carcinogen 
metabolism or protection against oxidative damage (Feitelson et al. 2002).   
The increasing number of chromosomal aberrations underlines the genetic 
instability in HCC with tumor progression (Kimura et al. 1996). The frequency of 
aneuploidy becomes more prominent as the lesions show an increasing resemblance to 
tumors (Attallah et al. 1999). LOH at 1p, 4q, 5q, 6q, 8p, 9p, 13q, 16p, 16q, and 17p 
were reported to occur at late stage or in large undifferentiated tumors, and in turn 
inactivate some well-known tumor suppressors including RB1 (13q14.3), LEU1 
(13q14), BRCA2 (13q12.3), RB2/p130 (16q12.2), p53 (17p13) and one or more JAK 
binding proteins (16p13) that negatively regulate the JAK/STAT pathway (Konishi et al. 
1993; De Souza et al. 1995; Kuroki et al. 1995; Kishimoto et al. 1996; Boige et al. 
1997; Marchio et al. 1997; Knuutila et al. 1999; Kusano et al. 1999; Wong et al. 1999; 
Laurent-Puig et al. 2001; Niketeghad et al. 2001; Wang et al. 2001; Yeh et al. 2001). 
Allelic gains or amplifications have also been reported on 1q, 6p, 8q and 17q (Wang et 
al. 2001), which presumably encode one or more oncogenes, for example, erbB2/NEU 
at 17q12-q21 (Knuutila et al. 1999). 
In some instances, epigenetic changes precede structural alterations in the same 
genes. For example, over-expression of the gene c-myc in HCCs is initially correlated 
with promoter hypo-methylation and later with gene amplification at 8q24.12-13 
(Kusano et al. 1999; Wong et al. 1999; Niketeghad et al. 2001). Reduced expression of 
p16INK4 is associated predominantly with promoter hyper-methylation, but loss of 
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heterozygosity at 9p21 (Wang et al. 2001), bi-allelic loss and mutation also contribute 
to the loss of expression of this gene in HCC (Biden et al. 1997; Huang et al. 2000).  
In summary, all genetic and epigenetic changes during the progression of HCC 
suggest that the molecular pathogenesis of HCC is accompanied by a sequential loss of 
differentiation, loss of normal cell adhesion, loss of the extracellular matrix, and 
constitutive activation of selected signal pathways that lead to accelerated cell growth 
and prolonged cell survival (Feitelson et al. 2002).  
 
1.1.4. Metastasis of HCC 
Biology of tumor metastasis 
Tumor metastasis is an extremely complex process, which occurs through a 
series of stepwise processes including the invasion of adjacent tissues, intravasation, 
transport through the circulatory system, arrest at a secondary site, extravasation and 
growth in a secondary organ (Mehlen and Puisieux 2006). In order for tumors to initiate 
metastasis and grow, neoplastic and endothelial cells must invade and migrate into 
surrounding tissues. The phenotypic change is mediated by alterations in the expression 
of cell-surface molecule integrins, release of proteases to remodel the extracellular 
matrix (ECM) and the deposition of new ECM proteins. These processes then activate a 
cascade of signaling pathways that regulate gene expression, cytoskeletal organization, 
cell adhesion and survival. Consequently, cancer cells acquire the abilities to be more 
invasive, migratory and able to survive in different microenvironments (Hood and 
Cherish 2002).  
During migration, cells project lamellipodia which attach to the ECM, and 
simultaneously break existing ECM contacts at their trailing edge. This allows the cell 
to pull itself forward (Sheetz et al. 1999). Extension of the lamellipodia is induced by 
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actin polymerization and facilitated by a localized decrease in membrane tension 
(Raucher and Sheetz 2000). Retraction of the cell edge is dependent on the adhesive 
extent of the environment. Usually, in highly adhesive environments, slow migration 
happens by fracturing the cell–ECM linkage, while in less adhesive environment, the 
retraction is achieved by simple dissociation of integrins and fast migration often occurs 
(Palecek et al. 1998; Palecek et al. 1999). Whereas, during invasion, cells release 
proteases that degrade and remodel the ECM, promoting cell passage through to the 
stroma and entrance into new tissues. This proteolytic process must be precisely 
controlled so that the ECM is sufficiently degraded to facilitate cell passage, but not so 
extensively degraded to make sure that the cellular traction is not lost (Hood and 
Cheresh 2002).  
 
ECM components 
The cellular migration and invasion are governed by several factors at both the 
extracellular and intracellular levels, and depend on the cell’s carefully balanced 
dynamic interaction with the ECM, which have to be tightly controlled (Hood and 
Cheresh 2002). As an essential component involved in cell migration and invasion, the 
extracellular matrix supports adhesion of cells and transmits signals through cell-
surface adhesion receptors. The ECM contains collagens, non-collageneous 
glycoproteins and proteoglycans. Alternative ECM constituents, such as tenascin, 
fibronectin and variant isoforms of laminin, are found in tumors and might stimulate 
cancer progression (Bissell and Radisky 2001). Vitronectin, on the other hand, is a 
multifunctional non-collageneous glycoprotein present in the ECM and in blood 
(Schvartz et al. 1999). The basement membrane (BM), a specialized ECM that 
separates the epithelial cells from the underlying stroma, provides the initial barrier 
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against invasion of carcinomas. It has a complex molecular architecture that mainly 
consists of laminins, type IV collagen, osteonectin, entactin and heparin sulphate 
proteoglycans. Fibrillar collagens (type I, II, III, V and XI) form fibrils and influence 
cellular functions through interactions with integrins, while the most prevalent 
basement membrane (BM) proteins – type IV collagens – are network-forming 
collagens of the BM. This covalent binding of collagens provides the mechanical 
stability of the basement membrane (Egeblad and Werb 2002; Hood and Cheresh 2002).  
Alterations in cell adhesion to these ECM/BM components are associated with 
various tumors. As an initial step towards metastasis, many epithelial tumors alter 
expression or localization of laminin-binding integrins, such as α6β4, which seems to 
promote both invasion through the BM and increased motility in the stroma, where 
tumor cells frequently remodel the matrix by depositing laminin. In addition, the 
expression of fibronectin-binding integrin α5β1 often disappears in tumor and its re-
expression in cell lines markedly reduces tumorigenesis (Varner et al. 1995). Previous 
studies also reported that many proteases that are up-regulated in metastatic tumors 
show high enzymatic activity against type IV collagen, and inhibition of these enzymes 
inhibits tumor invasion. Besides collagens, the non-collageneous glycoprotein 
vitronectin may play an important role in wound healing and in tumor progression as 
well, in view of the involvement of its receptor – integrin αvβ3 in angiogenesis (Varner 
and Cheresh 1996; Mousa 2002).  
 
Focal adhesion components 
The sites where the extracellular matrix (ECM), integrins and the cytoskeleton 
interact are called focal contacts or focal adhesion sites (Burridge and Fath 1989). 
These focal contacts are specialized regions where actin filaments are anchored, and 
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where integrins cluster and interact with ECM proteins and dynamic groups of 
structural and regulatory proteins that relay information bi-directionally across the 
plasma membrane to regulate cell proliferation, survival, adhesion and motility. To date, 
more than 50 different adhesion proteins have been identified as focal adhesion 
components that physically link the integrin receptor to actin, building the connection to 
the cytoskeleton (Partridge and Marcantonio 2006). For instance, the integrin-binding 
proteins paxillin and talin recruit focal adhesion kinase (FAK) and vinculin to focal 
contacts (Sastry and Burridge 2000; Calderwood and Ginsberg 2003). The α-actinin, a 
cytoskeletal protein that is phosphorylated by FAK, binds to vinculin and crosslinks 
actin stress fibers and tethers them to focal adhesion sites. Zyxin is an α-actinin- and 
stress-fibre-binding protein that is usually present in mature contacts, which are 
necessary for cell adhesion and spreading (Beckerle 1997; Mitra et al. 2005).  
In response to integrin engagement, tyrosine kinases FAK and Src are   
activated and recruited to the developing focal adhesions. Subsequent tyrosine 
phosphorylation of focal adhesion components promotes further recruitment of 
signaling and structural molecules and development of fully mature focal adhesions. 
These processes are mediated by multiple signaling pathways triggered by the tyrosine 
kinase activity at the focal contacts. For example, FAK signaling activates Rho-family 
of GTPases (RhoA/Rac/Cdc42) directing local actin assembly into stress fibers, 
lamellipodia or filopodia and thus control cytoskeletal dynamics and cell migration 
(Mitra et al. 2005). Upon activation, the Rho GTPases also activate a wide range of 
effector proteins that regulate cell adhesion as well as gene transcription (Bishop and 
Hall 2000). When bound to Grb2-Sos complex, tyrosine-phosphorylated FAK also 
activates Ras-Raf-MEK-MAPK and PI3K-Akt pathway involved in gene expression 
and cell proliferation (Mitra and Schlaepfer 2006). As dynamic regulation of focal 
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adhesions and reorganization of the actin cytoskeleton are crucial determinants for cell 
migration, dysregulation of these focal adhesion components and signaling is highly 
associated with tumor invasion and metastases (Carragher and Frame 2004). 
 
Clinical importance of HCC metastasis 
Tumor metastases are the primary cause of death in cancer patients, which are 
responsible for almost 90% of human cancer deaths (Nguyen and Massague 2007). 
Metastasis remains as one of the major challenges before HCC can be finally conquered. 
Though early HCC can be cured by surgical resection, the 5-year survival rate remains 
rather low as most patients encounter the recurrence of cancer, mostly due to metastasis 
(Llovet et al. 2003; Thomas and Zhu 2005). Case studies have showed that the human 
primary hepatocellular carcinoma can be metastasized to a wide range of organs, 
including skin (Yamanishi et al. 1989), mandible (Lalikos et al. 1992), spleen 
(Nakamuta et al. 1992), brain (Tanabe et al. 1994), lymph node (Ueno et al. 2001), 
renal (Aron et al. 2004), adrenal (Hanada et al. 2004), heart (Masci et al. 2004), bone 
(Fontana et al. 2004), pharynx (Oida et al. 2005), etc.  
 
Genetic determinants and bio-markers for HCC metastasis 
Despite its clinical importance, little is known about the underlying mechanisms 
or the genetic and biochemical determinants of HCC metastasis. Endeavors in the past 
decade have focused on identifying the molecular and genetic determinants for HCC 
metastasis and have claimed biomarkers as having the potential to predict metastatic 
recurrence and prognosis of HCC patients. These include genes covering a broad range 
of functional categories, such as tumor suppressor genes (e.g. p53, PTEN), oncogenes 
(e.g. c-myc, c-met), cell cycle regulators (e.g. cyclin D1, INK4 family), apoptosis-
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associated genes (e.g. Bcl-xL, survivin), angiogenic factors (e.g. VEGF, HIF-1α, 
angiopoietins), growth factor receptors (e.g. EGFR, leptin receptor), as well as those 
genes directly involved in invasion and metastasis process (e.g. MMP-2, E-cadherin) 
(Ueki et al. 1997; Yamamoto et al. 1997; Ito et al. 1999; Kawate et al. 1999; Niu et al. 
2000; Ito et al. 2001; Hu et al. 2003a; Matsuda et al. 2003; Fields et al. 2004; Watanabe 
et al. 2004; Huang et al. 2005; Iso et al. 2005; Wada et al. 2006; Wang et al. 2006). 
This wide coverage of gene functional groups, to some degree, reflects the fact that 
HCC metastasis is a complicated, multi-step and changing process. Nevertheless, it is 
recognizable that the knowledge on the roles of metastasis-associated genes in HCC is 
still rather limited. In a previous report from our lab, two metastasis related genes, 
Cyr61 and Lasp1 were identified to have aberrant expression of being down-regulated 
and up-regulated, respectively in HCC by comparing 37 pairs of matched HCC tumor 
and non-tumor liver samples using cDNA microarray analysis (Neo et al. 2004). 
Characterizing the functions of metastasis-associated genes, such as Cyr61 and Lasp1, 
will no doubt provide a more solid basis for the prediction and prevention of the 












1.2. The human Cyr61 (Cysteine-rich 61) gene 
1.2.1. The human CCN (Cyr61/CTGF/Nov) gene family 
Members of the human CCN gene family 
Cysteine-rich 61 (Cyr61) is the first cloned member of the CCN family, which 
includes Cyr61/CCN1, connective tissue growth factor (CTGF/CCN2), nephroblastoma 
overexpressed (Nov/CCN3), Wnt-1 induced secreted protein 1 (Wisp-1/CCN4), Wisp-
2/CCN5, and Wisp-3/CCN6 (Perbal 2004). Although originally regarded as a simple 
group of related proteins, the CCN family is now known to be more complex, with 
biologically active CCN isoforms generated either by post-translational processing or 
alternative splicing. According to the recommendations by the international CCN 
society, these isoforms are designated as CCN1-V1, CCN2-V1, CCN2-V2, CCN2-V3, 
CCN3-V1, CCN3-V2, CCN4-V1, and CCN6-V1, which are either expressed in normal 
conditions or in pathological conditions (Perbal 2004).  
 
Modular structures and functions 
Members of the CCN family are 30~40 kDa proteins that are extremely 
cysteine-rich (10% by mass). One of the most important features of CCN proteins is 
that they are multi-modular mosaic proteins containing a signal peptide and four 
conserved modules that resemble functional domains previously identified in major 
extracellular regulatory proteins (Figure 1.1). Module 1 is an insulin-like growth factor 
(IGF)-binding domain, module 2 is a von Willebrand type C domain, module 3 is a 
thrombospondin-1 domain, and module 4 is a C-terminal domain containing a putative 
cystine knot (Bork 1993; Brigstock 1999; Lau and Lam 1999; Perbal 2001).  
Although the biological roles for all these conserved modules are not fully 
identified, progress has been made to address the relationship between the structure and 
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function of the CCN protein family. The signal peptide encoded by all CCN proteins is 
generally believed to be responsible for secretion just as other proteins carrying signal 
peptide. Module I was named as IGFBP module, but it shares only 32% identity with 
the N-terminal part of the Insulin-like Growth Factor Binding Proteins (IGFBPs) (Bork 
1993). As such, the proposition that CCN proteins bind to IGF remains controversial 
and the biological significance of the structural relationship between IGFBPs and CCN 
proteins is still very much debated (Planque and Perbal 2003). Module II comprises a 
Von Willebrand type C repeat (VWC) that occurs in Von Villebrand factor as well as 
various secretory proteins such as mucins, thrombospondins, and collagens (Bork 1993). 
This module contains sequences that are proposed to drive protein oligomerization. 
Module III contains sequences sharing identity with the Thrombospondin type 1 repeat 
(TSP1) (WSXCSXXCG), and appears to be a cell attachment motif that is implicated in 
the binding of sulfated glycoconjugates (Holt et al. 1990). The presence of a TSP1 
module in the CCN proteins suggests that they might be implicated in functional 
interactions with multiple components of the ECM or play an active role in cell 
adhesion. Module IV, also designated as CT domain, exists in the C-termini of a wide 
range of unrelated extracellular proteins as well, including Von Willebrand factor and 
mucins, and appears to be critical for several of the biological functions attributed to the 
CCN proteins. Sequences similarities to Heparin-binding motifs are also found within 
this domain (Brigstock et al. 1997). The structure found in CT domain, known as 
"cystine knot" formed by six cysteines,  is implicated in the dimerization of growth 
factors such as TGF-β, PDGF, and Nerve Growth Factor (NGF) (Schlunegger and 
Grutter 1993). The cystine knot in the CCN proteins might allow both homotypic and 
heterotypic interactions with proteins containing a similar structure, such as Fibulin 1C, 
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Notch1, and even CCN protein itself, which were thought to be critical for controlling 
the cell adhesion (Perbal et al. 1999; Perbal 2001; Sakamoto et al. 2002).  
 
Gene expression and biological functions of human CCN family 
Early studies showed human CCN gene expression in a great variety of tissues 
during normal development (Brigstock 1999). The amount of RNA species appears to 
be controlled by tight spatiotemporal regulation, thus in most tissues that stained 
positive, high concentrations of CCN1 and CCN2 RNA are also detected. Low to high 
levels of CCN3 RNA are generally present in most positive tissues (Perbal 2001), 
whereas CCN5 and CCN6 have a more restricted expression pattern compared to 
CCN1-3 (Perbal et al. 2003). As the CCN proteins contain a signal peptide driving their 
secretion, whether they act at their site of production or can be transported away to 
execute their functions elsewhere remains as a central question (Perbal 2004).  
The CCN genes encode secreted proteins associated with the extracellular 
matrix (ECM) and cell membrane. The CCN family proteins were once thought as a 
new family of growth factor as they acted in a similar fashion to classical growth factors, 
but the attempts to identify unique signal transducing receptors with high affinity and 
specificity have been unproductive (Brigstock 2003). Based on results obtained over the 
past decades, CCN family proteins were believed to act as matricellular regulatory 
factors that bridge the functional and physical gap between ECM-associated proteins 
and cell surface molecules (Lau and Lam 1999; Perbal 2004).  
A number of studies showed that Cyr61/CCN1, CTGF/CCN2, and Nov/CCN3 
can bind to cell surface integrins and thereby induce intracellular signaling events that 
include kinase activation and gene transcription (Lau and Lam 1999; Chen et al. 2000; 
Chen et al. 2001a; Grzeszkiewicz et al. 2001; Grzeszkiewicz et al. 2002; Leu et al. 
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2002; Schober et al. 2002). The fact that CCN proteins and their corresponding RNA 
are widely expressed in tissues originating from the three germ layers with major sites 
of expression suggests that CCN family members have roles in the differentiation and 
functioning of nervous system, vasculature, muscle, bone etc. (Brigstock 1999; Planque 
and Perbal 2003). Collectively, CCN proteins exhibit multiple functions including 
proliferation, differentiation, survival, adhesion, migration, apoptosis, extracellular 
matrix (ECM) production, placentation, implantation, angiogenesis, embryogenesis, 
chondrogenesis and endochondral ossification (Brigstock 2003; Planque and Perbal 






Figure 1.1 Modular structure of the CCN protein family. (Modified from 
Brigstock 2003; Planque and Perbal 2003) Residues are numbered according to the 
human orthologs of each protein. SP, Signal Peptide; IGFBP, Insulin-like Growth 
Factor Binding Protein-like module; VWC, Von Willebrand Factor-like module; 
TSP1, Thrombospondin-like module; CT, cystine knot containing family of growth 








1.2.2. Expression and biological functions of Cyr61 
Cyr61, originally designated 3CH61, was first identified in 1985 as a growth 
factor inducible immediate-early gene in serum-stimulated mouse BALB/c 3T3 
fibroblasts (Lau and Nathans 1985). Its chicken ortholog (Cef-10) was cloned as a gene 
induced following the transformation of chick embryo fibroblasts by the v-src oncogene 
of the Rous Sarcoma Virus (RSV) (Simmons et al. 1989). In 1997, the complete cDNA 
of the human Cyr61 gene isolated from an embryonic source was mapped to 
chromosome 1p22-31 and shown to encode a protein with 381 amino acids carrying a 
signal peptide of 26 residues (Jay et al. 1997; Brigstock 2003).  
Encoded by a growth factor inducible immediate-early gene, Cyr61 can be 
transcriptionally activated by a variety of growth factors and other stimuli, such as fresh 
medium, platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and 
TPA (12-O-tetradecanoylphorbol-13-acetate) (O'Brien et al. 1990). Human Cyr61 is 
widely expressed in multiple adult tissues such as heart, uterus, pancreas, brain, lung 
and skeletal muscle (O'Brien et al. 1990; Jay et al. 1997; Kolesnikova and Lau 1998). 
In mouse embryos, Cyr61 mRNA is present at high levels on days 9.5-14.5, whereas 
placental expression of Cyr61 is highest on days 17.5-18.5 (O'Brien and Lau 1992).  
Cyr61 is a secreted protein and is associated with the extracellular matrix (ECM) 
and cell surfaces. Similar to other CCN family members, the multi-modular structure of 
Cyr61 provides the basis for its interactions with multiple ECM proteins and cell 
membrane receptors and hence the combinatorial cellular functions. As a heparin-
binding protein and a ligand to various integrins, including αIIbβ3, αvβ5, αvβ3, α6β1 
and αMβ1 (Jedsadayanmata et al. 1999; Grzeszkiewicz et al. 2001; Grzeszkiewicz et al. 
2002; Schober et al. 2002; Menendez et al. 2005), Cyr61 has been shown to participate 
in a great variety of cellular events including chondrongenesis, osteogenesis, 
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angiogenesis, cell proliferation and survival, adhesion and migration (Kireeva et al. 
1996; Wong et al. 1997; Babic et al. 1998; Chen et al. 2001b). The diverse activities of 
Cyr61 are often thought to be mediated in part through interaction with multiple 
integrin receptors and cell surface heparin sulfate proteoglycans in a cell type specific 
and cellular context dependent manner.   
 
1.2.3. Association of Cyr61 with cancer 
Associations of human CCN proteins with cancer 
The structural similarity observed between CCN and a number of ECM proteins, 
their localization in the ECM, and their ability to interact with several types of cell 
membrane receptors and regulatory proteins suggest that CCN proteins represent a new 
class of signaling matricellular molecules playing a critical role in the regulation of cell 
growth. Therefore, the production of abnormal levels of normal or altered CCN proteins 
might be associated with or involved in the initiation and progression of tumor growth 
(Planque and Perbal 2003). 
Increasing lines of evidence now draw relationships between aberrant 
expression of CCN proteins in a number of tumors and tumorigenesis. Including CCN1, 
all CCN family proteins have been shown to be highly related to the tumorigenesis of 
various types of tumors. CCN2 was found up-regulated in dermatofibromas, pyogenic 
granuloma, pancreatic tumors, endothelial cells of angiolipomas and angioleiomyomas, 
glioblastoma tumor cells, and mononuclear cells of the patients with acute 
lymphoblastic leukemia (Igarashi et al. 1998; Wenger et al. 1999; Pan et al. 2002; 
Vorwerk et al. 2002). The expression of CCN3 was reported to be correlated to 
increased proliferative index in the case of the prostate and renal cell carcinoma 
(Glukhova et al. 2001; Maillard et al. 2001). CCN4 and CCN6 expression was 
 
Introduction 20
significantly increased in most colon adenocarcinomas (Pennica et al. 1998). All these 
observations are in favor of the point that CCN proteins play a positive role in 
tumorigenesis by providing the stimulatory effects on cell growth that are required for 
the increased lifespan of tumor cells. The relationship that was built between increased 
expression of CCN proteins and tumorigenicity might involve a partial or complete 
abrogation of apoptotic pathway and affect the communication of tumor cells with the 
surrounding environment.  
By decreasing the adhesive activity of the cells and by providing an increased 
ability to migrate and invade surrounding tissues, the CCN proteins might also be key 
factors participating in the angiogenesis and metastasis of tumor cells. For example, 
elevated level of CCN2 was observed in breast carcinoma with more advanced features, 
invasive mammary ductal carcinoma, and high grade of astrocytomas (Frazier and 
Grotendorst 1997). The expression of CCN3 was also reported to be correlated to the 
higher metastatic potential of the Ewing’s carcinoma cells (Manara et al. 2002) 
 Interestingly, anti-proliferative effects of CCN family proteins were also 
observed in a number of tumors. Both CCN2 and CCN3 were reported to be down-
regulated in Wilm’s tumors and the expression of CCN3 was shown to match striated 
muscular differentiation. A strong association between CCN3 expression and tumor 
differentiation was also observed in neuroblastomas, chondrosarcomas, 
rhabdomyosarcomas and other musculoskeletal tumors, suggesting that the level of 
CCN3 expression may be used as a marker for heterotypic differentiation of these 






Associations of Cyr61 with cancer 
An increasing body of studies reveals sophisticated roles of Cyr61 in 
tumorigenesis like other members of CCN protein family, by interfering with complex 
signaling pathways. Up-regulation of Cyr61 expression is associated with advanced 
breast cancer, pancreatic cancer, gastric cancer, and gliomas (Tsai et al. 2002; Xie et al. 
2004; Holloway et al. 2005; Lin et al. 2005). Multiple critical signal pathways were 
reported being manipulated by Cyr61 to promote tumor development, either by 
promoting cell proliferation and survival, cell motility and invasion, or inducing 
resistance to apoptosis (Xie et al. 2004; Lin et al. 2005; Menendez et al. 2005). For 
example, increased Cyr61 protein expression was observed in a large number of 
primary breast tumors that were progesterone receptor positive but estrogen receptor 
negative – suggesting that it might be a novel mediator of progesterone activity in 
breast cancer (Sampath et al. 2002). Invasive breast cancer cell lines expressed high 
level of Cyr61 whereas less tumorigenic breast cancer cells, such as MCF-7, expressed 
lower; normal breast cells showed almost none. Forced expression of Cyr61 in MCF-7 
cells was sufficient to induce anchorage-independent cell growth in the absence of 
estrogen and to form colonies in matrigel in a αvβ3 integrin-dependent way. The tumors 
induced by these cells in ovariectomised athymic nude mice resembled human invasive 
carcinomas and were highly vascularised (Tsai et al. 2000; Xie et al. 2001; Tsai et al. 
2002). These observations suggested that Cyr61 was involved in the progression to 
more advanced stages of breast cancer. 
On the other hand, decreased Cyr61 expression is also frequently noted in 
prostate cancer, endometrial cancer, uterine leiomyoma, papillary thyroid carcinoma, 
and non-small cell lung carcinoma (Pilarsky et al. 1998; Sampath et al. 2001; Tong et al. 
2001; Wasenius et al. 2003; Chien et al. 2004). Tong et al reported that Cyr61 is a 
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tumor suppressor in non-small cell lung carcinoma (Tong et al. 2001). It was also 
demonstrated that Cyr61 suppressed the growth of non-small-cell lung cancer cells by 
triggering the β-catenin─c-myc─p53 signal pathway (Tong et al. 2004).  
The paradoxical expression of Cyr61 in different types of tumors suggests that 
Cyr61 may exert important and disparate functions in carcinogenesis depending on the 
tissue of origin and cellular context. Therefore, the identification of Cyr61 interacting 
partners in a particular cell type would be very helpful in establishing whether abnormal 
expression or associations of Cyr61 with physiological targets are involved in these 
processes. 
 
Associations of Cyr61 with HCC 
At least 5 previous studies reported the expression of Cyr61 in HCC. Three of 
them showed that Cyr61 was down-regulated in HCC (Xu et al. 2001; Chen et al. 
2002a; Wang et al. 2005), but two other studies failed to detect any difference of Cyr61 
expression (Hirasaki et al. 2001) or observed up-regulated Cyr61 (Zeng et al. 2004) in 
HCC. It was also demonstrated that increased d(CA) microsatellite repeat instability in 
the Cyr61 promoter may account in part for the down-regulation of Cyr61 in HCC 
(Wang et al. 2005). However, the potential roles of Cyr61 in the development of HCC 









1.3. The human Lasp1 (LIM and SH3 protein 1) gene 
1.3.1. The human LIM (LIN-11/Isl1/MEC-3) protein family 
Members of the human LIM protein family 
The Human LIM proteins represent a group of proteins containing the LIM 
domain, a tandem zinc-finger structure that thought to function as a modular protein-
binding interface. The term “LIM” was derived from the names of the first three 
discovered members – LIN-11, Isl1 and MEC-3. The LIM domain is found in proteins 
from a wide variety of eukaryotic organisms. In the human genome, there are at least 
135 identifiable LIM-encoding sequences located within 58 genes, as shown in Figure 
1.2b. Figure 1.2a shows the human LIM proteins and LIM-protein families that have 
been molecularly characterized so far (Kadrmas and Beckerle 2004).  
Individual LIM domains comprise of approximately 55 amino acids with 8 
highly conserved residues that are located at defined intervals. Normally, the 8 
conserved residues are either Cysteine or Histidine. The classical LIM consensus 
sequence was defined as CX2CX16-23HX2CX2CX2CX16-21CX2(C/H/D) (X denotes any 
amino acid) (Schmeichel and Beckerle 1994). The number and spacing of the highly 
conserved cysteine and histidine residues indicated that the LIM domain might be a 
metal-binding structure. In 1993, Michelsen et al. reported that the LIM motif defined a 
specific zinc-binding protein domain. There are eight most highly conserved residues 
functioning in binding to zinc, establishing a tandem zinc-finger topology (Michelsen et 
al. 1993).  
Human LIM proteins can contain as many as 1-5 LIM domains found either 
internally or near the N or C terminus. LIM proteins can be comprised of LIM domains 
only, or LIM domains can be linked to other domains including homeodomains, 
catalytic domains, cytoskeletal-binding domains or other protein-binding modules such 
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as src homology 3 (SH3) domain, LD or PDZ domains. These features highlight the 
modular nature of the LIM domain and the functional diversity of LIM proteins 
(Kadrmas and Beckerle 2004).  
 
Figure 1.2 Human LIM proteins. (Adapted from Kadrmas and Beckerle 2004) (a) 
Domain structures of the founding member and/or the best characterized example of 
the main LIM-protein families are shown. The number of known members of each 
family is indicated in parentheses. The colored boxes represent several commonly 
used categorization schemes. Individual LIM domains are shown as colored ovals that 
have been grouped according to the similarity within the LIM sequence. Heterologous 
domains include the LD motif, the mono-oxygenase domain, actin-binding domain 
and nebulin repeats. Domains with boundaries that are not precisely defined are 
shown as dashed boxes. Dashed lines indicate that scale is not preserved. (b) List of 
the identified members of each LIM family. ABLIM, actin-binding LIM protein; ACT, 
activator of cyclic AMP response element modulator (CREM) in the testis; ALP, α-
actinin-associated LIM protein; CH, calponin homology; CRP, cysteine-rich protein; 
EPLIN, epithelial protein lost in neoplasm; FHL, four-and-a-half LIM; GLY, glycine-
rich region; LASP, LIM and SH3 protein (red box); LHX, LIM-homeodomain protein; 
LIMK, LIM kinase; LMO, LIM only; MICAL, molecule interacting with CASL 
protein-1; PDZ, postsynaptic density-95, Discs large, zona occludens-1; PET, prickle, 
espinas and testin; PINCH, particularly interesting new cysteine and histidine-rich 
protein; SH3, Src-homology-3; VHP, villin head piece. 
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Biological functions of the human LIM protein family 
A large body of literature supports the point that the LIM domain functions as a 
modular protein-binding interface to mediate protein-protein interactions (Feuerstein et 
al. 1994; Arber and Caroni 1996; Kadrmas and Beckerle 2004). However, no specific 
consensus binding sequence or structural element has been defined as the general 
features of the LIM domain binding partners, as the LIM motif seems to recognize 
different protein targets in a variable manner that is dependent on the specific targeted 
proteins (Velyvis et al. 2003). By analyzing a huge number of LIM partners, LIM 
domains are now thought to contribute as either one or combination of the following 
four functions: adaptors, competitors, conformers and localizers (Kadrmas and Beckerle 
2004).  
LIM proteins have been identified in both the nucleus and the cytoplasm. Some 
LIM proteins, such as the LIM homeodomain proteins, are expressed exclusively in 
nucleus and have clear transcriptional roles during development (Hobert and Westphal 
2000). Nevertheless, most characterized LIM proteins are known to interact with the 
actin cytoskeleton in a direct or indirect way. Interestingly, many LIM proteins such as 
members of the zyxin, four-and-a-half LIM (FHL) and cysteine-rich protein (CRP) 
families, which were initially identified as cytoskeleton associated proteins, are now 
believed to be able to shuttle between the cytoplasm and nucleus of the cells to regulate 
gene expression (Muller et al. 2002; Chang et al. 2003; Cattaruzza et al. 2004). The 
ability of the dual localization of these LIM proteins is the most striking theme on 
global examination of LIM functions in encompassing aspects of cytoskeletal function 
and the control of gene expression.  
By binding to their partners, the LIM proteins participate in a wide variety of 
biological processes, including regulation of actin structure and dynamics, neuronal 
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pathfinding, integrin-dependent adhesion and signaling, cell-fate determination and 
tissue-specific gene expression. In the cytoplasm, several LIM proteins, for example, 
EPLIN (epithelial protein lost in neoplasm) and ALP (α-actinin-associated LIM protein) 
have been shown to directly regulate actin polymerization and de-polymerization (Xia 
et al. 1997; Pomies et al. 1999). In D. melanogaster, MICAL has been shown to be 
expressed in axons and paly a role in repulsive axon guidance (Terman et al. 2002). 
Like MICAL, an actin-binding domain containing protein, ABLIM, is essential for 
high-fidelity axon pathfinding. A high percentage of LIM protein is found localized at 
focal adhesions, such as migfilin (a distant zyxin-family member) (Takafuta et al. 2003; 
Tu et al. 2003) and NRAP (a muscle-specific protein of the LASP family) (Luo et al. 
1999; Tadokoro et al. 2003). These focal-adhesion LIM proteins can mediate integrin 
signaling. Moreover, LIM proteins from the LHX and LMO protein families have 
established their roles in tissue-specific gene expression and cell-fate determination.  
 
1.3.2. The human LASP gene family 
LASP (LIM and SH3 Protein) gene family, one sub-family of the LIM protein 
family, now includes Lasp1 (Tomasetto et al. 1995), Lasp2 (LIM-nebulette) (Li et al. 
2004), and NRAP (Luo et al. 1997).  Besides the N-terminal LIM domain, they also 
contain a C-terminal SH3 (src-homology-3) domain, which is involved in the protein-
protein interactions through binding to proline-rich sequences. All of the three proteins 
can also be classified as members of the nubulin family, which are modular proteins 
with key structural feature of the 35-residue nebulin modules (Panaviene and Moncman 
2007). This nebulin module,  defined by an N-terminal sequence motif of “SDXXYK”  
and a central sequence motif of “TPD/E” (Jin and Wang 1991), functions to bind to 
different actin isoforms.  
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Although all of the family members contain the actin-binding domain (nebulin 
module), each protein interacts with distinct cellular structures and has different 
expression profiles. Lasp1 and LIM-nebulette (Lasp2) are found in non-muscle cells 
and are components of the focal adhesions, membrane skeleton, and stress fibers (Chew 
et al. 1998; Li et al. 2004). Unlike Lasp1, the LIM-nebulette (Lasp2), which is the most 
recently identified member of the nebulin family of actin-binding proteins, is actually a 
splice variant of nebulette and contains much of the nebulette C-terminal sequences 
(Moncman and Wang 2000). The expression of LIM-nebulette has been analyzed, 
which has demonstrated high levels of expression in lung, brain, and kidney. Low levels 
of the mRNA have also been found in human and mouse adult heart (Li et al. 2004; 
Terasaki et al. 2004). NRAP, on the other hand, mainly found in both skeletal and 
cardiac muscle, localizes to cellular junctions, such as the myotendinous junction and 
intercalated disks (Luo et al. 1997) and has been shown to be up-regulated in animal 
model systems of dilated cardiomyopathies (Ehler et al. 2001).  
 
1.3.3. Expression and biological functions of Lasp1 
Modular structure and expression of Lasp1 
Lasp1 (LIM and SH3 protein) was initially identified from a cDNA library of 
human breast cancer metastases (Tomasetto et al. 1995). Human Lasp1 gene is mapped 
to chromosome 17q21 and encodes a protein of 261 amino acids containing an N-
terminal LIM domain followed by two actin binding sites and a C-terminal src 
homology SH3 domain (Figure 1.3). The actin binding domain is believed to be 
functioning as a mediator for protein-protein interactions between Lasp1 and the actin 
cytoskeleton, while the SH3 domain at the C-terminus is involved in binding to proline-
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rich sequences (Schreiber et al. 1998b; Chew et al. 2002; Butt et al. 2003; Keicher et al. 
2004).  
Lasp1 was shown to be widely expressed in normal epithelial tissues, muscles 
and brain (Chew et al. 1998). The murine Lasp1 expression was ubiquitous in almost all 
adult tissues and was detected from 7.5 to 17.5 days post-coitum of mouse embryonic 
stem cells, indicating its essential roles (Schreiber et al. 1998a). Lasp1 was previously 
reported to be localized within multiple sites of dynamic actin assembly such as focal 
contacts, focal adhesions, lamellipodia, membrane ruffles, and pseudopodia. At 
peripheral cell extentions in individual epithelial cells and in transformed fibroblastic 
cells, Lasp1 was revealed to co-localize with actin (Schreiber et al. 1998b).  In 2002, 
Chew et al reported that Lasp1 was expressed not only in gastric parietal cells but also 
in focal adhesions and focal complexes as well as in the extreme tips of lamellipodia 
and filopodia in gastric mucosal fibroblasts (Chew et al. 2002). In a more recent study, 
Lasp1 was reported to be highly expressed by CNS (Central Nervous System) neurons 
and is concentrated at synaptic sites, suggesting that it may also regulate cytoskeletal 
reorganization in dendritic spines, which is a known factor in synaptogenesis and 
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Figure 1.3 Modular structure of Lasp1. The modular domains and the protein 
kinase phosphorylation sites of Lasp1 are shown. LIM domain (light green); ABD: 
actin binding domain (dark green); SH3 domain: src homology 3 domain (light blue). 
The PKA/PKG phosphorylation sites are on Serine-61,-99, and -146. The Abl tyrosine 




Binding partners and biological functions of Lasp1 
Although a number of studies have been performed in order to identify the 
binding partners of Lasp1, the specific cellular functions of this LIM and SH3 domain 
containing protein have not yet to be fully characterized. Current knowledge only 
defines Lasp1 as a focal adhesion adaptor protein involved in cell migration based on its 
ability to interact and/or co-localize with a series of focal adhesion proteins, such as F-
actin, zyxin, lipoma preferred partner (LPP, member of the zyxin subfamily of LIM 
domain proteins), Krp1, vasodilator stimulated phosphoprotein (VASP) and dynamin, 
and the binding occurs between the C-terminal SH3 domain of Lasp-1 and the N-
terminal proline-rich domains of LPP, zyxin or VASP (Chew et al. 1998; Okamoto et al. 
2002; Keicher et al. 2004; Li et al. 2004; Spence et al. 2006).  
 
Regulations of Lasp1 
As a novel gene with its specific biological function largely unexplored, the 
knowledge on the regulation of Lasp1 gene expression and activity is also rather limited. 
Several reports have revealed Lasp1 as a phosphoprotein that can be phosphorylated by 
cAMP- or cGMP-dependent protein kinase, and c-Abl kinase (The phosphorylation 
sites are indicated in Figure 1.3) (Chew et al. 1998; Butt et al. 2003; Lin et al. 2004). 
These phosphorylation and de-phosphorylation processes tightly control the localization 
and function of Lasp1. For example, Lasp1 binds to non-muscle filamentous actin (F-
actin) in vitro in a phosphorylation-dependent manner (Chew et al. 2002). It was also 
reported that Abl kinase specifically phosphorylates Lasp1 in apoptotic cells, preventing 
Lasp1 translocation to focal complexes (Lin et al. 2004).  
On the other hand, Lasp1 was shown to be transcriptionally up-regulated in 
response to the morphogen Sonic Hedgehog in pluripotent mesenchymal cells (Ingram 
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et al. 2002) and induced in cells transformed by over-expression of  IGF-1 receptor 
dependent on PI3-Kinase activities (Loughran et al. 2005). As both altered Sonic 
Hedgehog and IGF-1 signaling have been reported to be associated with cancer 
progression (Hellawell et al. 2002; Lopez and Hanahan 2002; Nishimaki et al. 2004), it 
would be interesting to examine the expression and functional roles of Lasp1 in human 
cancer as well.  
 
1.3.4. Association of Lasp1 with cancer 
Since Lasp1 was initially identified from human breast cancer metastases by 
Tomasetto et al in 1995, both the expression level and functional roles of Lasp1 in 
breast cancer progression and metastases were reported (Tomasetto et al. 1995; 
Grunewald et al. 2006). Lasp1 was shown to be highly expressed in breast cancer tissue 
and metastatic breast cancer cells. Silencing of Lasp1 by siRNA retarded the cell 
proliferation and cell migration of breast cancer cells in vitro without influencing the 
expression of other proteins related to Lasp1 signaling pathway. In addition, 
knockdown of Lasp1 severely affected zyxin localization (Grunewald et al. 2006). 
More recently, Lasp1 has been shown to be involved in ovarian cancer. Knockdown of 
Lasp1 in ovarian cancer cells had the same effect as in breast cancer cells in arresting 
cells at G2/M phase, reducing cell proliferation and affecting zyxin localization 
(Grunewald et al. 2007). Apart from these previous studies, it is recognized that the 
potential roles of Lasp1 in the carcinogenesis of other types of tumors have not been 






1.4. The tumor suppressor p53 
1.4.1. The TP53 gene 
The tumor suppressor p53 was first reported as a 53kDa cellular protein 
associated with large T antigen in SV40 transformed cells by several independent 
studies in 1979 (Kress et al. 1979; Lane and Crawford 1979; Linzer and Levine 1979). 
It was initially described as an oncogene, since the sequences originally isolated from 
tumor cells which were later confirmed as missense mutants, induced neoplastic 
transformation (Oren and Levine 1983; Eliyahu et al. 1984; Harlow et al. 1985). As 
mutations in p53 and loss of heterozygosity at chromosome 17q (where the p53 resides) 
were later frequently noted in primary human tumors (Mackay et al. 1988; Baker et al. 
1989; Hollstein et al. 1991; Greenblatt et al. 1994), researchers started to re-define the 
role of p53. Further studies re-classify p53 as a tumor suppressor in view of the fact that 
the wild-type P53 protein derived from normal cells was found to inhibit tumor growth 
instead of triggering cellular transformation (Finlay et al. 1989; Baker et al. 1990; 
Mercer et al. 1990).  
The TP53 gene encodes a multi-modular protein containing 393 amino acids 
which is commonly divided into three major functional domains. The transcriptional 
activation activity of p53 requires its acidic amino-terminal domain, where its negative 
regulator MDM2 can bind (Chen et al. 1995). Most of the interactions between p53 and 
its abundant downstream target genes take place in the central core DNA-binding 
domain (Ho et al. 2006; Veprintsev et al. 2006). The carboxyl-terminal end containing 
a nuclear export signal, 3 nuclear localization sequences and the C-terminal regulatory 
domain, is also responsible for the oligomerization and functioning of p53 protein as it 
binds to the DNA targets as a tetramer (McLure and Lee 1998; Shu et al. 2007). 
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When two genes  — p63 and p73 exhibiting remarkable sequence homology 
with p53 were found, the TP53 gene was further characterized as a member of a small 
family of related proteins (Caput 1997; Jost et al. 1997; Yang et al. 1998; Melino et al. 
2002). Although structurally and functionally related, p63 and p73 have clear roles in 
normal development (Irwin and Kaelin 2001), whereas p53 seems to have evolved in 
higher organisms as a key tumor suppressor protein at the crossroads of cellular stress 
response pathways to prevent tumor development (Hussain and Harris 2006). It mainly 
functions as a transcription factor which is activated in response to several malignancy-
associated stress signals. These signals including loss of survival signals, ribonucleotide 
depletion, DNA damage, oncogenes, telomere erosion, and hypoxia/anoxia, often 
induce p53 by stabilizing the p53 protein, which leads to an accumulation in cellular 
p53 levels (Vousden and Lu 2002). Upon activation, p53 protein binds to specific DNA 
sequence located on the promoter or intron of a large number of its downstream target 
genes, activates or represses the expression of these genes and results in cell growth 
inhibition or cell death. The specific p53 binding motif is termed as the p53 response 
element (RE) with consensus sequences of “PuPuPuC(A/T)(A/T)GPyPyPy † PuPuPu 
C(A/T)(A/T)GPyPyPy” (Pu: purine, Py: pyrimidine, †: spacer of 0-13 nucleotides) (el-
Deiry et al. 1992). 
Characterizing the molecular targets of p53 provides critical information in 
uncovering its physiological and pathological functions. More than 150 identified p53-
regulated genes characterized so far have already well defined its role in cell cycle 
control, DNA damage repair, apoptosis, hypoxia, and angiogenesis (Dameron et al. 
1994; Polyak et al. 1997; Bouvet et al. 1998). A simple illustration of the p53 pathway 
involving its activation regulation and the main categories of its downstream target 
genes is shown in Figure 1.4. However, though the number of identified p53 targets 
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keeps growing, it is conceivable that a large number of p53 downstream genes have not 





















































Figure 1.4 Main categories of p53 target genes. In normal unstressed cells, the level 
of p53 protein is downregulated by binding of proteins such as MDM2, which 
promote p53 degradation via the ubiquitin/proteasome pathway. Stress signals (listed 
in yellow box) leads to activation of p53 in a two-step process. Firstly, p53 protein 
level is rapidly increased via the inhibition of its interaction with MDM2 and the other 
negative regulators. Secondly, a series of modulators (e.g. kinases) will activate p53 
transcriptional activity by phosphorylation. Upon p53 activation, a number of genes 
are activated by the transactivating properties of p53. This occurs via specific DNA 
binding of the p53 protein to a p53 response element that is found either in the 







1.4.2. Association of p53 with cancer 
The malignant progression is largely dependent on loss of p53 function, either 
through mutation in the TP53 gene itself that is frequently observed in the majority of 
human cancers or by defects in the signaling pathways that are upstream or downstream 
of p53. Unlike the mutational spectrum that is usually seen in most of other tumor 
suppressor genes, in which large deletions, frameshift or nonsense mutations often 
cause disappearance or aberrant synthesis of the proteins, tumor-associated mutations in 
TP53 are predominantly point mutations that result in single amino acid substitutions. 
Interestingly, six residues — 175, 245, 248, 249, 273 and 282 — of p53 show an 
unexpectedly high frequency of mutations, altogether accounting for 28% of p53 
mutations. These missense mutations lead to the synthesis of a relatively stable mutant 
protein losing the specific DNA-binding activity and accumulating in the nucleus of 
tumor cells (Vousden and Lu 2002; Soussi et al. 2005). In addition, many tumors that 
harbor point mutations in p53 also show loss of heterozygosity, which further 
eliminates the wild-type allele of TP53 (Greenblatt et al. 1994).  
 
Association of p53 with HCC 
Specifically in HCC, the defect in p53 pathway is frequently observed though 
the mutation spectra vary in different geographic areas. Somatic mutations in p53 
detected in HCC are often associated with AFB1 (aflatoxin B1) or viral infections as 
reviewed by Hussain et al (2007). AFB1 exposure frequently induces a point mutation 
of p53 at codon 249 leading to Arg → Ser (AGG → AGT) substitute and the resulting 
249Ser mutant effectively inhibits wild-type p53-mediated apoptosis, making tumor cells 
gain growth advantages (Bressac et al. 1991; Aguilar et al. 1993; Wang et al. 1995). 
The p53 mutation is also attributed to viral infections as it was suggested that the 
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combination of AFB1 intake and HBV infection may be critical to the high frequency 
of 249Ser mutation of p53 in HCC (Ming et al. 2002). As this 249Ser mutation of p53 is 
uncommon in other cancer types and it could be detected in serum and plasma of HCC 
patients, it may be used as a specific biomarker for AFB1 exposure and possibly early 
HCC (Kirk et al. 2000; Kirk et al. 2005). As introduced in section 1.1.2, HBxAg 
transactivation activity (Nijhara et al. 2001; Tarn et al. 2001) or its direct binding to p53 
may inactivate the p53-dependent activities, including p53 sequence-specific DNA-
binding activity in vitro and p53-mediated transcriptional activity in vivo, and even 
repress the transcription of TP53 gene  (Feitelson et al. 1993; Wang et al. 1994; Ueda et 
al. 1995; Lee and Rho 2000). In order to further examine the role of p53 in HCC, 
Okada et al (2003) analysed a number of TP53 mutant and TP53 wild-type HCC cases 
by microarray, showing that HCV-infected HCCs with wild-type p53 and those with 
mutant p53 differ significantly in their gene expression profiles. Some cell cycle and 
cell proliferation related  genes were over-expressed in mutant p53 tumors compared to 
wild-type p53 tumors, suggesting that HCV infection also contributes to 
hepatocarcinogenesis involving p53 pathways, and the mutant p53 HCC tumors have a 
high malignant potential than those carrying wild-type p53 (Okada et al. 2003).  
 
Association of p53 with cancer metastasis 
Recently, increasing lines of evidences indicate that p53 also functions in 
regulating cell migration, invasion, and cancer metastasis through targeting genes 
functionally linked to cytoskeletons. Several tumor metastasis suppressor genes, such as 
Maspin, KAI1/CD82 have been demonstrated to be bona fide p53 targets which can be 
transcriptionally activated by p53 (Mashimo et al. 1998; Zou et al. 2000; Liu and Zhang 
2006). Maspin was discovered as a human mammary tumor suppressor in 1994 (Zou et 
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al. 1994) and has been shown to inhibit tumor cell invasion and metastasis in breast 
tumor cells (Zou et al. 2000; Hojo et al. 2001; Maass et al. 2001). Its anti-tumor effects 
are also linked to prostate cancer (Sheng et al. 1996) and pancreatic cancer (Maass et al. 
2001). KAI1 was initially identified as a metastasis suppressor of prostate cancer (Dong 
et al. 1995), but it is now thought as a wide-spectrum tumor metastasis suppressor by 
primarily inhibiting cancer motility and invasiveness (Liu and Zhang 2006). Its 
expression was reported to be down-regulated during prostate tumor progression and 
low expression of KAI1 correlates well with the loss of p53 function. Despite the 
variable frequency of p53 mutations reported in primary prostate tumors, metastatic 
tumors exhibit a higher incidence of p53 mutations (Effert et al. 1992; Heidenberg et al. 
1996). These findings provide a mechanistic explanation for the increased metastatic 
susceptibility of tumors carrying p53 mutants, and suggest that elucidating the roles of 















1.5. Objectives of the study 
As the fifth most common cancer in the world, the prognosis in HCC is dismal, 
with high morbidity and mortality rates associated with tumor invasion and metastasis 
(Llovet et al. 2003). Metastasis is the major barrier to curative cancer treatments and the 
primary cause of death in cancer patients (Hunter 2006). However, the mechanisms 
underlying metastasis of HCC have not been completely elucidated (Tang et al. 2004). 
Thus characterizing roles of metastasis-associated genes will strengthen our 
understanding in the molecular pathogenesis of HCC metastasis as well as 
hepatocarcinogenesis for developing early diagnostic markers and effective therapeutic 
interventions.  
A number of gene expression profiling studies have been performed to reveal 
multiple genetic aberrations and heterogeneous dysregulation of oncogenic pathways in 
HCC development (Okabe et al. 2001; Shirota et al. 2001; Chen et al. 2002a). Our 
previous cDNA microarray study identified two metastasis related genes Cyr61 and 
Lasp1, which have aberrant expression of being down-regulated and up-regulated, 
respectively in HCC (Neo et al. 2004). As described in previous sections, both Cyr61 
and Lasp1 are located at the focal adhesion signaling network and functionally related 
to the dynamics of cytoskeleton and cell migration. In addition, Cyr61 is a well-studied 
gene associated with progression and angiogenesis of a variety of tumors, while Lasp1 
is thought to be highly related to breast cancer metastasis. However, their roles in the 
development and metastasis of HCC have yet to be explored. Therefore, the present 
study is mainly focused on investigating the potential roles of Cyr61 and Lasp1 in 
growth and metastasis of human HCC by in vitro study using HCC cell lines. 
The transcription factor p53 may also function in regulating tumor metastasis. 
However, though several tumor metastasis suppressor genes have been demonstrated to 
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be p53 targets that can be transcriptionally activated by p53, the understanding to the 
downstream targets of p53 involved in invasion/metastasis remains rather limited. In a 
recent study from Genome Institute of Singapore, 20 previously unidentified p53 targets 
involved in cell motility, adhesion, and migration were reported, suggesting that a 
number of novel p53 targets could be involved in p53-mediated suppression of tumor 
metastasis. Functional analysis of these genes could help to reveal a broader spectrum 
of p53 functions. Interestingly, Lasp1 was identified as one of the potential p53 target 
genes through this study by coupled ChIP with the paired-end ditag technologies (ChIP-
PET) (Wei et al. 2006) (Supplemental Data). These findings provide us with a clue that 
p53 may play a more diversified role in regulating cell migration by transcriptionally 
suppressing mRNA expression of genes involved in the dynamics of cytoskeletons as 
well. As such, the aims of the current study also include the validation of Lasp1 as a 
novel bona fide p53 target by showing the role of p53 in transcriptionally suppressing 
Lasp1 expression, which suggests a novel mechanism of p53 in inhibiting tumor 
metastasis.  
From the literature review, we noticed that Cyr61 inhibits the growth of the non-
small-cell lung cancer by up-regulating p53 through the Cyr61–integrin–β-catenin–c-
myc–p53 pathway (Tong et al. 2004). Since our microarray data showed that Cyr61 is 
also down-regulated in HCC, identification of the potential role of Cyr61 in up-
regulating p53 in HCC cells as well would be an appealing idea as it links Cyr61 and 
Lasp1 to the central master regulator of p53 in HCC. Hence, this study also aims to 
construct a pathway involving Cyr61 and Lasp1 by showing Cyr61 as an upstream 
regulator of p53 in HCC cells and in turn contribute to the existing knowledge and the 






The scope of this study thus includes the following aspects: 
1. To validate the microarray data of aberrant expression of Cyr61 and Lasp1 
using HCC clinical tumor samples and HCC cell lines.  
2. To identify the roles of Cyr61 and Lasp1 in regulating cell growth, adhesion, 
migration and invasion ability in HCC cell lines.  
3. To investigate possible mechanisms of Lasp1 in influencing cell migration and 
invasion in HCC cell lines. 
4. To explore possible mechanisms of Cyr61 in regulating HCC cell growth 
involving p53. 
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Media, Buffers and Solutions, and Chemicals 
The media, buffer and solutions, and chemicals used in this study are listed in 
Appendix I.  
 
2.1. Patient samples 
Total RNA from 8 pairs of matched tumor and non-tumor liver tissues were 
randomly selected from a collection of 37 HCC patients used in a previous microarray 
study (Neo et al., 2004).  
                
2.2. Cell culture techniques  
The human hepatocellular cancer cell lines HepG2 (ATCC HB-8065), Hep3B 
(ATCC HB-8064), Huh-7 and PLC/PRF/5 (ATCC CRL-8024) were originally 
obtained from the American Type Culture Collection (Manassas, VA) and stored 
frozen in liquid nitrogen at WHO Immunology Centre, National University of 
Singapore. The human colon cancer cell line HCT116 and its derived isogenic p53-/- 
cells were kindly provided by Dr. Bert Vogelstein (Johns Hopkins University, 
Baltimore, MD).  
          
2.2.1. Growth of HCC cell lines and colon cancer cell lines 
HCC cell lines stored frozen in liquid nitrogen were thawed quickly at 37°C 
water bath and re-suspended in 10ml of DMEM/10%FBS (Appendix I) under sterile 
conditions. Cells pelleted by centrifuging at 900rpm for 5 minutes were gently re-
suspended in 7ml of DMEM/10% FBS and transferred to 25ml culture flasks (Falcon, 
BD Biosciences, Franklin Lakes, NJ). The cell culture was incubated at 37°C in a 5% 
CO2 humidified incubator. The density of the cells was monitored and culture 
medium was changed as necessary. When cell density reached 90-100% confluence, 
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the cells were trypsinized in 0.25% trypsin/EDTA (Invitrogen, Carlsbad, CA) for 
5min at 37°C and stopped by adding fresh DMEM/10%FBS. Then all cells were 
transferred to a new 75ml culture flask. Cells were then maintained in 75ml culture 
flask or expanded into 150ml culture flasks depending on the number of cells needed 
for experiments.  
  
2.2.2. Freezing HCC cell lines and colon cancer cell lines  
Upon achieving 80-90% confluent growth, the cells cultured in 75ml or 150ml 
flask were trypsinized and collected by centrifuging at 1000rpm for 5 minutes and the 
supernatant discarded. The pellet was re-suspended in 3ml (75ml flask) or 5ml (150ml 
flask) ice-cold freezing medium (Appendix I) and transferred into labeled NUNC 
CyroTube vials (1ml per vial) (Thermo Fisher Scientific, Rochester, NY). The vials 
were kept at -80°C overnight before stored at liquid nitrogen.  
 
2.2.3. Harvesting HCC cell lines and colon cancer cell lines  
Upon achieving confluent growth, the cell cultures in the culture flask or 
culture plate were trypsinized and collected by centrifuging at 1000rpm for 5 minutes 
and the supernatant discarded. The pellet was washed in 1ml phosphate buffered 
saline (PBS) (Appendix I) after transferred to 1.7ml eppendorf tubes and centrifuged 
at 500 × g for 5 minutes, with the supernatant once again discarded. Cell pellets were 
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2.3. Polymerase chain reaction (PCR) 
2.3.1. Total RNA extraction 
As mentioned above, total RNA from 8 pairs of matched tumor and non-tumor 
liver tissues were randomly selected from a collection of 37 HCC patients used in a 
previous microarray study. Total RNA samples from 15 types of normal human 
tissues were purchased from Stratagene (La Jolla, CA). Total RNA from the 
experimental cells was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA) 
according to the manufacturer’s instructions. After quantified by Nanodrop (ND-1000) 
(Nanodrop Technologies, Delaware, USA), these RNA samples were either directly 
used for subsequent one-step real-time quantitative RT-PCR or subjected to cDNA 
(complementary DNA) synthesis followed by two-step real-time quantitative or semi-
quantitative RT-PCR. 
 
2.3.2. cDNA synthesis 
The cDNA was synthesized using Omniscript® RT kit (Qiagen) according to 
the manufacturer’s instructions. Briefly, total RNA was pretreated at 65°C for 10min 
and immediately transferred onto ice for 5min to denature the secondary structure of 
RNA. The 1st strand cDNA was synthesized in a total volume of 20μl reaction mixture, 
containing 2μl of 10 × buffer RT, 2μl of 5mM dNTP mix, 2μl of oligo-(dT)15-18 
primer (1μM final concentration), 1μl of RNase inhibitor (RNaseOut, Invitrogen), 1μl 
of omniscript reverse transcriptase, and 1μg of total RNA as template. The reaction 
was performed by incubating at 37°C waterbath for 1 hour and chilled on ice for 5min 
to stop the reaction. The first strand cDNA was then 10 times diluted by 
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2.3.3. Real-time quantitative RT-PCR 
One-step real-time RT-PCR 
To validate the microarray data, the expression of Cyr61 or Lasp1 mRNA in 
eight pairs of liver tissues was analyzed by one-step real-time quantitative RT-PCR 
using RNA Master SYBR Green I kit in a LightCycler (Roche Applied Science, 
Mannheim, Germany) with previously collected total RNA samples (Neo et al., 2004). 
All primers were synthesized by Sigma-Proligo (Singapore) and dissolved in 
DNase/RNase free H2O to give a final working concentration of 10μM (sequence 
listed in Table 2.1). In brief, 10ng of total RNA for each sample was loaded (in 
duplicate) in a 10µl reaction volume containing 3.7μl of 2.7 × RNA Master Mix 
SYBR, 0.65μl of Mn(OAc)2 stock solution (3.25mM final concentration), 0.5μM of 
each forward and reverse primer. After normalized to a housekeeping gene HPRT, 
data were presented as the fold change of the gene expression in each non-tumor 
tissue against its corresponding tumor sample for down-regulated gene (Cyr61) or that 
in each tumor against its matched non-tumor sample for up-regulated gene (Lasp1).  
 
Two-step real-time RT-PCR   
To measure the knockdown effect of siRNA and to examine the role of p53 in 
transcriptionally suppressing Lasp1 gene expression, two-step real-time quantitative 
RT-PCR was performed. After total RNA extraction, the first stand cDNA was 
synthesized using the Omniscript® RT kit. The real-time RT-PCR was then 
performed with 2µl of cDNA (10 times diluted) as the template in a 10µl reaction in 
triplicates using 2 × SYBR Green 1 PCR Master Mix (Applied Biosystems, Foster 
City, CA) according to the manufacturer’s instructions in the ABI PRISM 7500 
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system. The primer sequences were listed in Table 2.1, with HPRT used as the 
housekeeping gene.  
 
2.3.4. Gel-based semi-quantitative RT-PCR 
RT-PCR was carried out in an ABI GeneAmp PCR 9700 system in a final 
volume of 20μl reaction containing 0.5μl of synthesized cDNA (5μl of 10 × diluted 
cDNA) as template, 0.5μM of each forward or reverse primer (Table 2.2), and 10μl of 
2 × High Fidelity PCR Master Mix (Roche). After initial denaturing at 94°C for 2 min, 
the amplification was carried out for 25-35 cycles each consisting of denaturing for 
30sec at 94°C, annealing for 30-60sec at 52-60°C (depending on primers’ Tm), and 
extension for 30-120sec (depending on the product size) at 68 or 72°C, followed by a 
final extension for 6-20 min at 68 or 72°C before cooling down to 4°C. Total PCR 
products were separated on 1-1.5% agarose gel electrophoresis in TBE buffer 
(Appendix I) and stained with ethidium bromide (Bio-Rad, Hercules, CA). Gel photos 
were taken under UV transilluminator and the band intensities of gel-based RT-PCR 
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Oligonucleotide Sequence Length Position
Product 
Size
Cyr61 Cyr61-F1 5' AAGGGGCTGGAATGCAA 3' 17bp 220-236 193bp
Cyr61-R1 5' GTTCTTGGGGACACAGAGGA 3' 20bp 412-393
Lasp1 Lasp1-F 5' GTATCCCACGGAGAAGGTGA 3' 20bp 111-130 275bp
Lasp1-R 5' TGTCTGCCACTACGCTGAAA 3' 20bp 385-366
p53 p53-F 5' CCAGGGCAGCTACGGTTTC 3' 19bp 429-447 205bp
p53-R 5' CTCCGTCATGTGCTGTGACTG 3' 21bp 633-613
p21 p21-F 5' GACACCACTGGAGGGTGACT 3' 20bp 403-422 331bp
p21-R 5' GGATTAGGGCTTCCTCTTGG 3' 20bp 733-714
HPRT HPRT-F 5' GTAATGACCAGTCAACAGGGGAC 3' 23bp 402-424 177bp








Primer Sequence Length Position Product Size
Cyr61 Cyr61-F2 5' TCCCTGTTTTTGGAATGGAG 3' 20bp 657-676 240bp
Cyr61-R2 5' TGGTCTTGCTGCATTTCTTG 3' 20bp 896-877
Lasp1 Lasp1-F 5' GTATCCCACGGAGAAGGTGA 3' 20bp 111-130 275bp
Lasp1-R 5' TGTCTGCCACTACGCTGAAA 3' 20bp 385-366
14-3-3σ 14-3-3σ-F 5' ACCACAGTCCATGCCATCA 3' 19bp 56-74 279bp
14-3-3σ-R 5' TCCACCACCCTGTTGCTGTA 3' 20bp 334-315
GADD45 GADD45-F 5' ACGAGGACGACGACAGAGAT 3' 20bp 468-487 262bp
GADD45-R 5' TCCCGGCAAAAACAAATAAG 3' 20bp 729-710
GAPDH GAPDH-F 5' ACCACAGTCCATGCCATCA 3' 19bp 601-619 452bp
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2.4. Molecular cloning techniques 
2.4.1. General cloning protocol 
Insert preparation 
The Insert DNA was prepared by PCR using High Fidelity PCR Master Kit 
(Roche) in ABI GeneAmp PCR 9700 system following the manufacturer’s 
instructions. The template used was cDNA (for gene open reading frame, ORF) or 
genomic DNA (for gene promoter region) from certain tissue samples or cell lines. 
The primer sequences were listed in Table 2.3 and Table 2.6. The PCR products were 
monitored for quantity and quality by 1% agarose gel electrophoresis and were used 
directly or purified (PEG purification, gel purification, or by PCR purification kit) 
before any cloning reactions will be performed.  
 
Enzyme digestion 
The purified PCR products, the parental vectors or the intermediate vectors 
were digested at 37°C waterbath for 2 hours or overnight in a 30-100μl total reaction 
volume containing PCR products or 1-6μg of plasmids, 1/10 total volume of 10 × 
appropriate NEB buffer, 1μl 100 × BSA (10mg/ml), and 5-20U of specific restriction 
enzyme(s) (New England Biolabs, Ipswich, MA) (Table 2.4 and Table 2.7). The DNA 
fragments with expected sizes or linearized vectors were gel purified or 
phenol/chloroform purified.  
 
Ligation 
The ligation reaction was normally performed at 16°C waterbath with 
overnight incubation (for blunt ends) or at room temperature for 30 minutes (quick 
ligation for sticky ends) in a 20µl reaction containing 4µl of ligation buffer (5 ×), 1µl 
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The library efficiency® DH5αTM chemically competent E.coli (Invitrogen) 
was chosen for all transformations in this study. For each transformation, 50μ1 of 
competent cells were aliquoted into a sterile 5ml polypropylene falcon tube.  1~2μ1 of 
the cloning reaction product was added into the tube containing the competent cells 
and mixed gently by tapping followed by incubation on ice for 30 minutes. Heat-
shock the cells for 45-60 seconds at 42ºC waterbath without shaking before 
immediately transferred onto the ice. Add 250~450μ1 of room-temperature S.O.C. 
medium (Invitrogen) and shake the tube horizontally at 200rpm in a 37ºC incubator 
shaker for 30-60min to recover the cells. Spread 20~100μ1 from each transformation 
on a pre-warmed LB plate containing appropriate antibiotics (50μg/ml Kanamycin or 
100μg/ml Ampicillin) and incubate at 37ºC overnight.  
 
Screening for positive clones 
6~12 clones were initially screened by colony PCR using cloning primers or 
internal primers for specific genes. Then those clones showing positive PCR results 
with correct sizes were inoculated and propagated by culturing in LB medium 
containing appropriate antibiotics with overnight shaking incubation at 37°C. The 
bacteria cultures were then subjected to plasmid extraction using Wizard® Plus SV 
Minipreps DNA Purification System (Promega). The isolated plasmids were used for 
enzyme digestion and further confirmation by sequencing analysis.  
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Sequencing 
All sequencing analysis was performed by the Scientific Community 
Sequencing Facility (SCSF) at Genome Institute of Singapore. The primers used in 
sequencing the vectors constructed in this study were summarized below in Table 2.5 
and 2.8. 
 
2.4.2. Gateway cloning for gene ORF 
The GatewayTM Technology with lambda-based recombination system from 
Invitrogen was used in this study to clone Cyr61 and Lasp1 gene ORF into two 
pcDNA3.1 derived expression vectors, pcDNA-DEST40 with V5-epitope tag and 
pcDNA-DEST47 with fused green fluorescent protein (GFP). The pDONRTM221 
(Figure 2.1), pcDNA-DEST40 (Figure 2.2) and pcDNA-DEST47 vectors (Figure 2.3) 
were kindly provided by Dr. Chia-Lin Wei (Genome Institute of Singapore, 
Singapore). Briefly, the full ORF of Cyr61 or Lasp1 was amplified from normal liver 
cDNA and normal colon cDNA respectively by two rounds of PCR. A BP 
recombination reaction was then performed by using the attB-flanking Cyr61 or 
Lasp1 PCR product and the attP-containing pDONRTM221 vector to create a Cyr61-
221 and Lasp1-221 entry clone. Further LR recombination reactions between the attL-
containing entry clone and the attR-containing destination vectors (pcDNA-DEST40 
or pcDNA-DEST47) produced the final Cyr61 and Lasp1 expression constructs 
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Propagating Gateway vectors 
Due to the lethal effects of the CcdB protein, all Gateway vectors containing 
the ccdB gene must be propagated in an E.coli strain that is resistant to CcdB effects. 
Hence, the DB3.1 E.coli strain (Invitrogen) which contains a gyrase mutation 
(gyrA462) rendering it resistant to CcdB effects was used in propagating the Gateway 
vectors pDONR221, pcDNA-DEST40 and pcDNA-DEST47.  
 
Insert preparation 
Two rounds of PCR reactions were performed to amplify the Cyr61 or Lasp1 
ORF from normal liver total RNA and normal colon cDNA respectively. Primers 
were dissolved in DNase/RNase free H2O to give a final concentration of 10μM. The 
first set of primers were for gene-specific amplification and included 12 bases of the 
attB1 or attB2 site on the 5’ end of forward or reverse primer respectively (GW-
Cyr61-F, GW-Cyr61-R; GW-Lasp1-F, GW-Lasp1-R). The second set of adaptor-
primers to install the complete attB sequences were attB1 (forward) and attB2 
(reverse) (sequence listed in Table 2.3, with the attB-flanking sequences highlighted 
in blue).  
 
Table 2.3 Oligonucleotide primers used in Gateway cloning 
GENE Primer Name Primer Sequence Length
Cyr61 GW-Cyr61-F 5' AAAAAGCAGGCTCCACAATGAGCTCCCGCATC 3' 32bp
GW-Cyr61-R 5' AGAAAGCTGGGTAGTCCCTAAATTTGTGAATGTC 3' 34bp
Lasp1 GW-Lasp1-F 5' AAAAAGCAGGCTCAACCATGAACCCCAACTGC 3' 32bp
GW-Lasp1-R 5' AGAAAGCTGGGTAGATGGCCTCCACGTAGTTG 3' 32bp
att B1 5' GGGGACAAGTTTGTACAAAAAAGCAGGCT 3' 29bp
att B2 5' GGGGACCACTTTGTACAAGAAAGCTGGGT 3' 29bp
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The compositions of the RT-PCR reaction mixtures were as the following: 
For 1st PCR: 
2 × PCR Master Mix (Tube 1)                   12.5 μl 
Forward Primer (10μM) 0.5 μ1 
Reverse Primer (10μM)                             0.5 μ1 
Template cDNA                                        1 μ1 
H2O (PCR grade) (Tube 2)                        10.5 μl 
Total Volume                                             25 μl 
 
The PCR profile was as follows: 
1 cycle 94ºC 2min 
15~18 cycles 94ºC 15sec 
 53~58ºC 30sec 
 68ºC 1min per 1kb 
1 cycle 4ºC forever 
 
For 2nd PCR: 
2 × PCR Master Mix (Tube 1)                   25 μl 
attB1 (10μM) 2.5 μ1 
attB2 (10μM)                             2.5 μ1 
1st PCR product                                        10 μ1 
H2O (PCR grade) (Tube 2)                        10 μl 
Total Volume                                             50 μl 
 
The PCR profile was as follows: 
1 cycle 94ºC 2min 
5 cycles 94ºC 15sec 
 45ºC 30sec 
 68ºC 1min per 1kb 
20 cycles 94ºC 15sec 
 53~58ºC 30sec 
 68ºC 1min per 1kb 
1 cycle 68ºC 7min 
 4ºC forever 
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The 2nd PCR reaction product (2-3µl) was analyzed using agarose gel 
electrophoresis in order to verify the quality and yield. Then purification of the PCR 
product by PEG/MgCl2 solution was performed in order to remove attB primers and 
any primer-dimers. Firstly, add 150µl of TE buffer (pH 8.0) and 100µl of 30% PEG 
8000/30mM MgCl2 (Invitrogen) to a 50µl amplification reaction containing the attB-
PCR product. After thoroughly mixed by vortexing, the mixture was centrifuged 
immediately at 10,000 × g for 15 minutes at room temperature. Carefully remove the 
supernatant, dissolve the pellet in 50µl TE buffer (to concentration > 10ng/µl), and 
check the quality and quantity of the recovered attB-PCR product on an agarose gel 
again. 
 
BP recombination cloning 
BP recombination reaction was performed between PEG purified attB-PCR 
product and the Gateway donor vector pDONRTM221. The following components 
were added in order into a 0.2ml PCR tube at room temperature and mix. 
attB-PCR product 1-10 μl 
pDONRTM221 (150ng/µl) 2 μ1 
5  × BP ClonaseTM Reaction Buffer                          4 μ1 
TE Buffer (pH 8.0)                                        to 16 μ1 
 
Remove BP Clonase enzyme mix from -80ºC and thaw on ice (~2min). After 
vortexing twice briefly (~2 sec each time), add 4µl to each reaction and vortex briefly 
to mix well. Incubate the reaction at 25ºC in a PCR machine for 1 hour. Add 2μ1 of 
Proteinase K into each reaction and incubate at 37ºC waterbath for 10 minutes. Then 
1μl of the BP recombination reaction product was transformed into the library 
efficiency® DH5αTM chemically competent E.coli according to standard protocol as 
described in section 2.4.1. Spread 50~100μ1 from each transformation on a pre-
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warmed LB plate containing 50μg/ml of Kanamycin and incubate at 37ºC overnight. 
10~12 clones were initially screened by colony PCR using internal primers of Cyr61 
or Lasp1 gene. Then positive clones were inoculating and propagating by culturing in 
LB medium containing 50µg/ml of Kanamycin overnight for plasmid extraction. The 
isolated plasmids were used for enzyme digestion (Table 2.4) and further 
confirmation by sequencing (Table 2.5).  
 
LR recombination cloning 
LR recombination reaction was performed between attL-containing entry 
clone Cyr61-DONOR221 or Lasp1-DONOR221 and the attR-containing destination 
vector pcDNA-DEST40 or pcDNA-DEST47. The following components were added 
in order into a 0.2ml PCR tube at room temperature and mix. 
Cyr61-DONOR221/Lasp1-DONOR221 (50ng/µl) 6 μl 
pcDNA-DEST40/pcDNA-DEST47 (150ng/µl) 2 μ1 
5  × BP ClonaseTM Reaction Buffer                           4 μ1 
TE Buffer (pH 8.0)                                        4 μ1 
 
Similarly as in BP reaction, add 4µl of LR Clonase enzyme mix to each LR 
reaction and vortex briefly to mix well. Incubate the reaction at 25ºC in a PCR 
machine for 1 hour. Add 2μ1 of Proteinase K into each reaction and incubate at 37ºC 
waterbath for 10 minutes. Then 1μ1 of the LR recombination reaction product was 
transformed into the library efficiency® DH5αTM chemically competent E.coli 
according to standard protocol as described before. Spread 30~50μ1 from each 
transformation on a pre-warmed LB plate containing 100μg/ml of Ampicillin and 
incubate at 37ºC overnight. 4-6 colonies were picked for each transformation and 
inoculated into 3ml LB medium containing 100µg/ml of Ampicillin and cultured 
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overnight for plasmid extraction. The isolated plasmids were used for enzyme 
digestion (Table 2.4) and further confirmation by sequencing (Table 2.5).  
 
Propagating expression vectors 
The final constructed expression vectors (Cyr61-DEST40, Cyr61-DEST47, 
Lasp1-DEST40, and Lasp1-DEST47) were propagated in LB medium and extracted 
by using QIAfilterTM Plasmid Maxi kit (Qiagen) according to the manufacturer’s 
instructions.  
 
Table 2.4 Restriction enzymes used in Gateway cloning 
Construct Restriction Enzyme Buffer Expected Fragment Size
Cyr61-DONOR221 Nco I + EcoR V NEB3 749bp, 2943bp
Cyr61-DEST40 Pvu II NEB2 538bp, 1071bp, 1096bp, 3879bp
Cyr61-DEST47 Hind III NEB2 1291bp, 5931bp
Nco I NEB1~4 735bp, 814bp, 814bp, 1512bp, 3347bp
Lasp1-DONOR221 EcoR V + Sph I NEB2 815bp, 2517bp
Lasp1-DEST40 Nco I NEB1~4 487bp, 735bp, 1655bp, 3347bp
Lasp1-DEST47 Hind III NEB2 931bp, 5931bp
Nco I NEB1~4 490bp, 735bp, 778bp, 1512bp, 3347bp
 
 
Table 2.5 Oligonucleotide primers used in sequencing Gateway vectors 
Primer Name Primer Sequence Length Vector Origin
M13-forward 5' GTAAAACGACGGCCAG 3' 16bp pDONR221
M13-reverse 5' CAGGAAACAGCTATGAC 3' 17bp pDONR221
T7-promoter 5' TAATACGACTCACTATAGGG 3' 20bp pcDNA-DEST40, 
pcDNA-DEST47










Figure 2.1 Map of the pDONRTM221 vector. The map shows the cloning frames 
and main features of the vector. The att sites and M13 forward and reverse priming 










                                
                
Figure 2.2 Map of the pcDNA-DEST40 vector. The map shows the features of the 
recombination region and all basic elements of the vector. The V5 epitope and 6 × His 














Figure 2.3 Map of the pcDNA-DEST47 vector. The map shows the features of the 
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2.4.3. pGL3- cloning for gene promoter region 
The pGL3 luciferase reporter vector system (Promega) provides a basis for the 
quantitative analysis of factors that potentially regulate mammalian gene expression. 
In this study, pGL3-Basic vector was chosen to clone the DNA of Lasp1 promoter 
region for luciferase assay in order to investigate the role of p53 in regulating Lasp1 
promoter activity. Briefly, part of the Lasp1 promoter DNA was amplified from 
genomic DNA extracted from HepG2 cells and cloned into pCR®-TOPO-BluntII 
(Invitrogen) (Figure 2.4) as an intermediate vector. Then the Lasp1-PR was sub-
cloned into the pGL3-Basic vector (Figure 2.5).  
 
Genomic DNA extraction 
Genomic DNA was extracted from HepG2 cells using DNeasy Mini Kit 
(Qiagen) according to manufacturer’s instructions and quantified by Nanodrop.  
 
Insert preparation 
To prepare the insert, PCR reaction was performed by using HepG2 genomic 
DNA as template. In order to efficiently amplify the GC-rich Lasp1 promoter region, 
the PCR grade DMSO (5%) was included in the PCR reaction. The primer sequences 
were listed in Table 2.6.  
The compositions of the PCR reaction mixtures were as the following: 
2 × PCR Master Mix (Tube 1)                   12.5 μl 
Lasp1-PR-F (10μM) 1 μ1 
Lasp1-PR-R (10μM)                             1 μ1 
Total DNA template (50ng/µl)                           2 μ1 
H2O (PCR grade) (Tube 2)                        7.25 μl 
DMSO (PCR grade) 1.25 μl     (5%) 
Total Volume                                             25 μl 
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The PCR profile was as follows: 
1 cycle 94ºC 2min 
40 cycles 94ºC 15sec 
 53ºC 45sec 
 72ºC 2.5min 
1 cycle 72ºC 20min 
 4ºC forever 
 
The PCR products (5μl) were separated in a 1.0% agarose gel and visualized 
under UV transilluminator for quality and quantity control. The PCR product with 
expected size (~1.9kb) was purified by QIAquick PCR purification kit (Qiagen) 
according to the manufacturer’s instruction before used for the following TOPO-Blunt 
cloning.   
 
TOPO-Blunt cloning 
According to the guide of pCR®-Blunt II-TOPO cloning kit (Invitrogen), 1μl 
salt solution, 4μl purified PCR product and 1μl linearized pCR®-Blunt II-TOPO 
vector (Figure 2.4) were mixed up gently in a total 6μl reaction volume in a 0.2ml 
PCR tube and incubate at room temperature for at least 5 minutes. Then the reaction 
product was transformed into the library efficiency® DH5αTM chemically competent 
E.coli according to standard protocol. Spread 50~100μ1 from the transformation on a 
pre-warmed LB plate containing 50μg/ml of Kanamycin and incubate at 37ºC 
overnight. To analyze positive clones, around 10 colonies were initially screened by 
colony PCR using the original primer set for PCR. Then positive clones were 
inoculated and propagated by culturing in LB medium containing 50µg/ml of 
Kanamycin overnight for plasmid extraction. The isolated plasmids were used for 
enzyme digestion (Table 2.7) and further confirmation by sequencing (Table 2.8). The 
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constructed plasmid was defined as TOPO-Lasp1-PR, which was then propagated in 
LB medium and extracted using QIAfilterTM Plasmid Maxi kit.  
 
Sub-clone from TOPO-Lasp1-PR to pGL3-Basic vector 
15µg of TOPO-Lasp1-PR vector (1µg/µl) was digested by Kpn I and EcoR V 
in a total 100µl reaction volume at 37°C overnight and the DNA fragment with 
expected size (~2kb) was cut out and purified using a QIAquick Gel Extraction Kit 
(Qiagen) according to the manufacturer’s instruction. 20µl of DNase/RNase free H2O 
was used to re-dissolve the Lasp1-PR DNA fragment carrying the Kpn I and EcoR V 
overhang. 6µg of pGL3-Basic vector (Figure 2.5) was first digested by Kpn I to 
generate a Kpn I sticky end, and the digested vector was purified by 
phenol/chloroform followed by ethanol purification. Then the linearized vector was 
digested by Smal I to generate a blunt end which can be ligated to the EcoR V end. 
The digested vector was treated with 2µl of CIP (Calf Intestine Phosphatase) for 1 
hour before purified by phenol/chloroform. The ethanol precipitated DNA was re-
dissolved in 25µl DNase/RNase free H2O. The ligation reaction was then performed 
at 16°C waterbath with overnight incubation in a 20µl reaction containing 4µl of 
ligation buffer (5 ×), 1µl of linearized vector DNA, 14µl of insert DNA, and 1µl of T4 
DNA ligase. Then 2µl of the ligation reaction product was transformed into the 
library efficiency® DH5αTM chemically competent E.coli according to standard 
protocol. Spread 100μ1 recovered culture on a pre-warmed LB plate containing 
100μg/ml of Ampicillin and incubate at 37ºC overnight. 10-12 colonies were 
inoculated and propagated by culturing in LB medium containing 100µg/ml of 
Ampicillin overnight for plasmid extraction. The isolated plasmids were used for 
enzyme digestion (Table 2.7) and further confirmation by sequencing using primers 
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listed in Table 2.8. The constructed positive clone was defined as pGL3-Lasp1-PR, 
which was then propagated and prepared by QIAfilterTM Plasmid Maxi kit.   
 
pGL3-Lasp1-PR deletion construct cloning 
11 forward primers plus 1 common reverse primer (sequence listed in Table 
2.6, with Kpn I or Hind III restriction sites highlighted as bold) were designed to 
produce a series of deletion constructs carrying different sizes of Lasp1 promoter 
region. PCR amplification using pGL3-Lasp1-PR as template DNA was performed to 
generate DNA fragment of Lasp1 promoter region with different sizes carrying Kpn I 
and Hind III restriction sites. After purified by QIAquick PCR purification kit 
(Qiagen), the PCR product was cloned into pCR®4-TOPO® vector (Figure 2.6) and 
transformed into the library efficiency® DH5αTM chemically competent E.coli 
according to standard protocol. Spread 100μ1 recovered culture on a pre-warmed LB 
plate containing 50μg/ml of Kanamycin and incubate at 37ºC overnight. Positive 
clones were confirmed by double enzymatic digestion (Kpn I + Hind III) and 
sequencing.  
Both pGL3-Basic vector and those positive clones were digested by Kpn I and 
Hind III. The linearized vector was purified by phenol/chloroform and precipitated in 
ethanol, while the DNA fragments with expected sizes (listed in Table 2.6) were cut 
out and purified by QIAquick gel purification kit. The ligation reaction was 
performed at 16°C waterbath with overnight incubation in a 20µl reaction containing 
4µl of ligation buffer (5 ×), 1µl of linearized vector DNA, 14µl of insert DNA, and 
1µl of T4 DNA ligase. Then 2µl of the ligation reaction product was transformed into 
the library efficiency® DH5αTM chemically competent E.coli according to standard 
protocol. Spread 100μ1 recovered culture on a pre-warmed LB plate containing 
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100μg/ml of Ampicillin and incubate at 37ºC overnight. To select positive clones, 6 
colonies for each deletion construct were picked for plasmid extraction, and the 
isolated plasmids were used for enzyme digestion (Table 2.7) and further 
confirmation by sequencing analysis (Table 2.8). The positive clones with correct 
sequences were designated as pGL3-Lasp1-PR-DelA~K as listed in Table 2.7. 
 
 
Table 2.6 Oligonucleotide primers used in pGL3- cloning 
Primer Name Primer Sequence Length Product Size
Lasp1-PR-F 5' TAAAACTGGTTCCTCCTGGGTTTTGC 3' 26bp 1946bp
Lasp1-PR-R 5’GTTCCGAGAAAAGCTGGGGCGGGGAC 3’ 26bp
Lasp1-PR-1561F (DelA) 5' GGTACCACGCAGCCAGCAGATACTTG 3' 26bp 1690bp
Lasp1-PR-1273F (DelB) 5' GGTACCGGATGAACACAGCACGTCCA 3' 26bp 1402bp
Lasp1-PR-1087F (DelC) 5' GGTACCTCTGACCCATCTGAGGCT 3' 24bp 1216bp
Lasp1-PR-952F (DelD) 5' GGTACCGGTTGAAAAATGAGGAAGATA 3' 27bp 1081bp
Lasp1-PR-790F (DelE) 5' GGTACCGATCTGCAGTCAAATGCTC 3' 25bp 919bp
Lasp1-PR-544F (DelF) 5' GGTACCGCAGGGTCCAAGAGGGAGG 3' 25bp 673bp
Lasp1-PR-446F (DelG) 5' GGTACCCGGTCCGCAGATTCATGCC 3' 25bp 575bp
Lasp1-PR-255F (DelH) 5' GGTACCCAGTCAGCCTGAGAGCGCT 3' 25bp 384bp
Lasp1-PR-97F (DelI) 5' GGTACCCCCCGCTGTGTTTATTAGG 3' 25bp 226bp
Lasp1-PR-27F (DelJ) 5' GGTACCGCTGCCTGTGTAGTTGCAGC 3' 26bp 156bp
Lasp1-PR+10F (DelK) 5' GGTACCCAGCTCGCCTCGGGGAA 3' 23bp 120bp
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Table 2.7 Restriction enzymes used in pGL3- cloning 
Construct Restriction Enzyme Buffer Expected Fragment Size
TOPO-Lasp1-PR Kpn I + EcoR V NEB2 3488bp, 1977bp
pGL3-Basic Kpn I NEB1 linearized vector, 4818bp
pGL3-Basic-Kpn I Sma I NEB4 4795bp, 23bp
pGL3-Lasp1-PR Kpn I + Hind III NEB2 4770bp, 2002bp
pGL3-Lasp1-PR-Del A Kpn I + Hind III NEB2 4770bp, 1690bp
pGL3-Lasp1-PR-Del B Kpn I + Hind III NEB2 4770bp, 1402bp
pGL3-Lasp1-PR-Del C Kpn I + Hind III NEB2 4770bp, 1216bp
pGL3-Lasp1-PR-Del D Kpn I + Hind III NEB2 4770bp, 1081bp
pGL3-Lasp1-PR-Del E Kpn I + Hind III NEB2 4770bp, 919bp
pGL3-Lasp1-PR-Del F Kpn I + Hind III NEB2 4770bp, 673bp
pGL3-Lasp1-PR-Del G Kpn I + Hind III NEB2 4770bp, 575bp
pGL3-Lasp1-PR-Del H Kpn I + Hind III NEB2 4770bp, 384bp
pGL3-Lasp1-PR-Del I Kpn I + Hind III NEB2 4770bp, 226bp
pGL3-Lasp1-PR-Del J Kpn I + Hind III NEB2 4770bp, 156bp
pGL3-Lasp1-PR-Del K Kpn I + Hind III NEB2 4770bp, 120bp
 
 
Table 2.8 Oligonucleotide primers used in sequencing TOPO- and pGL3- 
Vectors 
Primer Name Primer Sequence Length Vector Origin
M13-forward 5' GTAAAACGACGGCCAG 3' 16bp pCR-BluntII-TOPO, 
pCR4-TOPO
M13-reverse 5' CAGGAAACAGCTATGAC 3' 17bp pCR-BluntII-TOPO, 
pCR4-TOPO
RVprimer3  5’ CTAGCAAAATAGGCTGTCCC 3’ 20bp pGL3-Basic
GLprimer2 5’ CTTTATGTTTTTGGCGTCTTCCA 3’ 23bp pGL3-Basic













Figure 2.4 Map of the pCR®-Blunt II-TOPO® vector. The map shows the features 
of pCR®-Blunt II-TOPO® and the sequence surrounding the TOPO® cloning site. 
Restriction sites are labeled to indicate the actual cleavage site. The arrows indicate 















Figure 2.5 Map of the pGL3-Basic vector. The map shows the main features of this 
vector and the restriction enzyme sites surrounding the multiple cloning sites. The 



















Figure 2.6 Map of the pCR®4-TOPO® vector. The map shows the features of 
pCR®4-TOPO® and the sequence surrounding the TOPO® cloning sites. Restriction 
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2.5. Transfection 
Transfection of either plasmids or siRNAs into human HCC cell lines or 
human colon cancer cell lines was mediated by Lipofectamine2000 reagent 
(Invitrogen). The optimal cell seeding amount for transfection of different types of 
DNA (plasmid/siRNA) or different cell lines or for different experimental purpose 
was optimized by checking the overnight confluence and listed below in Table 2.9.  
 

































2.5.1. Plasmid transfection 
Transient transfection of the expression plasmids (4-6μg/well) into HCC or 
colon cancer cells plated in 6-well plates with 80-90% confluence was mediated by 
Lipofectamine 2000 reagents according to the manufacturer’s instructions.  
As the transient transfection efficiency of HepG2 cells is usually low, stable-
transfected cells were established from HepG2 cells 48 hours after transfection with 
Cyr61-DEST40/V5 or Lasp1-DEST40/V5. The cells were trypsinized and replated in 
DMEM/10% FBS supplemented with 800μg/ml geneticin (G418) (Invitrogen). Two 
to three weeks later, around 20 well-isolated cell colonies were picked and re-seeded 
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in 96-well plates. The clones were expanded to 24-well plates and the stable 
expression of the V5 fusion proteins were screened by Western blot. Two G418-
resistant stable clones for each gene (HepG2-Cyr61-1, HepG2-Cyr61-2; HepG2-
Lasp1-1, HepG2-Lasp1-2) were selected. One G418-resistant clone isolated from 
empty vector pcDNA3.1 transfected cells was designated as HepG2-Neo control. 
These stable clones were expanded, freezed and stored in liquid nitrogen until use.  
For luciferase assay, Hep3B or HCT116 (p53-/-) cells were seeded in 96-well 
Flat Bottom Black Polystyrene Plates (Corning Inc. Lindfield, Australia) with 50-60% 
overnight confluence. The pGL3- constructs were co-transfected with PRL-null and 
p53, p53-R175H or pcDNA3.1 control plasmid by using Lipofectamine 2000 reagents. 
The detailed protocol will be described in 2.13.  
 
2.5.2. siRNA transfection 
The siRNA oligos targeting Cyr61 (#1, ID 10104; #2, ID 10192) and Lasp1 
(#1, ID 17398; #2, ID 17494) and Negative Control siRNA (Catalog No: 4611) that 
does not target any human gene product were synthesized by Ambion, Inc. (Austin, 
TX). The siRNA targeting TP53 (sip53, Catalog No: M-003329-01) and its 
corresponding control siRNA (siControl) were purchased from Dharmacon (Lafayette, 
CO). The oligos were re-constituted in RNase free H2O (supplied by Ambion) or 
buffer (supplied by Dharmacon) to make a 100μM stock. 
Transient transfection of siRNA (40-100nM) into HepG2, Hep3B or HCT116 
(p53+/+) cells seeded in 6-well plates with 30-40% (Cyr61 and Lasp1 siRNA) or 80-
90% (p53 siRNA) overnight confluence was mediated by Lipofectamine 2000 
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2.6. Western blot 
2.6.1. SDS-polyacrylamide gel electrophoresis (SDS-PAGE)  
Extraction of protein lysate 
Cell pellets of HCC cell lines including HA22T, Huh-1, Huh-4, Tong, 
SNU182, SNU449, SNU475, Huh-6, Mahlavu, and SK-Hep1 were kindly provided 
by the WHO Immunology Center, (Singapore). The experimental cells or cell pellets 
were washed twice with PBS and then lysed in NP-40 lysis buffer (Appendix I) 
containing 1 × complete mini protease inhibitor mixture (Roche Applied Science) and 
1mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich, St. Louis, MO) on ice 
for 30min. The lysates were centrifuged at 13,200 rpm for 15 min at 4°C, and the 
protein concentration was measured using a Bradford Protein Assay Kit (Bio-Rad). 
Briefly, standard bovine serum albumin (BSA) was diluted to give 4 different 
concentrations ranging from 500μg/ml to 4000μg/ml. 1μl of each of standards or 
samples was mixed with 1ml of diluted dye reagent (1 × ) in separate cuvette. The 
mixture was incubated at room temperature for at least 5min (less than 30min) prior to 
measuring the absorbance at 595nm. A standard calibration curve was constructed by 
plotting absorbance versus concentration of the BSA standards and the concentration 
of samples was then calculated according to the calibration curve.  
 
Preparation of SDS-polyacrylamide gels 
Separating gels with acrylamide concentrations of 7.5%, 10%, 12.5% were 
used in this study, while 5% of stacking gels was consistently applied. Gels were cast 
using the Mini-PROTEAN electrophoresis cell apparatus (Bio-Rad). Gel Formulas 
were listed in Table 2.10. The recipes were sufficient for the preparation of 2 slab 
mini-gels (1.5mm thick and 100 × 70mm2) and the components were mixed in the 
order shown. Polymerization began as soon as 10% APS and TEMED added.  
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Sample preparation and electrophoresis 
While the stacking gel was polymerizing, the protein samples were mixed with 
equal amount of 2 × SDS-PAGE sample buffer (Appendix I) and heated at 100°C for 
6 minutes. The ECL DualVue Western Blotting Marker (Amersham Pharmacia 
Biotech, Piscataway, NJ) was used as a marker for the transfer efficiency and an 
indication of the protein molecular weight when exposed to film in the following 
Western blot. Up to 30μl (20-30μg) of each sample and sample buffer mixture was 
loaded into the bottom of the wells. Electrophoresis was carried out in the presence of 
1 × Tris-Glycine SDS-PAGE running buffer (Appendix I) under the constant current 
of 20mA per gel. The running was stopped when the dye front reached the bottom of 
the separating gel. After removed quickly from the electrophoresis apparatus, the gel 
could be used to establish a Western blot.  
 
Table 2.10 SDS-PAGE gel recipes 
Separating gels 7.5% 10% 12.5%
H2O 9.7ml 8.0
30% acrylamide mix (Bio-Rad) 5.0ml 6.6ml 8.3ml
1.5M Tris (pH8.8) (Bio-Rad) 5.0ml 5.0ml 5.0ml
10% SDS 200μl 200μl 200μl
10% APS  (Bio-Rad) 100μl 100μl 100μl
TEMED (Bio-Rad) 20μl 20μl 20μl
Total (for 2 gels) 20ml 20ml 20ml
Stacking gels 5% 5% 5%
H2O 2.84ml 2.84ml 2.84ml
30% acrylamide mix (Bio-Rad) 0.83ml 0.83ml 0.83ml
0.5M Tris (pH6.8) (Bio-Rad) 1.25ml 1.25ml 1.25ml
10% SDS 50μl 50μl 50μl
10% APS  (Bio-Rad) 25μl 25μl 25μl
TEMED (Bio-Rad) 5μl 5μl 5μl
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2.6.2. Western blot  
About 20~30μg of protein was separated on 7.5%-12.5% SDS-polyacrylamide 
gel electrophoresis, and transferred to Hybond PVDF membranes (Amersham 
Pharmacia) by using a semi-dry Transblot apparatus (Bio-Rad). Briefly, the gel was 
equilibrated in 1 × Transfer buffer (Appendix I) and meanwhile the PVDF membrane 
cut to gel size was re-activated in methanol before transferred into the 1 × Transfer 
buffer in a separate container.  A sandwich was assembled by putting a sheet of extra 
thick filter paper (100 × 70mm, Bio-Rad) pre-soaked in 1 × Transfer buffer onto the 
platinum anode, followed by the pre-wetted PVDF membrane, the equilibrated gel, 
and another sheet of soaked filter paper. Air bubbles should be carefully removed 
from between each layer. After the cathode and the safety cover were placed onto the 
stack, the electrophoretic transfer was performed at a constant voltage of 20V for 30-
60 minutes at room temperature.  
Antibodies against V5-tag (mouse monoclonal) (Invitrogen), Cyr61 (42kDa) 
(rabbit polyclonal), p53 (53kDa) (mouse monoclonal, DO-1), p21 (21kDa) (rabbit 
polyclonal) (Santa Cruz Biotechnology, Santa Cruz, CA), Lasp1 (30kDa) (rabbit 
polyclonal) (Chemicon International, Temecula, CA), zyxin (82kDa) (mouse 
monoclonal) (Invitrogen), VASP (50kDa) (mouse monoclonal) (BD Biosciences), 
paxillin (68kDa) (mouse monoclonal) (Millipore-Upstate) were used as primary 
antibodies in this study for protein detection, followed by reacting to appropriate 
HRP-conjugated Goat-anti-Mouse or Donkey-anti-Rabbit secondary antibodies (Dako, 
Denmark). Equal loading of protein samples was verified with antibodies to α-tubulin 
(50kDa) (mouse monoclonal) (Sigma-Aldrich) or β-actin (42kDa) (mouse monoclonal) 
(Chemicon International). The membranes were extensively washed with TBST 
buffer (Appendix I), and the immunoreactive signals were visualized by reacting with 
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enhanced chemiluminescence (ECL PlusTM) reagents followed by exposure to the 
Hyperfilm (Amersham Pharmacia). 
 
2.7. WST-1 cell proliferation assay      
Cell proliferation rate in monolayer was analyzed by a modified MTT assay 
(WST-1 reagent, Roche Applied Science) according to the manufacturer’s protocol. 
Briefly, HepG2, Hep3B, Huh-7 or PLC/PRF/5 cells seeded in 6-well plates were 
transiently transfected with either plasmid or siRNA. 24 hours after transfection, the 
cells were trypsinized in 0.05% trypsin/EDTA (Invitrogen) and replated into 96-well 
plates at the concentration of 1-5 × 104 cells/well in 100μl DMEM/10%FBS in 
triplicates and cultured for additional 3-5 days. 10μl of WST-1 reagent was then 
added into each well at different time points followed by incubation at 37°C for 40 
min. The absorbance was measured by a multiscan plate reader at 450nm with 690nm 
reference (Thermo Labsystems, Cambridge, UK). For each different cell line, a 
standard curve was constructed by plotting absorbance versus the number of cells 
plating in single well (range from 1 × 104 to 100 × 104 per well) and the number of the 
experimental cells cultured in the plate was then calculated according to the standard 
curve. The growth rate of stably transfected HepG2 cells cultured up to 6 days in 96-
well plates was analyzed in a similar manner.  
    
2.8. Soft agar assay 
For the anchorage-independent colony formation assay, HepG2, Huh-7 or 
PLC/PRF/5 cells were trypsinized 24 hours after transfection with either expression 
plasmid or siRNA, and 0.5 - 1 × 104 cells re-suspended in 0.25ml of 0.35% agar 
dissolved in DMEM/10%FBS were plated in 24-well plate in triplicates overlying a 
0.7% agar bottom layer and cultured at 37°C with 5% CO2. Fresh medium was added 
 
Materials and Methods 73
every 4 to 5 days. Three weeks later, the medium was gently removed and the top 
layer of the culture was stained with 1mg/ml p-iodonitrotetrazolium (Sigma-Aldrich). 
The colonies were visualized and photographed under an MZFL3 stereomicroscope 
(Leica Microsystems, Heidelberg, Germany), and the colonies > 100μm in diameter 
were then counted and analyzed using the Leica QWin imaging software.  
 
2.9. Cell adhesion, migration and invasion assay 
2.9.1. Cell adhesion assay 
Cell adhesion activity was determined by using the CytoMatrixTM screening 
kit (Chemicon International) according to the manufacturer’s instruction with 
modifications. Briefly, HepG2 or Hep3B cells transfected with equal amount of 
expression plasmids (4μg/well for 6-well plates) or siRNA oligos (40nM) were 
harvested with 0.05% trypsin/EDTA 48 hours after transfection. Cells were washed 
once with PBS and resuspended in serum-free medium (DMEM/0.5%FBS) at 2 × 106 
cells/ml. 100μl of the cell suspension was added into 96-well plates individually pre-
coated with fibronectin, vitronectin, laminin, collagen I, and collagen IV, each in 
triplicates. After 1 hour incubation at 37°C in a CO2 incubator, the wells were gently 
washed 3 times with PBS containing Ca++/Mg++ (Appendix I), and 110μl of DMEM 
medium containing 10μl of WST-1 reagent was added, followed by additional 40min 
incubation at 37°C. The number of adhesive cells in the wells was determined by 
measuring the absorbance at 450nm with 690nm reference.  
 
2.9.2. Cell migration and invasion assay 
Cell migration and invasion activities were analyzed using 24-well 
fluorimetric migration kit (ECM509) and invasion kit (ECM554) respectively based 
on the Boyden chamber principle according to the manufacturer’s protocols 
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(Chemicon International). The migration assay was performed in microporous 
membrane inserts with an 8μm pore size, while the invasion assay utilized same 
inserts coated with an extra layer of ECMatrixTM, a reconstituted basement membrane 
matrix of proteins derived from the Engelbreth Holm-Swarm (EHS) mouse tumor. 
Briefly, 24 hours after transfection (transient transfection) or seeding (stable 
transfection), cells were starved in serum-free medium (DMEM/0.5%FBS) for 
another 24 hours. Both migration and invasion inserts need to be pre-warmed to room 
temperature and the invasion inserts were re-hydrated with 300μl serum-free medium. 
Then 0.5 - 6.0 × 105 of cells resuspended in 250μl DMEM/0.5%FBS were added into 
the migration or invasion inserts which were loaded in wells of 24-well plate 
containing 500μl of DMEM/10%FBS. After cultured in 37°C with 5% CO2 for 16-18 
hours, the migrated or invaded cells towards the DMEM/10%FBS to the bottom of the 
insert membrane were dissociated from the membrane by incubating with Cell 
Detachment Buffer and subsequently lysed and detected by CyQuant GR® dye 
staining. The fluorescent intensity was measured in a fluorescent microplate reader 
(Tecan, Mannedorf, Switzerland) using 480/520nm filter set.  
 
2.10. 5-Fluorouracil (5-FU) and UV treatment 
2.10.1. 5-FU and UV treatment for cell cycle analysis 
In order to study the role of Cyr61 in cell cycle regulation, stable cell lines 
HepG2-Cyr61-1, HepG2-Cyr61-2 and HepG2-Neo controls were plated in 6-well 
plates in DMEM/10%FBS/G418 (800μg/ml). Upon reaching 50-60% confluences, the 
cells were treated with 5-FU (50μg/ml, Sigma-Aldrich) or UV irradiation (20J/m2) 
and cultured for additional 24 hours. Then cells were ready for harvest and the 
following PI staining for flow cytometry analysis.  
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2.10.2. 5-FU and UV treatment for Cyr61 expression study 
To investigate the endogenous expression of Cyr61 upon genotoxic stress 
induction, the HCC cell lines HepG2 and Hep3B were plated in 6-well plates for 
overnight incubation. At 50-60% confluences, the cells were treated with 5-FU 
(50μg/ml) or UV irradiation (20J/m2). At different time points up to 48 hours, cells 
were harvested for total RNA and lysate collection separately. These total RNA and 
lysates were used for following RT-PCR or Western blot analysis. To further confirm 
the observation, the colon cancer cell lines HCT116 and HCT116 (p53-/-) were also 
treated with 5-FU (50μg/ml) and the cell lysates were collected for Western blot 
analysis. 
 
2.10.3. 5-FU treatment for Lasp1 expression regulation study 
To examine the role of p53 in transcriptionally suppress Lasp1, the HCC cell 
lines HepG2, Hep3B and the colon cancer cell lines HCT116 and HCT116 (p53-/-) 
were treated with 5-FU (50μg/ml) to induce the activation and accumulation of 
endogenous p53. Total RNA and cell lysates were collected for time course analysis 
of Lasp1 mRNA and protein expression by real-time quantitative RT-PCR and 
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2.11. Flow cytometry 
Cell cycle progression was analyzed in stable cell lines HepG2-Cyr61-1, 
HepG2-Cyr61-2 and HepG2-Neo controls at 60-70% confluences either untreated or 
treated with 5-FU or UV irradiation. The cells were harvested by trypsinization using 
0.05% trypsin/EDTA to obtain single-cell suspension and the cells were fixed in ice-
cold 70% ethanol overnight. After wash with ice-cold PBS for twice, the cells were 
treated with RNase A (100μg/ml) for 5min and then stained with propidium iodide 
(50μg/ml) (Sigma-Aldrich) for 60min in dark at room temperature. The DNA content 
of the stained cells was analyzed using FACSCalibur and CellQuest software (BD 
Biosciences).  
 
2.12. Chromatin immunoprecipitation (ChIP) 
ChIP assays using HCT116 or HepG2 cells were carried out as described by 
Weinmann et al. (Weinmann et al. 2001; Wells and Farnham 2002). Briefly, at 50-
60% confluence, cells seeded in 500cm2 cell culture dishes (Corning Inc.) were 
treated with 5-FU (375μM). Six hours later, cells were cross-linked with 1% 
formaldehyde (final concentration) (Sigma-Aldrich) for 10min at room temperature. 
Formaldehyde was inactivated by addition of 125mM glycine. After wash with ice-
cold PBS, cells were harvested and lysed in FA cell lysis buffer (Appendix I) 
followed by sonication to shear the chromatin-DNA. Then chromatin extracts 
containing DNA fragments of average size of 500bp were immuno-precipitated using 
anti-p53 DO1 monoclonal antibody (Santa Cruz Biotechnology) and Dynabead® 
Protein G (Invitrogen). After extensive wash of the immuno-precipitated complex in a 
series of washing buffers (0.1% SDS FA lysis buffer, NP-40/LiCl buffer), the DNA-
protein complex was eluted in ChIP elution buffer (Appendix I). Finally, 2.5M 
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glycine was added to de-crosslink the protein from DNA. After purification by 
Phenol/Chlorofom and ethanol precipitation, the purified ChIP-DNA dissolved in TE 
buffer was ready as the template for ChIP-qPCR. All ChIP-qPCR primers were 
designed by Oligo 6 software and the sequences were listed in Table 2.11. The 
analyses for the ChIP-qPCR were performed using ABI PRISM 7900 Sequence 
Detection System and SYBR Green Master Mix. Threshold cycles (Ct) were 
determined for both immuno-precipitated DNA and a known amount of DNA from 
the input sample for different primer pairs. Relative occupancy values (also known as 
fold enrichments) were calculated by determining the immuno-precipitation efficiency 
(ratios of the amount of immuno-precipitated DNA to that of the input sample) and 
normalized to the level observed at a control region, which was defined as 1.0.  
 





Primer Sequence Length Position
Product 
Size
ChIP-L-F1 ATTAATAGTCAAGGATGAACACAGCACGTC 30bp -1285~-1256 213bp
ChIP-L-R1 CTCAGATGGGTCAGACAGTTCGAGGTG 27bp -1073~-1099
ChIP-L-F2 CCTCCACCCCCAAAAGGAACGCCAAGTTGA 30bp -1179~-1150 156bp
ChIP-L-R2 CATTACTCGCGCCAGAGGTGTAGGGATTTC 30bp -1024~-1053
ChIP-L-F3 GAAGGTGCACTGCAGGGGCTCGAGAG 26bp -598~-573 216bp
ChIP-L-R3 CCTGAACGCTGGAACTGATTCACCGCATTC 30bp -383~-412
ChIP-L-F4 GGAAAGGGTGTGGGCCGGAAGAGAGCTAAG  30bp -501~-472 169bp
ChIP-L-R4 GCGGGAGGCGGGCTAACCCCTCAAG 25bp -333~-357
ChIP-L-F5 CTGTGTTTATTAGGGGAAGGAGGGCGGAGG 30bp -92~-63 189bp
ChIP-L-R5 CCGGGCGCAGTTGGGGTTCATGGTTCCGAG 30bp +96~+67
ChIP-L-F6 TGTTTATTAGGGGAAGGAGGGCGGAGG 27bp -89~-63 158bp
ChIP-L-R6 CGGGCGCAGTTGGGGTTCATGGTTCCGA 27bp +68~+42
ChIP-L-F7 AGGAGATCTGGGGCGAGGCGGGAAGTCCAC 30bp +315~+344 98bp
ChIP-L-R7 TCCCCCAACACACCCCGGCGCCTGAC 26bp +412~+387
ChIP-L-F8   GGCTGGGGGGCCCTGCAAAACCGTC    25bp +581~+605 153bp
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2.13. Luciferase assay 
2.13.1. Study of the role of p53 in regulating Lasp1 promoter 
HCT116 (p53-/-) or Hep3B cells were transfected by Lipofectamine2000 
reagent (Invitrogen) according to the manufacturer’s instructions. Transfections were 
done in triplicates. Briefly, exponentially growing cells were plated at a density of 
30000/well for HCT116 (p53-/-) or 9000/well for Hep3B in 150μl DMEM/10%FBS 
in 96-well Flat Bottom Black Polystyrene Plates (Corning Inc.). Cells were cultured 
overnight before transfection. For each well, 100ng of luciferase reporter construct 
pGL3-Lasp1-PR or positive control vector pGL3-PTPRM2-PR were co-transfected 
with increasing doses (2, 10, 25 and 50ng) of wild-type (pCMV-p53) or mutant p53 
(pCMV-p53-R175H) expression vectors (kindly provided by Dr. Bert Vogelstein), 
together with 1ng of Renilla luciferase control vector PRL-null (Promega). The total 
amount of transfected DNA in each well was kept constant by adding empty vector 
pcDNA3.1 plasmid. 36 hours after transfection, the culture medium was discarded 
and the cells were washed with PBS twice. Then the reporter Firefly luciferase 
activity was measured using the Dual-Luciferase® Reporter Assay System kit 
(Promega). Firstly, cells were lysed in passive lysis buffer provided by the kit at room 
temperature for 30min with gentle shaking at 400rpm. Next, the luciferase activity 
was measured in Dual-Injector Luminometer System (Centro LB 960, Berthold 
Technologies, Germany) with pre-defined program. To correct for variations in 
transfection efficiency, the reporter Firefly luciferase activity was normalized to 
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2.13.2. Localization study of the important regulators in Lasp1 promoter 
The deletion constructs were constructed as described in section 2.4.3. As in 
section 2.13.1, exponentially growing HCT116 (p53-/-) or Hep3B cells plated in 96-
well Flat Bottom Black Polystyrene Plates were cultured overnight before transfection. 
For each well, 100ng of luciferase reporter constructs (pGL3-Lasp1-PR; pGL3-Lasp1-
PR-DelA, B, C, D, E, F, G, H, I, J, K) were co-transfected with 1ng of Renilla 
luciferase control vector PRL-null. 36 hours post transfection, the reporter Firefly 
luciferase activity was measured by the Dual-luciferase Reporter Assay System kit 
with normalization to the Renilla luciferase activity (F/R ratio) to correct for variation 
in transfection efficiency. 
 
2.13.3. Localization study of the p53 response element in Lasp1 promoter 
In order to define the genuine p53 response element in Lasp1 promoter, all 
pGL3- constructs containing fragments of different sizes of Lasp1 promoter region 
plus the pGL3-Basic vector (100ng/well) were co-transfected with p53 wild-type 
expression vector (pCMV-p53) or control vector (pcDNA3.1) (10ng/well) into 
HCT116 (p53-/-) or Hep3B cells plated in 96-well plate. 36 hours post transfection, 
the reporter Firefly luciferase activity was measured by the Dual-luciferase Reporter 
Assay System kit as described above. The response to p53 for each deletion construct 
was presented as the F/R ratio observed in pCMV-p53 co-transfected cells 
standardized to the ratio in control vector pcDNA3.1 co-transfected cells, which was 
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2.14. Confocal microscopy 
2.14.1. Cellular localization analysis of Cyr61  
For cellular localization analysis for Cyr61, HepG2, Hep3B and Huh-7 cells 
were seeded on coverslips in 6-well plates for overnight culture and transfected with 
pDEST47-Cyr61/GFP plasmids at 70% confluences. 48 hours after transfection, the 
coverslips were washed twice with PBS and then fixed with 4% paraformaldehyde for 
30min at room temperature. After briefly rinsed with PBS, the coverslips were placed 
upside down to clean slides applied with Vectashield® mounting medium (Vector 
Laboratories, Burlingame, CA) and sealed with nail polish. Fluorescent images were 
observed and photographed under a confocal microscope (LSM510 Meta, Carl Zeiss, 
UK) using Plan-Neofluar 100×/1.3 oil immersion objective with 488nm wavelength. 
 
2.14.2. Mechanism analysis of Lasp1 over-expression in regulating HCC cell 
migration and invasion 
To investigate the mechanism of Lasp1 further over-expression in regulating 
cell migration and invasion ability in HCC cells, the co-localization of Lasp1 with a 
series of focal adhesion and/or F-actin binding proteins were examined. Hep3B and 
Huh-7 cells were seeded in 6-well plates for overnight culturing and transfected with 
pDEST47-Lasp1/GFP plasmids at 70-80% confluences. Twenty-four hours after 
transfection, the cells were trypsinized by 0.05% trypsin/EDTA and re-plated onto the 
35mm glass bottom microwell dishes (MatTek Corporation, Ashland, MA) at a 
concentration to reach 50-60% confluence after overnight incubation. Cells were 
washed three times with PBS and fixed with 4% paraformaldehyde for 10min at room 
temperature. Fixed cells were permeabilized in 0.1% Triton-X100 (Bio-Rad) for 3 
minutes. Before antibody incubation, cells were blocked in 5% BSA in PBS at room 
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temperature for 2 hours. Then mouse monoclonal antibodies specific to zyxin 
(Invitrogen), VASP (BD Biosciences), and paxillin (Upstate) were used as primary 
antibodies to stain the respective cellular proteins at 4°C overnight. On the next day, 
goat-anti-mouse secondary antibodies conjugated with Alexa Fluor® 647 (Molecular 
Probes, Invitrogen) were applied and incubated at room temperature for 30min. F-
actin was stained by Alexa Fluor® 635 phalloidin (Molecular Probes) at room 
temperature for 20min according to the manufacturer’s instructions. Finally, the cells 
were mounted with the Prolong Gold Antifade Reagent (Molecular Probes) after the 
excessive moisture had been removed and the culture dishes stored at 4°C overnight 
were ready for con-focal microscopy analysis. Note that the extensive wash by PBS 
for 3 times was applied between each step. Fluorescent images were observed and 
photographed under a confocal microscope (LSM510 DUO system, Carl Zeiss) using 
Plan-Neofluar 63×/1.40 oil DIC immersion objective with 488nm (Argon laser) and 
633nm (Hene laser) wavelength.  
 
2.15. Statistical analysis 
All functional tests were carried out in triplicates and repeated three times with 
similar results. Representative data were shown as mean ± SD from triplicate wells. 
Differences of averages and percentages between controls and Cyr61 or Lasp1 
plasmid/siRNA transfectants were statistically analyzed using Student’s t-test. The 
correlation between the fold change of Cyr61 or Lasp1 mRNA expression in matched 
HCC tissues measured by real-time quantitative PCR and cDNA microarray study 
was established by calculating the Pearson’s correlation coefficient (r). P-value less 


















































3.1. Part I: Cyr61 exerted inhibitory roles in HCC growth and metastasis 
3.1.1. Expression study of Cyr61 in HCC 
Expression of Cyr61 in HCC clinical samples 
The current study started from the validation of our previous microarray data. 
An experimental procedure was established in this study to validate the microarray 
data (section 2.3.3, modified from Neo et al., 2004). To confirm our early observation 
from cDNA microarray analysis that Cyr61 was down-regulated in HCC tumors, 
mRNA expression of Cyr61 in clinical specimens was assessed by quantitative real-
time PCR. Eight pairs of HCC tumor and adjacent non-tumor samples were randomly 
chosen from a set of 37 HCC patients (Neo et al., 2004). Total RNA was subjected to 
one-step real-time quantitative RT-PCR using Cyr61 specific primers (Cyr61-F1, 
Cyr61-R1, sequence listed in Table 2.1). The run has been repeated for three times 
and representative result was shown in Figure 3.1A. Data were presented as the fold 
change of Cyr61 expression in each non-tumor tissue relative to its corresponding 
tumor sample after normalized to a housekeeping gene HPRT. In almost all eight 
pairs of samples, Cyr61 expression was down-regulated in tumor tissues compared to 
the corresponding non-tumor liver specimens. Moreover, the fold change of Cyr61 
expression for each pair of samples was well correlated to the value obtained in our 
earlier cDNA microarray study by calculating the Pearson’s correlation coefficient (r 
= 0.878, P < 0.05, Figure 3.1B), further confirming the down-regulated expression of 
Cyr61 observed in HCC tumors (Neo et al., 2004).  
 
Expression of Cyr61 in normal tissues 
Next, the expression level of Cyr61 in normal human tissues was checked by 
semi-quantitative RT-PCR. Complementary DNA (cDNA) was synthesized as 
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described in section 2.3.2 from a collection of total RNA of 15 different normal 
human tissues. Then the cDNA was subjected to semi-quantitative gel-based RT-PCR 
using internal primer set specific to Cyr61 (Cyr61-F2, Cyr61-R2) with housekeeping 
gene GAPDH as a quality and quantity control (sequence listed in Table 2.2). The 
results showed that Cyr61 was ubiquitously expressed in 13 normal adult human 
tissues of a variety of organs, including male and female adult liver tissues, while its 
expression was barely detectable in fetal liver tissues (Figure 3.2). This finding 
suggests that Cyr61 expression may be under certain extent of suppression in newly 
regenerating hepatocytes, which had been known to resemble hepatic neoplasm in 
many aspects. 
 
Expression of Cyr61 in HCC cell lines 
The expression profile of Cyr61 protein was further analyzed in 14 HCC cell 
lines by Western blot. Cell lysates from 14 HCC cell lines were extracted and the 
protein concentrations were measured by Bradford protein assay as described in 
section 2.6.1. Then the proteins were separated by 10% SDS-PAGE followed by 
Western blot using a specific rabbit-anti-Cyr61 antibody with α-tubulin as a protein 
loading control. As shown in Figure 3.3, Cyr61 protein level was fairly low or 
undetectable in 10 out of 14 cell lines tested, e.g. Hep3B, Huh-7 and HepG2 cells, 
though it had moderate to high expression in HA22T, SNU449, Mahlavu and Sk-











Figure 3.1 Cyr61 mRNA expression in HCC clinical samples. (A) Cyr61 mRNA 
expression was down-regulated in eight randomly chosen HCC tumors detected by 
one-step real-time quantitative RT-PCR. Data were presented as the fold change of 
the gene expression in each non-tumor tissue sample against its corresponding tumor 
sample after normalized to a housekeeping gene HPRT. Negative number reflects 
decreased fold change. (B) Correlation of the fold changes in each paired tumor and 
non-tumor samples between the results of real-time quantitative RT-PCR and the 







    
 
Figure 3.2 Cyr61 mRNA expression in human normal tissues. Cyr61 mRNA 
expression in 15 normal human tissues was measured by semi-quantitative RT-PCR 





   
 
Figure 3.3 Cyr61 protein expression in HCC cell lines. 20μg of cell lysates from 14 
HCC cell lines were separated on 10% SDS-PAGE gel and analyzed by Western blot 
with specific antibody against Cyr61. α-tubulin was used as a control for protein 








3.1.2. Gateway cloning of Cyr61 expression constructs 
To examine the potential biological roles of Cyr61 in HCC cell growth and 
metastasis, two recombinant expression vectors pDEST40-Cyr61/V5 and pDEST47-
Cyr61/GFP were constructed by using Gateway cloning system. The detailed protocol 
of the Gateway cloning strategy was described in Chapter 2.4.2. The constructed 
Cyr61 Gateway plasmids were illustrated in Figure 3.4A. Briefly, the full Cyr61 ORF 
(1143bp) was first amplified from normal adult liver cDNA by two rounds of PCR by 
using gene-specific primers including part of attB1 or attB2 site sequence (GW-
Cyr61-F, GW-Cyr61-R) and a set of adaptor-primers (attB1, attB2) (sequence listed 
in Table 2.3) (Figure 3.4B). A BP recombination reaction was then performed by 
using the attB-flanking Cyr61 PCR product (~1200bp) and the attP-containing 
pDONRTM221 vector (Figure 2.1 in section 2.4.2) to create a Cyr61-221 entry clone 
(also named as Cyr61-DONOR221). Further LR recombination reactions between the 
attL-containing entry clone Cyr61-221 and the attR-containing destination vectors 
pcDNA-DEST40 (Figure 2.2) or pcDNA-DEST47 (Figure 2.3) produced the final 
Cyr61 expression constructs pDEST40-Cyr61/V5 (also named as Cyr61-DEST40 or 
Cyr61-40) and pDEST47-Cyr61/GFP (also named as Cyr61-DEST47 or Cyr61-47). 
Enzymatic digestion (Figure 3.4C) and sequencing validated the sequence of the 




    
 
Figure 3.4 Gateway cloning for Cyr61 ORF. (A) Illustrations of the constructed 
plasmids. SP: Signal Peptide. attL1 (pink), attL2 (purple), attB1 (red), attB2 (blue) 
sites and the restriction enzyme sites (▲) are indicated. (B) PCR amplification of 
Cyr61 ORF carrying part of attB recombination sites. Lane1: 100bp DNA Ladder; 
Lane2: attB-Cyr61 PCR product of about 1200bp. (C) Enzyme digestion of the 
constructed donor and expression vectors. Lane1 and Lane6: 1kb plus DNA ladder; 
Lane2: Cyr61-DONOR221 uncut; Lane3: Cyr61-DONOR221 EcoR V + Nco I 
digested, 2 fragments (749bp, 2943bp); Lane4: Cyr61-DEST40 uncut; Lane5: Cyr61-
DEST40 Pvu II digested, 4 fragments (538bp, 1071bp, 1096bp, 3879bp); Lane7: 
Cyr61-DEST47 uncut; Lane8: Cyr61-DEST47 Hind III digested, 2 fragments (1291bp, 
5913bp); Lane9: Cyr61-DEST47 Nco I digested, 5 fragments (735bp, 814bp, 814bp, 
1512bp, 3347bp).  
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The constructed Cyr61 expression vectors were transfected into HCC cell lines 
with low abundant endogenous Cyr61. Also, two HepG2 stable cell lines with Cyr61 
over-expression (HepG2-Cyr61-1 and HepG2-Cyr61-2) and one control clone with 
Neo-resistant gene (HepG2-Neo) were established by selecting in DMEM/G418, 
which usually generate more consistent results by removing the variability of different 
transient transfection efficiency frequently observed in HepG2 cells. Next, a series of 
functional assays, such as WST-1 cell proliferation assay, soft agar assay, cell 
adhesion assay, cell migration and invasion assay, cell cycle analysis by flow 
cytometry, and cellular localization study by confocal microscopy, were performed 
based on Cyr61 transient or stable over-expression.  
In addition, in order to expand our understanding in the roles of Cyr61 in 
hepatocarcinogenesis, we obtained commercially available Cyr61 specific siRNA to 
further knockdown Cyr61 level in HCC cell lines and examined the function of Cyr61 
in HCC cell growth.  
 
 
3.1.3. Function study of Cyr61 on HCC cell growth 
Effect of Cyr61 transient over-expression in monolayer 
The recombinant plasmid pDEST40-Cyr61/V5 and pcDNA3.1 control plasmid 
were transfected into HepG2, Hep3B and Huh-7 HCC cell lines, all of which had 
minimal levels of Cyr61 protein (Figure 3.3). Over-expression of Cyr61-V5 fusion 
protein in these cell lines was confirmed by Western blot by using specific mouse 
anti-V5 antibody with α-tubulin blotting as a protein loading control (Figure 3.5). 24 
hours after transfection, the cells were trypsinized, counted and replated 
proportionally into 96-well plates (1-4 × 104 per well) in triplicates. Then the effect of 
Cyr61 expression on cell growth in monolayer was measured by WST-1 cell 
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proliferation assay daily as described in section 2.7. As shown in Figure 3.6, all three 
HCC cell lines with over-expressed Cyr61-V5 exhibited suppressed proliferation rate 
over a 3-day culturing period as compared to corresponding control cells transfected 
with pcDNA3.1 empty vector. At Day 3 post transfection, the cell number of Cyr61 
over-expressed HepG2 cells reached 119.7 × 103 per well, which is only 55.6% of that 
of the pcDNA3.1 control transfected cells  (215.2 × 103 per well). While in Hep3B 
and Huh-7 cells, the cell number of pDEST40-Cyr61/V5 transfected cells were about 
42.6% (Hep3B) and 68.4% (Huh-7) respectively of that of the corresponding control 
cells (P < 0.01). 
 
 




Figure 3.5 Cyr61-V5 fusion protein expression in transient Cyr61 over-expressed 
HCC cells. 48 hours after transfection of pDEST40-Cyr61/V5 (+: pDEST40-Cyr61) 
or pcDNA3.1 (–: pcDNA) into HepG2, Hep3B or Huh-7 cells, the cell lysates were 
collected and the proteins were separated by 10% SDS-PAGE followed by Western 
blot using a specific anti-V5 antibody. The V5-tagged over-expressed protein is 




                    
 
 
Figure 3.6 Cyr61 transient over-expression inhibited HCC cell proliferation in 
monolayer. pcDNA3.1 (pcDNA, open square) or pDEST40-Cyr61/V5 (Cyr61, filled 
circle) transfected HepG2, Hep3B or Huh-7 cells were replated into 96-well plates in 
triplicates 24 hours after transfection. The growth rates at indicated time points were 
measured by WST-1 reagent. The mean ± SD of triplicates are also shown for each 
point. In all three cell lines, pDEST40-Cyr61/V5 transfected cells showed a reduced 




Effect of Cyr61 stable over-expression in monolayer 
Two HepG2 stable cell lines with Cyr61 over-expression (HepG2-Cyr61-1 
and HepG2-Cyr61-2) and one control cell line with Neo-resistant gene (HepG2-Neo) 
were established for this study. Firstly, HepG2 stable transfectants were selected after 
cultured in DMEM/10%FBS supplemented with 800µg/ml geneticin (G418) for 2 
weeks. The stable over-expression of Cyr61 was confirmed by Western blot. As 
shown in Figure 3.7, over-expression of Cyr61-V5 fusion protein was maintained in 
HepG2-Cyr61-1 and HepG2-Cyr61-2 stable cell lines up to 4 passages. The HepG2-
Cyr61-2 had an even higher Cyr61-V5 expression level than HepG2-Cyr61-1 at the 
same passage, while in HepG2-Neo control cells, Cyr61 level remained to be 
undetectable as shown by blotting with rabbit anti-Cyr61 specific antibody.  
 
 
               
Figure 3.7 Cyr61-V5 fusion protein expression in HepG2-Cyr61 stable cell lines. 
HepG2 stable transfectants were selected in DMEM/10% FBS supplemented with 
800μg/ml G418. Cell lysates from different passages were collected and the over-
expression of Cyr61 in two HepG2-Cyr61 stable clones (Cyr61-1, Cyr61-2) compared 
to the HepG2-Neo control clone (Neo) was confirmed by Western blot with both 






At the passage of three to four, these two HepG2-Cyr61 stable cell lines and 
HepG2-Neo control cells cultured in tissue culture flask were trypsinized, counted, 
seeded at the same concentration (~2 × 104 /well) into 96-well plates in triplicates. 
The WST-1 cell proliferation assay was performed daily to monitor the growth rate of 
each cell line. In order to remove the variations generated by manual cell counting, 
the data were presented at each time point as the percentage relative to the cell 
number seeded at Day 0 for each line, which was arbitrarily set at 100% as Day 0 
control. Figure 3.8 clearly demonstrated that HepG2-Cyr61 stable expression also 
exhibited inhibitory effect on cell growth in monolayer. At Day 4 post seeding, the 
cell number of Cyr61 stable clones was only 71.8% (HepG2-Cyr61-1) (749.4% of 
Day 0 control) and 38.7% (HepG2-Cyr61-2) (404.2% of Day 0 control) respectively 
of that of HepG2-Neo control cells (1043.8% of Day 0 control) (P < 0.05). The fact 
that HepG2-Cyr61-2 had a higher Cyr61-V5 expression level than HepG2-Cyr61-1 
(Figure 3.7) may explain the observation that HepG2-Cyr61-2 had a stronger effect in 























Figure 3.8 Cyr61 stable over-expression inhibited cell proliferation in HepG2 
cells. Two HepG2-Cyr61 stable transfectants (HepG2-Cyr61-1, HepG2-Cyr61-2) and 
one HepG2-Neo control cell line were seeded in 96-well plate in triplicates and the 
cell growth rates were monitored daily by WST-1 assay. Data were presented as the 
percentage at each time point relative to the cell number seeded at Day 0 for each line, 
which was arbitrarily set at 100% as Day 0 control. The mean ± SD of triplicates are  
shown for each point. Both HepG2-Cyr61-1 (filled circle) and HepG2-Cyr61-2 (filled 
triangle) stable cell lines showed reduced cell proliferation rate compared to HepG2-









Effect of Cyr61 siRNA knockdown in monolayer 
To examine the role of endogenous Cyr61, siRNA was introduced into HepG2 
and Hep3B cells. 48 hours after transfection, total RNA and cell lysates were 
separately collected and the knockdown effect was measured by both two-step real-
time quantitative RT-PCR and Western blot. After normalized to a housekeeping gene 
HPRT, the Cyr61 mRNA expression in Negative Control siRNA transfected cells was 
arbitrarily set as 1.0. As shown in Figure 3.9A, both Cyr61 siRNA oligos down-
regulated Cyr61 mRNA to the level lower than 40% of that of the control. The protein 
level was further reduced based on the trace amount of Cyr61 protein left in the 
parental HepG2 and Hep3B cells, as indicated by showing the Cyr61 protein in 
Negative Control siRNA transfected cells (Figure 3.9B). A relatively long exposure 
time was utilized here so that the extremely low level of endogenous Cyr61 protein 
can be detected, through which the knockdown effect could be observed easily.  
The WST-1 assay of both cell lines transfected with Cyr61 siRNA oligos 
(Cyr61#1, Cyr61#2) showed an increase in cell proliferation rate compared to 
Negative Control siRNA transfected cells. At Day 4 post transfection in Hep3B, the 
cell number of Cyr61#1 and Cyr61#2 oligo transfected cells was 143.4% (93.1 × 103 
per well) and 131.8% (85.5 × 103 per well) of that of Negative Control siRNA 
transfected cells (64.9 × 103 per well), respectively (P < 0.01). Whereas in HepG2 
cells, the effect of Cyr61 siRNA knockdown was more prominent, as the cell number 
of the siRNA treated cells reached 220.8% (321.9 × 103 per well) (Cyr61#1) and 
232.4% (338.9 × 103 per well) (Cyr61#2) of control (145.8 × 103 per well) (P < 0.01) 
(Figure 3.10). In conclusion, these results demonstrated that Cyr61 exerted growth 








                
 
Figure 3.9 Cyr61 siRNA oligos further down-regulated the mRNA and protein 
expression in HCC cells. Both Cyr61 mRNA and protein level was down-regulated 
by Cyr61 siRNA oligos (Cyr61#1, Cyr61#2) compared to Negative Control siRNA 
(Neg Ctrl) transfected HepG2 or Hep3B cells. 48 hours after transfection, the total 
RNA and cell lysates were separately collected. (A) Total RNA was subjected to 
cDNA synthesis and subsequent real-time quantitative RT-PCR analysis. In each cell 
line, after normalized to a housekeeping gene HPRT, the Cyr61 mRNA expression in 
Negative Control siRNA (Neg Ctrl) transfected cells was arbitrarily set as 1.0. The 
mean ± SD of triplicates are shown. (B) Protein lysates were separated on 10% SDS-
PAGE followed by Western blot using a rabbit anti-Cyr61 specific antibody with β-








              
 
Figure 3.10 Cyr61 siRNA knockdown enhanced HCC cell proliferation in 
monolayer. Negative Control siRNA (open square), Cyr61#1 (filled circle), or 
Cyr61#2 (filled triangle) transfected HepG2 or Hep3B cells were replated into 96-
well plates in triplicates 24 hours after transfection and the growth rates at indicated 
time points were measured by WST-1 reagent. The mean ± SD of triplicates are 
shown for each point. Both siRNA oligos (Cyr61#1, Cyr61#2) transfected HepG2 or 
Hep3B cells showed an increased cell proliferation rate than Negative Control siRNA 







Effect of Cyr61 transient over-expression in soft agar assay 
To further explore the inhibitory effects of Cyr61 on HCC cell growth under 
more stringent conditions, an anchorage-independent assay was performed to examine 
the colony formation ability in soft agar culture. Anchorage-independent growth is a 
hallmark of cellular transformation, and colony formation in semi-solid medium such 
as soft agar is a key assay for measuring this growth (Shin et al. 1975). The colony 
number and colony size formed in soft agar usually reflect the cloning efficiency and 
cell proliferation rate, respectively (Claassen et al. 2004). As described in section 2.8, 
HepG2 cells transfected with either pDEST40-Cyr61/V5 or pcDNA3.1 control 
plasmid were replated for soft agar assay. After culture at 37°C for additional three 
weeks, the colonies were stained, photographed and the colonies > 100μm in diameter 
were counted. The images clearly showed that, in sharp contrast to the controls 
transfected with pcDNA3.1, HepG2 cells transfected with pDEST40-Cyr61/V5 
formed much fewer and smaller colonies in semi-soft agar (Figure 3.11A), the colony 
forming efficiency of which was only about 40% of control as reflected by colony 
count (P < 0.05) (Figure 3.11B). These results indicated that over-expression of 
Cyr61 significantly reduced the anchorage-independent growth of HepG2 cells, 











                
 
Figure 3.11 Cyr61 over-expression inhibited anchorage-independent growth of 
HepG2 cells in soft agar. HepG2 cells transfected with pDEST40-Cyr61/V5 or 
pcDNA3.1 control were trypsinized 24 hours after transfection. 1 × 104 cells were re-
suspended in 0.25ml of 0.35% agar dissolved in DMEM/10%FBS and plated in 24-
well plate in triplicates overlying a 0.7% agar bottom layer and cultured at 37°C with 
5% CO2 for 3 weeks. Then the cells were stained and the colonies were visualized and 
photographed under microscope. (A) Representative images showed that HepG2 cells 
transfected with pDEST40-Cyr61/V5 (Cyr61) formed much smaller and fewer 
colonies in soft agar than those transfected with pcDNA3.1 control (pcDNA). (B) The 
colonies > 100μm in diameter were counted by Leica QWin imaging software. The 
colony forming efficiency was calculated as the percentage of the colony number 
formed by pDEST40-Cyr61/V5 transfected cells (grey bar) relative to that formed by 
pcDNA3.1 transfected cells (white bar), which was arbitrarily set at 100% (mean± 





3.1.4. Function study of Cyr61 on HCC cell adhesion, migration and invasion 
Effect of Cyr61 on cell adhesion to ECM proteins 
As a secreted heparin-binding protein, Cyr61 has been shown to be associated 
with altered ECM-cell interactions to regulate the adhesion activities of a variety of 
cells, such as fibroblasts, endothelial cells, and smooth muscle cells (Chen et al. 2000; 
Grzeszkiewicz et al. 2002; Leu et al. 2002). As described in section 1.1.4, there are 
various ECM proteins. By considering their functional associations with cancer, the 
role of Cyr61 in mediating HCC cell adhesion ability to 5 selected types of ECM 
proteins, including fibronectin, vitronectin, laminin, collagen I, and collagen IV were 
examined in this study. HepG2 and Hep3B cells transfected with either pDEST40-
Cyr61/V5 or pcDNA3.1 control vectors were tested for their adhesion activities to the 
5 various ECM proteins as described in section 2.9.1. It was first noted that the 
parental HepG2 cells without any treatment adhered strongly to vitronectin, laminin, 
collagen I and collagen IV, but barely to fibronectin (Figure 3.12A). This suggests a 
selective decreased adhesion to certain types of ECM proteins in HCC cells. While 
the pcDNA3.1 transfected HepG2 cells showed similar pattern of adhesion to ECM 
proteins as non-treated cells (data not shown), over-expression of Cyr61 extensively 
improved the adhesion of HepG2 cells to various ECM proteins, namely vitronectin to 
144%, laminin to 132%, collagen I to 155%, collagen IV to 149% (P < 0.05), and 
most remarkably, fibronectin to about 260% as compared to the control (P < 0.01) 
(Figure 3.12B). The parental Hep3B cells adhered to the almost same extent to the 
fibronectin, laminin, collagen I and collagen IV, but weakly to vitronectin. The 
adhesion ability of Hep3B cells to vitronectin is only 26.3-44.6% of that to other 4 
types of ECM proteins (P < 0.01) (Figure 3.12C). Over-expression of Cyr61 also 
significantly increased the adhesion of Hep3B cells to fibronectin to 132%, laminin to 
 
Results 101
144%, collagen I to 147%, collagen IV to 144% (P < 0.05), and vitronectin to 170% 
(P < 0.01) (Figure 3.12D). In conclusion, over-expression of Cyr61 promoted cell 
adhesion of HCC cells to a variety of ECM proteins.  
                  
Figure 3.12 Cyr61 over-expression enhanced HCC cell adhesion to ECM 
proteins. Adhesiveness of non-treated HepG2 (A) and Hep3B (C) cells to ECM 
proteins, including fibronectin (FN), vitronectin (VN), laminin (LN), collagen I (Col I) 
and collagen IV (Col IV). Forty-eight hours after transient transfection with 
pDEST40-Cyr61/V5 (grey bars) or pcDNA3.1 (white bars), HepG2 (B) and Hep3B 
(D) cells were replated for cell adhesion assay. Adhesion efficiency to each ECM 
protein was presented as the percentage relative to that of the pcDNA3.1 control 
transfected cells, which was arbitrarily set at 100% (mean ± SD of triplicates). ** P < 
0.01, * P < 0.05. 
 
Results 102
Effect of Cyr61 on HCC cell migration and invasion ability  
Cell adhesion to ECM proteins is the initial step for cell migration and 
invasion. Dynamic regulations of adhesion assembly and disassembly are crucial 
determinants to control cell movement (Hood and Cheresh 2002; Ridley et al. 2003). 
Since Cyr61 was shown to be involved in the regulation of HCC cell adhesion, its 
potential role in cell migration and invasion during HCC progression was further 
explored. Microporous membrane inserts are widely used for cell migration and 
invasion assays. Currently, the most widely accepted assay is the Boyden chamber 
assay originally designed for the analysis of leukocyte chemotaxis (Chen 2005; Cheng 
et al. 2007). Firstly, the effect of transient over-expression of Cyr61 on cell migration 
and invasion ability in HepG2 or Hep3B cells was tested by using the modified 
Boyden chamber assay as described in section 2.9.2. The results reflected that the 
migratory activities of pDEST40-Cyr61/V5 transfected cells were inhibited 30.5% in 
HepG2 cells (Figure 3.13A) and up to 60.5% in Hep3B cells (Figure 3.13B) (P < 0.01) 
respectively as compared to pcDNA3.1 control. Furthermore, the invasive activities 
through ECM proteins were suppressed in both HepG2 (65.9% of control, P < 0.05) 
(Figure 3.13C) and Hep3B cells (44.8% of control, P < 0.01) (Figure 3.13D). 
In addition, the HepG2 cell lines with stable Cyr61 over-expression (HepG2-
Cyr61-1 and HepG2-Cyr61-2) and the control clone with Neo-resistant gene (HepG2-
Neo) were also used for this study. The Boyden chamber assay showed that the 
migratory activities of the HepG2-Cyr61 stable cell lines were inhibited up to 58.6% 
(HepG2-Cyr61-1) and 55.0% (HepG2-Cyr61-2) respectively as compared to HepG2-
Neo control (P < 0.01) (Figure 3.14A). Furthermore, the invasive activities through 
ECM proteins were suppressed in both HepG2-Cyr61 stable clones (40.7% and 28.0% 
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of control respectively, P < 0.01) (Figure 3.14B). These results support the conclusion 
that Cyr61 negatively regulated cell motility and invasiveness of human HCC cells.  
 
    
Figure 3.13 Cyr61 transient over-expression inhibited migration and invasion 
activities of HCC cells. After serum starvation for 24 hours, pcDNA3.1 (pcDNA, 
white bars) or pDEST40-Cyr61/V5 (Cyr61, grey bars) transfected HepG2 (1.0 × 105 
cells / well) or Hep3B (5.0 × 104 cells /well) cells were replated for cell migration and 
invasion assays. Inhibitory effects on migration and invasion were presented as the 
percentage of fluorescent readings standardized to pcDNA3.1 control (mean ± SD of 
triplicates). *P < 0.05, ** P < 0.01. (A) Migration assay through 8μm microporous 
membranes in HepG2 cells. (B) Migration assay through 8μm microporous 
membranes in Hep3B cells. (C) Invasion assay through ECM proteins in HepG2 cells. 











           
 
Figure 3.14 Cyr61 stable over-expression inhibited migration and invasion 
activities in HepG2 cells. After serum starvation for 24 hours, two stable clones 
HepG2-Cyr61-1 (Cyr61-1, grey bars), HepG2-Cyr61-2 (Cyr61-2, black bars), and the 
HepG2-Neo control cells (Neo, white bars) were plated (5.0 × 105 cells/well) for cell 
migration and invasion assays. Inhibitory effects on migration and invasion were 
presented as the percentage of fluorescent readings standardized to HepG2-Neo 
control (mean ± SD of triplicates). ** P < 0.01. (A) Migration assay through 8μm 





3.1.5. Cellular localization study of Cyr61 in HCC 
The protein cellular localization study may help to better understand the 
function and pathway of proteins in a particular cell type. In order to determine the 
intracellular distribution of Cyr61 protein in HCC cells, the Cyr61 fusion construct 
with green fluorescent protein (pDEST47-Cyr61/GFP) was transfected into HepG2, 
Hep3B and Huh-7 cells. 48 hours after transfection, the cells were fixed and analyzed 
under fluorescent confocal microscope. The fluorescent signals clearly showed that 
Cyr61/GFP fusion protein was present in perinuclear region and cytoplasmic granules, 
suggesting that Cyr61 was localized to the secretory pathway of cells (Figure 3.15A). 
Correspondingly, a substantial level of secreted Cyr61-V5 protein (~46kDa) was 
detected in the culture supernatant of pDEST40-Cyr61/V5 transfected HepG2, Hep3B 
and Huh-7 cells by Western blot, while culture medium from cells transfected with 
pcDNA3.1 empty vector showed no detectable Cyr61 secretion over a 48 hour’s 
















         
 
Figure 3.15 Subcellular localization of Cyr61 in HCC cells. (A) Intracellular 
distribution of Cyr61-GFP fusion protein observed under the fluorescent confocal 
microscope. HepG2, Hep3B and Huh-7 cells were transfected with pDEST47-
Cyr61/GFP plasmid. 48 hours later, the fluorescent signals were observed and 
photographed (100 ×) under a confocal microscope. Cells transfected with pcDNA3.1 
empty vector were used as background control. (B) Secreted Cyr61/V5 protein was 
detected in culture supernatant (S/N) by Western blot. Supernatant was collected from 
the culturing medium of HepG2, Hep3B or Huh-7 cells 48 hours after transfection 
with pDEST40-Cyr61/V5 or pcDNA3.1 plasmids, and separated on 10% SDS-PAGE 







In summary, a comprehensive experimental in vitro system using human HCC 
cell lines was established in this study to explore the potential roles of Cyr61 in 
growth and metastasis of human HCC.  
The cell proliferation study indicated that down-regulation of Cyr61 in HCC 
may represent a strategy developed by tumor cells to gain growth advantages. Over-
expression of Cyr61 significantly suppressed the proliferation rate of HCC cells in 
monolayer. Cyr61 transfected cells formed fewer colonies in soft agar compared to 
mock transfected controls. It was also showed that the capability of anchorage-
independent growth, which is an important indicator of malignant transformation, was 
inhibited by Cyr61 expression as well. Knockdown of endogenous Cyr61 by siRNA 
in HCC cell lines enhanced cell proliferation rate in monolayer instead, further 
confirmed that Cyr61 exerted an inhibitory effect in HCC cell growth.  
Moreover, HCC may acquire high mobility and metastatic potential by 
suppressing Cyr61 expression as shown by the cell adhesion, migration and invasion 
study. Enhanced adhesion to ECM proteins was observed in Cyr61 over-expressing 
cells. Both transient and stable over-expression of Cyr61 in HCC cells efficiently 
inhibited cell migration and invasion abilities as compared to controls. All these 










3.2. Part II: Lasp1 exerted enhancing roles in HCC growth and metastasis 
3.2.1. Expression study of Lasp1 in HCC 
Expression of Lasp1 in HCC clinical samples 
Similarly as in Cyr61 expression study, in order to confirm our early 
observation from cDNA microarray analysis that Lasp1 was up-regulated in HCC 
tumors, mRNA expression of Lasp1 in clinical specimens was assessed by one-step 
quantitative real-time RT-PCR using Lasp1 specific primers (Lasp1-F, Lasp1-R, 
sequence listed in Table 2.1). The experiment has been repeated for three times and a 
representative result is shown in Figure 3.16A. Data were presented as the fold 
change of Lasp1 expression in each tumor tissue relative to its corresponding non-
tumor sample after normalized to the housekeeping gene HPRT. In the same 
collection of eight pairs of randomly chosen samples from 37 HCC patients, Lasp1 
expression was up-regulated in all tumor tissues compared to the corresponding non-
tumor liver specimens. Moreover, the fold change of Lasp1 expression for each pair 
of samples was highly correlated to the value obtained in our cDNA microarray study 
(r = 0.992, P < 0.01, Figure 3.16B), further confirming the up-regulated expression of 
Lasp1 observed in HCC tumors (Neo et al., 2004). 
 
Expression of Lasp1 in normal tissues 
Next, the expression level of Lasp1 in normal human tissues was checked by 
semi-quantitative RT-PCR. The cDNA synthesized from the total RNA of 15 types of 
normal human tissues was here used for detecting Lasp1 mRNA expression with 
Lasp1 specific primer set (Lasp1-F, Lasp1-R) with GAPDH as the housekeeping gene. 
Lasp1 was shown to be ubiquitously expressed in most human normal tissues, 
including fetal liver tissues, whereas its expression was barely detectable in adult liver 
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tissues and in skeletal muscle (Figure 3.17). The high level of Lasp1 mRNA 
expression in normal human fetal liver tissues suggests that Lasp1 may have 
important roles in newly regenerating hepatocytes.  
 
Expression of Lasp1 in HCC cell lines 
The expression profile of Lasp1 was further analyzed in 14 HCC cell lines. 
The cell lysates from the 14 HCC cell lines were separated by 10% SDS-PAGE 
followed by Western blot using a rabbit-anti-Lasp1 specific antibody with α-tubulin 
as a protein loading control. As indicated in Figure 3.18, except in PLC/PRF/5 and 
Huh-6, Lasp1 had high level of expression in HCC cell lines, further confirming the 


















   
 
Figure 3.16 Lasp1 mRNA expression in HCC clinical samples. (A) Lasp1 mRNA 
expression was up-regulated in eight randomly chosen HCC tumors detected by one-
step quantitative real-time PCR. Data were presented as the fold change of the gene 
expression in each tumor tissue against its corresponding adjacent non-tumor tissue 
sample after normalized to a housekeeping gene HPRT. (B) Correlation of the fold 
changes in each paired tumor and non-tumor samples between the results of real-time 







        
 
Figure 3.17 Lasp1 mRNA expression in human normal tissues. Lasp1 mRNA 
expression in 15 normal human tissues was measured by semi-quantitative RT-PCR 
analysis. GAPDH was used as an internal control for the quality and quantity of RNA 




          
 
Figure 3.18 Lasp1 protein expression in HCC cell lines. 20μg of cell lysate from 14 
HCC cell lines was separated on 10% SDS-PAGE gel and analyzed by Western blot 
with specific antibody against Lasp1. α-tubulin blotting was used as a control for 







3.2.2. Gateway cloning of Lasp1 expression constructs 
To examine the potential roles of Lasp1 in human HCC growth and metastasis, 
the Lasp1 expression vectors pDEST40-Lasp1/V5 and pDEST47-Lasp1/GFP were 
constructed by using Gateway cloning system. The constructed Lasp1 Gateway 
plasmids were illustrated in Figure 3.19A. As Lasp1 mRNA has the highest 
expression level in normal human colon tissue among 15 different tissue samples 
tested (Figure 3.17), the full ORF of Lasp1 (783bp) was first amplified from the 
normal colon tissue cDNA by two rounds of PCR using gene-specific primers (GW-
Lasp1-F, GW-Lasp1-R) and a set of adaptor-primers (attB1, attB2) (sequence listed 
in Table 2.3) (Figure 3.19B). BP recombination reaction was then performed by using 
the purified attB-flanking Lasp1 PCR product and the attP-containing pDONRTM221 
vector (Figure 2.1) to create the Lasp1-221 entry clone (also names as Lasp1-
DONOR221). Further LR recombination reactions between the entry clone and the 
destination vectors produced the Lasp1 expression constructs pDEST40-Lasp1/V5 
(also named as Lasp1-DEST40 or Lasp1-40) and pDEST47-Lasp1/GFP (also named 
as Lasp1-DEST47 or Lasp1-47). Enzymatic digestion (Figure 3.19C) and sequencing 
validated the right sequence of desired donor and expression vectors, with reference 











Figure 3.19 Gateway cloning for Lasp1 ORF. (A) Illustrations of the constructed 
plasmids. attL1 (pink), attL2 (purple), attB1 (red), attB2 (blue) sites and the 
restriction enzyme sites (▲) are indicated. (B) PCR amplification of Lasp1 ORF 
carrying part of attB recombination sites. Lane1: attB-Lasp1 PCR product of about 
800bp; Lane2: 100bp Ladder. (C) Enzyme digestion of the constructed donor and 
expression vectors. Lane1: 1kb plus ladder; Lane2: Lasp1-DONOR221 uncut; Lane3: 
Lasp1-DONOR221 EcoR V + Sph I digested, 2 fragments (815bp, 2517bp); Lane4: 
Lasp1-DEST40 uncut; Lane5: Lasp1-DEST40 Nco I digested, 4 fragments (487bp, 
735bp, 1655bp, 3347bp); Lane6: Lasp1-DEST47 uncut; Lane7: Lasp1-DEST47 Hind 
III digested, 2 fragments (931bp, 5931bp); Lane8: Lasp1-DEST47 Nco I digested, 5 
fragments (490bp, 735bp, 778bp, 1512bp, 3347bp). 
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In order to understand the potential biological roles of Lasp1 in human HCC, 
commercially available Lasp1 specific siRNA oligos were used to knockdown the 
high endogenous expression of Lasp1 in HCC cell lines followed by examination of 
the role of Lasp1 in HCC cell proliferation, anchorage-independent growth, cell 
migration and cell invasion ability.  
In addition, the constructed recombinant expression vectors pDEST40-
Lasp1/V5 and pDEST47-Lasp1/GFP were also utilized to transfect selected HCC cell 
lines to over-express Lasp1 level in these cells. Two HepG2 stable cell lines with 
Lasp1 over-expression (defined as HepG2-Lasp1-1 and HepG2-Lasp1-2) were 
established for this study as well. The same control clone (HepG2-Neo) used in 
section 3.1 were included as the control cell line in all experiments in this part of 
study when using HepG2-Lasp1 stable transfectants. Next, a series of functional 
assays, including WST-1 cell proliferation assay, soft agar assay, cell migration and 
invasion assay, and cellular localization study by confocal microscopy, were 
performed based on Lasp1 transient or stable over-expression.  
 
 
3.2.3. Function study of Lasp1 on HCC cell growth 
Effect of Lasp1 siRNA knockdown in monolayer 
To characterize the potential roles of Lasp1 in HCC cell growth, Lasp1 
specific siRNA were transfected into HepG2, Hep3B and Huh-7 cell lines, all of 
which had high level of Lasp1 expression (Figure 3.18). 48 hours after transfection, 
total RNA and cell lysates were separately collected and the knockdown effect was 
confirmed by both two-step real-time quantitative RT-PCR and Western blot. As 
shown in Figure 3.20A, both Lasp1 siRNA oligos significantly down-regulated Lasp1 
mRNA. Correspondingly, the Lasp1 protein level was significantly reduced based on 
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the endogenous high amount of Lasp1 protein in the parental HCC cells, as indicated 
by showing the Lasp1 protein in Negative Control siRNA transfected cells (Figure 
3.20B). Lasp1#2 had a more significant effect in decreasing both Lasp1 mRNA and 
protein expression in all three HCC cells. Especially in HepG2 cells, Lasp1#1 only 
slightly reduced Lasp1 protein level, whereas Lasp1#2 effectively down-regulated the 
Lasp1 protein.  
Twenty-four hours after transfection, the cells were replated proportionally 
into 96-well plates (2-5 × 104 per well) in triplicates. The effect on cell growth in 
monolayer was measured by WST-1 cell proliferation assay daily. Figure 3.21 
showed that the Lasp1 siRNA transfected cells had a reduced proliferation rate 
compared to Negative Control siRNA transfected cells, and the inhibitory effect 
corresponded well to the knockdown effect of Lasp1 protein level. At Day 4 post 
transfection, the cell number of Lasp1#2 transfected HepG2 cells was only 65.8% 
(98.8 × 103 per well) of that of Negative Control siRNA transfected HepG2 cells 
(145.8 × 103 per well), which was significant (P < 0.01). While in Hep3B and Huh-7 
cell lines, both Lasp1#1 and Lasp1#2 siRNA transfected cells showed suppressed cell 
proliferation rate compared to Negative Control siRNA transfected cells as both 
oligos significantly down-regulated Lasp1 protein level (Figure 3.20B). In Hep3B, at 
Day 5, the cell number of Lasp1#1 and Lasp1#2 transfected cells was only 67.4% 
(76.4 × 103 per well) and 33.4% (35.1 × 103 per well) respectively of control (115.9 × 
103 per well) (P < 0.01). At Day 4 post transfection, the cell number of Lasp1#1 and 
Lasp1#2 transfected Huh-7 cells was about 72.7% (157.5 × 103 per well) (P < 0.05) 
and 36.0% (76.8 × 103 per well) (P < 0.01) of Negative Control siRNA transfected 
Huh-7 cells (217.5 × 103 per well). These results reflected that the endogenous Lasp1 









Figure 3.20 Lasp1 siRNA oligos efficiently down-regulated the mRNA and 
protein expression in HCC cells. Both Lasp1 mRNA and protein level was down-
regulated by Lasp1 siRNA oligos (Lasp1#1, Lasp1#2) compared to Negative Control 
siRNA (Neg Ctrl) transfected HepG2, Hep3B and Huh-7 cells. 48 hours after 
transfection, the total RNA and cell lysates were separately collected. (A) Total RNA 
was subjected to real-time quantitative RT-PCR analysis. In each cell line, after 
normalized to a housekeeping gene HPRT, the Lasp1 mRNA expression in Negative 
Control siRNA (Neg Ctrl) transfected cells was arbitrarily set as 1.0. The mean ± SD 
of triplicates are shown. (B) Protein lysates were separated on 10% SDS-PAGE 
followed by Western blot using a rabbit anti-Lasp1 specific antibody with β-actin 









               
 
 
Figure 3.21 Lasp1 siRNA knockdown inhibited HCC cell proliferation in 
monolayer. Negative Control siRNA (open square), Lasp1#1 (filled circle) or 
Lasp1#2 (filled triangle) transfected HepG2, Hep3B or Huh-7 cells were replated into 
96-well plates in triplicates 24 hours after transfection and the growth rates at 
indicated time points were measured by WST-1 reagent. The mean ±  SD of 
triplicates are shown for each point. Both siRNA oligos transfected Hep3B or Huh-7 
cells (Lasp1#1, Lasp1#2) showed a reduced cell proliferation rate than Negative 
Control siRNA transfected cells. However in HepG2, only Lasp1#2 transfected cells 
showed obvious inhibition in cell proliferation rate.  
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Effect of Lasp1 transient over-expression in monolayer 
To further examine the potential biological effects of Lasp1 in growth of HCC, 
The recombinant plasmid pDEST40-Lasp1/V5 was introduced into HCC cell lines. 
As a cell line with extremely low endogenous Lasp1 protein level compared to other 
HCC cell lines, PLC/PRF/5 was included in this study besides HepG2 and Hep3B 
cells. Over-expression of Lasp1-V5 fusion protein in these cell lines was confirmed 
by Western blot by using specific mouse anti-V5 antibody with α-tubulin blotting as a 








Figure 3.22 Lasp1-V5 fusion protein expression in transient Lasp1 over-
expressed HCC cells. 48 hours after transfection of pDEST40-Lasp1/V5 (+: 
pDEST40-Lasp1) or pcDNA3.1 (–: pcDNA) into Hep3B, HepG2 or PLC/PRF/5 cells, 
the cell lysates were collected and the proteins were separated on 10% SDS-PAGE 
followed by Western blot using a specific anti-V5 antibody. The V5-tagged over-
expressed protein was clearly shown as indicated by the arrow. α-tubulin blotting was 







After 24 hours of transfection, the cells were trypsinized, counted and replated 
proportionally (1-3 × 104 per well) into 96-well plates in triplicates. Then the effect of 
Lasp1 over-expression on cell growth in monolayer was measured by WST-1 assay 
daily. As obviously shown in Figure 3.23, all three HCC cell lines transfected with 
pDEST40-Lasp1/V5 showed increased cell growth rates over a 4 to 5-day culturing 
period as compared to control cells transfected with pcDNA3.1 empty vector. At Day 
4 post transfection, the cell number of Lasp1 over-expressed HepG2 and PLC/PRF/5 
cells reached 132.7% (131.1 × 103 per well) and 133.1% (32.4 × 103 per well) 
respectively of their corresponding control cells (P < 0.05). While in Hep3B cells, the 
difference is more significant by exhibiting a 1.3 fold increase (230%) in cell number 
in Lasp1 over-expressed cells (280.2 × 103 per well) compared to the pcDNA3.1 
















                     
 
 
Figure 3.23 Lasp1 transient over-expression enhanced HCC cell proliferation in 
monolayer. pcDNA3.1 (pcDNA, open square) or pDEST40-Lasp1/V5 (Lasp1, filled 
circle) transfected HepG2, Hep3B or PLC/PRF/5 cells were replated into 96-well 
plates in triplicates 24 hours after transfection and the growth rates at indicated time 
points were measured by WST-1 reagent. The mean ± SD of triplicates are shown 
for each point. In all three cell lines, pDEST40-Lasp1/V5 transfected cells showed an 





Effect of Lasp1 stable over-expression in monolayer 
Two HepG2 stable cell lines with Lasp1 over-expression (HepG2-Lasp1-1 and 
HepG2-Lasp1-2) were established for this study as well. The stable over-expression 
of Lasp1 was confirmed by Western blot. As shown in Figure 3.24, over-expression 
of lasp1-V5 fusion protein was maintained in both HepG2-Lasp1-1 and HepG2-
Lasp1-2 stable cell lines up to 9 passages. While in HepG2-Neo control cells (same 
control used in HepG2-Cyr61 stable cell lines), Lasp1 protein level was relatively 
lower than HepG2-Lasp1-1 and HepG2-Lasp1-2 if compared at the same passage 
number, as shown by blotting with rabbit anti-Lasp1 specific antibody.  
At the passage of three to four, two HepG2-Lasp1 stable cell lines and HepG2-
Neo control cells cultured in tissue culture flask were trypsinized, counted, seeded at 
the same concentration (~ 2 × 104 /well) into 96-well plates in triplicates. WST-1 cell 
proliferation assay were performed daily to examine the growth rate of each cell line. 
The results of WST-1 assay at each time point were presented as the percentage 
relative to the cell number seeded at Day 0 for each line, which was set at 100% as 
Day 0 control. Figure 3.25 demonstrated that Lasp1 stable expression also promoted 
HepG2 cell growth in monolayer. At Day 4 post seeding, the cell number of HepG2-
Lasp1 stable cell lines reached 186.8% (HepG2-Lasp1-1, 1469.2% of Day 0 control) 
and 239.6% (HepG2-Lasp1-2, 1925.9% of Day 0 control) relative to that of the 
HepG2-Neo control (1043.8% of Day 0 control), respectively (P < 0.01). These 
results further demonstrated that Lasp1 played a promoting role in HCC cell growth 




                  
 
Figure 3.24 Lasp1-V5 fusion protein expression in HepG2-Lasp1 stable cell lines. 
HepG2 stable transfectants were selected in DMEM/10% FBS supplemented with 
800μg/ml G418. Cell lysates from different passage were collected and the Lasp1 
over-expression of two stable HepG2-Lasp1 clones (Lasp1-1, Lasp1-2) was 
confirmed by Western blot with both specific anti-V5 and anti-Lasp1 antibody. β-
actin blotting was used as a protein loading control. 
 
             
 
Figure 3.25 Lasp1 stable over-expression enhanced cell proliferation in HepG2 
cells. Two HepG2-Lasp1 stable transfectants (HepG2-Lasp1-1, HepG2-Lasp1-2) and 
the HepG2-Neo control cell line were seeded in 96-well plate in triplicates. The cell 
growth rates were monitored daily by WST-1 assay. At each time point, the data were 
presented as the percentage relative to the cell number seeded at Day 0 for each line, 
which was arbitrarily set at 100% as Day 0 control. The mean ± SD of triplicates are 
shown for each point. Both HepG2-Lasp1-1 (filled circle) and HepG2-Lasp1-2 (filled 
triangle) stable cell lines showed increased cell proliferation rate compared to HepG2-




Effect of Lasp1 siRNA knockdown in soft agar assay 
In order to explore the roles of Lasp1 on HCC cell growth under more 
stringent conditions, the anchorage-independent assay was performed to test the 
colony formation ability in soft agar culture. HepG2 or Huh-7 cells transfected with 
either Lasp1 siRNA (Lasp1#1, Lasp1#2) or Negative Control siRNA (Neg Ctrl) were 
trypsinized 24 hours after transfection, 5 × 103   and/or 1 × 104 cells re-suspended in 
0.25ml of 0.35% agar dissolved in DMEM/10%FBS were plated in 24-well plate in 
triplicates overlying a 0.7% agar bottom layer and cultured at 37°C for additional 
three weeks. The colonies were stained, photographed and the number of colonies > 
100μm in diameter was counted. In sharp contrast to the controls transfected with 
Negative Control siRNA, HepG2 cells transfected with Lasp1#2 siRNA formed much 
fewer colonies in semi-soft agar. The colony number formed by the panel of cells of 
10000 cells/well at the starting point (Figure 3.26A, upper panel) was counted. 
Lasp1#2 siRNA transfected cells only formed 16.3% of colonies compared to that of 
control (P < 0.01) (Figure 3.26B). While in Huh-7 cells, since both siRNA oligos 
significantly down-regulated Lasp1 protein level (Figure 3.20), substantial differences 
were observed between cells transfected with Lasp1#1 or Lasp1#2 siRNA oligo and 
that transfected with Negative Control siRNA. The colony formation efficiency was 
only 14.8% (Lasp1#1) and 12.3% (Lasp1#2) respectively of that of control as 
reflected by colony count (P < 0.01) (Figure 3.26C, 3.26D). These results indicated 
that knockdown of Lasp1 expression by siRNA significantly inhibited the anchorage-










Figure 3.26 Lasp1 siRNA knockdown inhibited anchorage-independent growth 
of HCC cells in soft agar. HepG2 or Huh-7 cells transfected with Lasp1 siRNA 
(Lasp1#1, Lasp1#2) or Negative Control siRNA (Neg Ctrl) were replated for soft agar 
assay. After three weeks of incubation, the cells were stained and the colonies were 
photographed and counted. The colony forming efficiency was calculated as the 
percentage of the colony number formed by Lasp1 siRNA oligos transfected cells 
(Lasp1#1, grey bar; Lasp1#2, black bar) relative to that formed by Negative Control 
siRNA transfected cells (white bar), which was arbitrarily set at 100%. The mean± 
SD of triplicates are shown as well. (A) Representative images showed that HepG2 
cells transfected with Lasp1 siRNA (Lasp1#2) formed much smaller and fewer 
colonies in soft agar than those transfected with Negative Control siRNA (Neg Ctrl).  
The starting cell number was 5000 or 10000 per well, which were shown in the upper 
and lower panel respectively. (B) Colony count (10000 cells per well at starting point) 
for HepG2 cells. **P < 0.01. (C) Representative images showed Huh-7 cells 
transfected with Lasp1 siRNA oligos (Lasp1#1, Lasp1#2) formed much smaller and 
fewer colonies in soft agar than those transfected with control siRNA (Neg Ctrl).  The 









Effect of Lasp1 transient over-expression in soft agar assay 
Similarly, an anchorage-independent assay was performed to examine the 
function of over-expression of Lasp1 in colony formation ability in soft agar culture 
by using HepG2 and PLC/PRF/5 cells. 24 hours after transfection with pDEST40-
Lasp1/V5 or pcDNA3.1, 1 × 104 cells re-suspended in 0.25ml of 0.35% agar dissolved 
in DMEM/10%FBS were plated in 24-well plate in triplicates overlying a 0.7% agar 
bottom layer and cultured at 37°C for additional three weeks. In sharp contrast to the 
controls transfected with pcDNA3.1, both HepG2 and PLC/PRF/5 cells transfected 
with pDEST40-Lasp1/V5 formed much more micro-colonies in semi-soft agar 
(Figure 3.27A, Figure 3.27C), which is about 273.0% (Figure 3.27B) and 178.0% 
(Figure 3.27D) respectively of control (P < 0.05). These results reflected that Lasp1 
over-expression significantly enhanced the anchorage-independent growth of HepG2 
and PLC/PRF/5 cells, suggesting that Lasp1 can promote both HCC cell proliferation 
















       
 
 
Figure 3.27 Lasp1 over-expression enhanced anchorage-independent growth of 
HCC cells in soft agar. HepG2 or PLC/PRF/5 cells transfected with pDEST40-
Lasp1/V5 or pcDNA3.1 control were trypsinized 24 hours after transfection and 
replated for soft agar assay. After three weeks of incubation, the cells were stained 
and the colonies were photographed and counted. The colony forming efficiency was 
calculated as the percentage of the colony number formed by pDEST40-Lasp1/V5 
transfected cells (grey bar) relative to that formed by pcDNA3.1 transfected cells 
(white bar), which was arbitrarily set at 100%. The mean± SD of triplicates are 
shown as well. (A) Representative images showed that HepG2 cells transfected with 
pDEST40-Lasp1/V5 (Lasp1) formed more and larger colonies in soft agar than those 
transfected with pcDNA3.1 control (pcDNA). The starting cell number was 10000 per 
well. (B) Colony count for HepG2 cells. *P < 0.05. (C) Representative images 
showed that PLC/PRF/5 cells transfected with pDEST40-Lasp1/V5 (Lasp1) formed 
more and larger colonies in soft agar than those transfected with pcDNA3.1 control 
(pcDNA). The starting cell number was 10000 per well. (D) Colony count for 






3.2.4. Function study of Lasp1 on HCC cell adhesion, migration and invasion 
Effect of Lasp1 on cell adhesion to ECM proteins 
Lasp1 was reported to be necessary for cell migration, but not adhesion and 
spreading on the ECM using Cos-7 cells as a model (Lin et al. 2004). However, by 
considering that the cell adhesion to ECM proteins is the initial and critical step for 
cell migration and invasion, the role of Lasp1 on HCC cell adhesion was still tested in 
this study. HepG2 and Hep3B cells transfected with either Lasp1#2 siRNA oligo or 
pDEST40-Lasp1/V5 were examined for their adhesion activities to the set of 5 
different ECM proteins (fibronectin, vitronectin, laminin, collagen I and collagen IV). 
No significant difference in cell adhesion ability to the 5 types of ECM proteins was 
observed in cells either with reduced Lasp1 expression by siRNA knockdown (Figure 
3.28, P > 0.05) or with over-expressed Lasp1 by transfection of pDEST40-Lasp1/V5 
(Figure 3.29, P > 0.05) compared to their corresponding control cells. These results 
indicate that, consistent with previous report, Lasp1 does not play important roles in 

















          
 
 
Figure 3.28 Lasp1 siRNA knockdown did not alter HCC cell adhesion ability to 
ECM proteins. 48 hours after transient transfection with Lasp1#2 siRNA (Lasp1#2, 
black bars) or Negative Control siRNA (Neg Ctrl, white bars), HepG2 (A) and Hep3B 
(B) cells were replated for cell adhesion assay. Adhesion efficiency to each ECM 
protein was presented as the percentage relative to that of the Negative Control 
siRNA transfected cells, which was arbitrarily set at 100% (mean ± SD of triplicates). 











          
 
 
Figure 3.29 Lasp1 over-expression did not alter HCC cell adhesion ability to 
ECM proteins. 48 hours after transient transfection with pDEST40-Lasp1/V5 (grey 
bars) or pcDNA3.1 (white bars), HepG2 (A) or Hep3B (B) cells were replated for cell 
adhesion assay. Adhesion efficiency to each ECM protein was presented as the 
percentage relative to that of the pcDNA3.1 control transfected cells, which was 
arbitrarily set at 100% (mean ± SD of triplicates). FN: fibronectin, VN: vitronectin, 









Effect of Lasp1 on HCC cell migration and invasion ability 
As Lasp1 was reported to be involved in breast cancer metastasis, the function 
of Lasp1 in regulating cell migration and invasion ability in HCC cell lines was 
further explored as an indicator of its potential role in HCC metastasis. Firstly, the 
migration and invasion ability of Lasp1 siRNA transfected HepG2, Hep3B and Huh-7 
cells was tested. The results from the modified Boyden chamber assay showed that 
the migratory activities of Lasp1#2 transfected HepG2, Hep3B cells or Huh-7 were 
inhibited by 74.2% (Figure 3.30A), 74.3% (Figure 3.30B) (P < 0.01) and 86.9% 
(Figure 3.30C) (P < 0.05) respectively, as compared to corresponding Negative 
Control siRNA transfected cells. Furthermore, the invasive activities through ECM 
proteins were also suppressed in HepG2 (46.1% of control, P < 0.01) (Figure 3.30D), 
Hep3B (53.3% of control, P < 0.05) (Figure 3.30E) and Huh-7 cells (35.0% of control, 
P < 0.01) (Figure 3.30F). These results indicate that depletion of Lasp1 by siRNA in 
HCC cells suppresses the cell migratory and invasive ability, suggesting that HCC 















   
Figure 3.30 Lasp1 siRNA knockdown inhibited migration and invasion activities 
of HCC cells. After serum starvation for 24 hours, Negative Control siRNA (white 
bars) or Lasp1#2 siRNA (black bars) transfected HepG2 (1.0 × 105 cells / well), 
Hep3B cells (5.0 × 104 cells /well) or Huh-7 cells (5.0 × 104 cells /well) were replated 
for cell migration and invasion assays. Inhibitory effects on migration and invasion 
were presented as the percentage of fluorescent readings standardized to Negative 
Control siRNA transfected cells (mean ± SD of triplicates). *P < 0.05, ** P < 0.01. 
(A) Migration assay through 8μm microporous membranes in HepG2 cells. (B) 
Migration assay through 8μm microporous membranes in Hep3B cells. (C) Migration 
assay through 8μm microporous membranes in Huh-7 cells. (D) Invasion assay 
through ECM proteins in HepG2 cells. (E) Invasion assay through ECM proteins in 






The migration and invasion ability of Lasp1 transient over-expression in both 
HepG2 and Hep3B cells were examined as well. We first noticed that several previous 
studies showed that further over-expression of Lasp1 in cancer cell lines which 
already up-regulated Lasp1 expression level also inhibited cell migration and invasion 
activities (Lin et al. 2004; Grunewald et al. 2006). Consistent with these previous 
reports, HepG2 cells transfected with pDEST40-Lasp1/V5 showed 41.2% (P < 0.01) 
inhibition in cell migration and 33.5% (P < 0.05) inhibition in cell invasion activity 
compared to pcDNA3.1 transfected cells (Figure 3.31A and 3.31D). The experiments 
were repeated using Hep3B and Huh-7 cells with similar results achieved (Figure 
3.31B, 3.31C, 3.31E and 3.31F).  
In addition, the HepG2 cell lines with Lasp1 stable over-expression (HepG2-
Lasp1-1 and HepG2-Lasp1-2) and the control clone with Neo-resistant gene (HepG2-
Neo) were used for this study. The results showed that the migratory activities of both 
Lasp1 stable cell lines were inhibited up to 36.3% (HepG2-Lasp1-1) and 45.8% 
(HepG2-Lasp1-2) respectively as compared to HepG2-Neo control (P < 0.01) (Figure 
3.32A). The invasive activities through ECM proteins were also significantly 
suppressed in both HepG2-Lasp1 stable clones (40.8% and 28.3% of control 
respectively, P < 0.01) (Figure 3.32B).  
These results support the conclusion that Lasp1 plays important roles in 












Figure 3.31 Lasp1 transient over-expression inhibited migration and invasion 
activities of HCC cells. After serum starvation for 24 hours, pcDNA3.1 (white bars) 
or Lasp1-DEST40/V5 (grey bars) transfected HepG2 (1.0 × 105 cells / well), Hep3B 
(5.0 × 104 cells /well) or Huh-7 (5.0 × 104 cells /well) cells were replated for cell 
migration and invasion assays. Inhibitory effects on migration and invasion were 
presented as the percentage of fluorescent readings standardized to pcDNA3.1 control 
(mean ± SD of triplicates). *P < 0.05, ** P < 0.01. (A) Migration assay through 8μm 
microporous membranes in HepG2 cells. (B) Migration assay through 8μm 
microporous membranes in Hep3B cells. (C) Migration assay through 8μm 
microporous membranes in Huh-7 cells. (D) Invasion assay through ECM proteins in 
HepG2 cells. (E) Invasion assay through ECM proteins in Hep3B cells. (F) Invasion 








          
 
 
Figure 3.32 Lasp1 stable over-expression inhibited migration and invasion 
activities in HepG2 cells. After serum starvation for 24 hours, two stable clones 
HepG2-Lasp1-1 (grey bars), HepG2-Lasp1-2 (black bars), and a HepG2-Neo control 
(white bars) were plated (5.0 × 105 cells/well) for cell migration and invasion assays. 
Inhibitory effects on migration and invasion were presented as the percentage of 
fluorescent readings standardized to HepG2-Neo control (mean ± SD of triplicates). 
** P < 0.01. (A) Migration assay through 8μm microporous membranes. (B) Invasion 








3.2.5. Cellular localization study of Lasp1 in HCC 
Two recent reports uncovered that depletion of Lasp1 by specific siRNA led to 
change of zyxin localization in both breast cancer and ovarian cancer cells, which 
may explain the phenomenon that Lasp1 siRNA knockdown inhibited the cell 
migration and invasion ability in these cancer cell lines (Grunewald et al. 2006; 
Grunewald et al. 2007).  As both previous reports and the current study showed that 
further over-expression of Lasp1 in those cancer cell lines which had already up-
regulated Lasp1 level also significantly suppressed the cell migration and invasion 
activities, it would be interesting to explore the mechanism underneath. Thus, in this 
study, the confocal microscopy analyses were performed to determine whether over-
expression of Lasp1 can influence the localization of zyxin as well as some other 
focal adhesion proteins.  
Hep3B and Huh-7 cells were chosen for this study due to their ability to form 
monolayer when cultured in vitro, which is suitable for immunofluorescence study. 
The Gateway expression vector pDEST47-Lasp1/GFP was introduced into Hep3B or 
Huh-7 cells plated in 6-well plate by transient transfection. 24 hours later, cells were 
replated onto the 35mm glass bottom microwell dishes for overnight incubation. The 
cells were then fixed and stained with specific mouse monoclonal antibodies to zyxin, 
VASP, and paxillin followed by staining with goat-anti-mouse secondary antibody 
conjugated with Alexa Fluor-647. F-actin was stained by Alexa Fluor-635 conjugated 
Phalloidin.  
Similar to the depletion of Lasp1 by specific siRNA in breast cancer or 
ovarian cancer cells, Lasp1 over-expression in both Hep3B (Figure 3.33A) and Huh-7 
(Figure 3.33B) cells which had high endogenous Lasp1 expression (Figure 3.18), also 
changed the localization of zyxin. In Lasp1 over-expressed Hep3B cells, zyxin 
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showed diffused distribution in both cytoplasm and nucleus co-localized with Lasp1-
GFP (yellow color, white arrow), whereas in cells without Lasp1-GFP expression, 
zyxin was mainly localized to the site of the focal adhesion. Similarly in Huh-7 cells, 
zyxin lost its localization at focal contact or along the F-actin fibers, but co-localized 
with over-expressed Lasp1-GFP as indicated in the merged picture. More 
interestingly, the morphology of the Lasp1-GFP expressing cells was quite different 
from Lasp1-GFP non-expressing cells. Those cells with very high level of Lasp1-GFP 
expression were often observed in oval shape without obvious polarity. However, the 
Lasp1-GFP non-expressing Hep3B or Huh-7 cells tend to spread out with clear 
lamellipodia structures and/or with extended shape showing obvious F-actin fibers, as 
observed in Huh-7 cells (enlarged images for the areas defined by white boxes) 
(Figure 3.33B, bottom panel).  
Besides zyxin, localization of VASP and paxillin was also tested in this study. 
As shown in Figure 3.34, the confocal microscopy study revealed that Lasp1 also 
altered the localization of VASP, which was reported to be a binding partner of Lasp1 
and play an important role in actin dynamics as a scaffolding protein in F-actin 
polymerization (Krause et al. 2003). It was clearly shown that VASP was fully co-
localized with Lasp1-GFP (yellow). In Lasp1 over-expressed cells (white arrow), 
VASP was diffused in the whole cell instead of being localized exclusively at the cell 
peripheral as observed in cells without Lasp1-GFP expression.  
Paxillin, a focal-adhesion LIM protein which binds to various cytoskeletal and 
signaling proteins and can mediate integrin signaling (Schaller 2001), was also shown 
to be co-localized with Lasp1 as indicated in yellow in the merged pictures. Further 
over-expression of Lasp1 in Hep3B and Huh-7 cells significantly changed its 
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localization from focal adhesion site at the cell peripheral to the whole cell body 
(white arrow) (Figure 3.35).  
The protein lysates were extracted from Lasp1 over-expressed cells and 
subjected to Western blot using the same antibodies applied in confocal staining in 
order to show the antibody specificity and to exclude the possibility that Lasp1 over-
expression affect their expression. As shown in Figure 3.36, the protein level of zyxin, 
VASP or paxillin as compared to pcDNA3.1 control transfected cells in all three cell 
lines did not have obvious change upon Lasp1 over-expression. Another noteworthy 
finding was that the expression of zyxin in HepG2 cells was almost undetectable as 
compared to that in Hep3B or Huh-7 cells. Lasp1 blotting showed over-expression of 
Lasp1, with β-actin blotting used as a protein loading control.  
Zyxin, VASP and paxillin were reported to be involved in focal adhesion 
signaling and/or F-actin dynamics (Turner 2000b; Welch and Mullins 2002). Also, 
Lasp1 was shown to be an actin binding protein and function as a scaffold protein in 
F-actin polymerization and cell migration. Thus, it would be interesting to test 
whether the F-actin polymerization is also affected by Lasp1 further over-expression 
in HCC cell lines. F-actin was stained by Alexa Fluor-635 conjugated Phalloidin. The 
results showed that much fewer F-actin stress fibers were detected in Lasp1 over-
expressed Hep3B or Huh-7 cells, while those cells without expressing Lasp1-GFP had 











Figure 3.33 Lasp1 over-expression changed the localization of zyxin. pDEST47-
Lasp1/GFP was transfected into Hep3B (A) or Huh-7 (B) cells plated in 6-well plate. 
24 hours after transfection, cells were replated onto glass bottom microwell dishes for 
overnight incubation. Zyxin was stained with specific mouse monoclonal anti-zyxin 
antibody followed by goat-anti-mouse AF647. The images were captured under 
confocal microscope for Lasp1-GFP (green, 488nm), zyxin (red, 633nm). The areas 
defined by white boxes were shown as enlarged images at the bottom panel. Co-
localization of Lasp1 and zyxin was shown in the merged pictures as yellow indicated 













Figure 3.34 Lasp1 over-expression changed the localization of VASP. pDEST47-
Lasp1/GFP was transfected into Hep3B or Huh-7 cells plated in 6-well plate. 24 hours 
after transfection, cells were replated onto glass bottom microwell dishes for 
overnight incubation. VASP was stained with specific mouse monoclonal anti-VASP 
antibody followed by goat-anti-mouse AF647. The images were captured under 
confocal microscope for Lasp1-GFP (green, 488nm), VASP (red, 633nm). Co-
localization of Lasp1 and VASP was shown in the merged pictures as yellow 

















Figure 3.35 Lasp1 over-expression changed the localization of paxillin. pDEST47-
Lasp1/GFP was transfected into Hep3B or Huh-7 cells plated in 6-well plate. 24 hours 
after transfection, cells were replated onto glass bottom microwell dishes for 
overnight incubation. Paxillin were stained with specific mouse monoclonal anti-
paxillin antibody followed by goat-anti-mouse AF647. The images were captured 
under confocal microscope for Lasp1-GFP (green, 488nm), paxillin (red, 633nm). Co-
localization of Lasp1 and paxillin was shown in the merged pictures as yellow 




















               
 
 
Figure 3.36 Lasp1 over-expression did not alter the protein level of zyxin, VASP 
or paxillin. 48 hours after transfection of pDEST40-Lasp1/V5 (+: pDEST40-Lasp1) 
or pcDNA3.1 (–: pcDNA) into HepG2, Hep3B or Huh-7 cells, the cell lysates were 
collected and the proteins were separated by 10% SDS-PAGE followed by Western 
blot using a series of antibodies, including Rabbit-anti-Lasp1, Mouse-anti-zyxin, 
Mouse-anti-VASP and Mouse-anti-paxillin. β-actin blotting was used as a protein 

















             
 
 
Figure 3.37 Lasp1 over-expression inhibited the formation of F-actin bundles. 
pDEST47-Lasp1/GFP was transfected into Hep3B or Huh-7 cells plated in 6-well 
plate. 24 hours after transfection, cells were replated onto glass bottom microwell 
dishes for overnight incubation. F-actin was stained with Phalloidin-AF635. The 
images were captured under confocal microscope for Lasp1-GFP (green, 488nm), F-
actin (red, 633nm). Lasp1-GFP expressing cells were indicated by white arrow. 










In summary, a similar in vitro experimental system used in Cyr61 functional 
characterizations was applied in this part of study to explore the possible roles of 
Lasp1 in HCC growth and metastasis.  
The cell proliferation study indicated that up-regulation of Lasp1 in HCC also 
represented a strategy of tumor cells to gain growth advantage. Knockdown of Lasp1 
significantly inhibited the proliferation rate of HCC cells in monolayer. The capability 
of anchorage-independent growth, which is an important indicator of malignant 
transformation, was also suppressed by depleting Lasp1. Whereas, further over-
expression of Lasp1 in HCC cell lines promoted cell growth both in monolayer and in 
soft agar, confirmed that Lasp1 exerted an enhancing effect in HCC cell growth.  
In addition, both siRNA knockdown and further over-expression of Lasp1 in 
HCC cell lines suppressed the cell migratory and invasive activities, suggesting that 
Lasp1 functions within a certain optimal concentration in cancer cells in regulating 
cell migration and invasion ability. The confocal microscopy study implied the 
possible mechanism for Lasp1 in regulating HCC cell migration and invasion ability. 
As a scaffolding protein, Lasp1 may determine the localization of a series of focal 
adhesion proteins, such as zyxin, VASP and paxillin, which in turn affect the F-actin 









3.3. Part III: p53 is a central master protein in the pathway involving Cyr61 and 
Lasp1 in HCC 
3.3.1. Cyr61 is an upstream regulator of p53 in HCC 
Role of Cyr61 in HCC cell cycle regulation 
Cell cycle analysis was carried out in an attempt to understand the 
mechanisms involved in the suppression of HCC cell growth by Cyr61. As described 
in section 2.10.1 and 2.11, HepG2-Cyr61 stable transfectants (HepG2-Cyr61-1 and 
HepG2-Cyr61-2) and HepG2-Neo control cell lines were either untreated or treated 
with 5- Fluorouracil (5-FU, 50μg/ml) or UV irradiation (20J/m2) for flow cytometry 
analysis. It was first noted that both stable cell lines without any treatment had higher 
percentage of cells (16.5% and 18.6% respectively) arrested in the G2/M phase 
compared to the Neo control (13.1%) (Figure 3.38, 1st row). Furthermore, a more 
prominent G2/M arrest was maintained in the two HepG2-Cyr61 stable cells lines 
(13.7% and 12.7% respectively) compared to HepG2-Neo control (5.5%) after being 
subjected to 5-FU treatment (Figure 3.38, 2nd row). Similar observation was obtained 
from the cells undergone UV irradiation, which caused a dramatic reduction of cells at 
G2/M phase as observed in HepG2-Neo control cells (5.7%) compared to HepG2-
Cyr61 stable cells (15.8% and 13.1% respectively) (Figure 3.38, 3rd row). However, 
















Figure 3.38 Cyr61 over-expression induced G2/M arrest of HepG2 cells. HepG2-
Cyr61 stable cells (HepG2-Cyr61-1, HepG2-Cyr61-2) and HepG2-Neo cells under 
different treatments were separately collected, fixed in 70% ethanol, treated with 
RNase A (100μg/ml) and stained with propidium iodide (50μg/ml) for flow cytometry 
analysis. The percentage of cells in G2/M and Sub-G1 phase is indicated. Cell cycle 
analysis of non-treated HepG2-Cyr61 stable cell lines and HepG2-Neo cells is shown 
on the top panel, and the analyses of 5-FU (50μg/ml) or UV (20J/m2) treated cells are 








Cyr61 up-regulates p53 expression in p53 wild-type HCC cells 
At the same passage (4th passage), cellular proteins extracted from HepG2-
Cyr61-1, HepG2-Cyr61-2 and HepG2-Neo cells were separated by SDS-PAGE 
followed by Western blot using a series of antibodies specific to Cyr61, p53 and p21, 
the latter two of which were known to be important cell cycle regulators involved in 
G1, S and G2/M arrests. The protein levels of p53 and its downstream target gene p21 
were shown to be significantly up-regulated in HepG2-Cyr61 stable cells (Figure 3.39, 
left panel). Similar findings were observed in HepG2 cells transiently transfected with 
pDEST40-Cyr61/V5 plasmid, which showed up-regulating levels of p53 and p21 
proteins in HepG2 cells with increasing expression of Cyr61/V5 (Figure 3.39, upper 
right panel). In addition, the mRNA levels of two G2/M arrest marker gene, 14-3-3σ 
and GADD45 (Hermeking et al. 1997; Wang et al. 1999), were tested by semi-
quantitative RT-PCR with GAPDH as a housekeeping control. The results 
demonstrated up-regulation of the mRNA of both 14-3-3σ and GADD45 upon 
transient transfection of increasing doses of pDEST40-Cyr61/V5 in HepG2 cells 
(Figure 3.39, lower right panel). All the above findings suggested that over-expression 
of Cyr61 in HepG2 cells induced G2/M arrest, at least in part, by up-regulating the 

















                         
 
 
Figure 3.39 Cyr61 over-expression led to up-regulation of p53 and its 
downstream targets. Western blot and RT-PCR indicated up-regulation of protein 
and mRNA level of p53 and several well-defined p53 downstream targets in Cyr61-
expressing cells. The left panel shows the results of cell lysates collected from HepG2 
stable cell lines (Cyr61-1, Cyr61-2, and Neo control), while the data from HepG2 
cells transiently transfected with increasing dose of pDEST40-Cyr61/V5 are shown 
on the upper right panel. Semi-quantitative RT-PCR showed the mRNA up-regulation 
of two G2/M arrest marker gene 14-3-3σ and GADD45 in Cyr61 transient over-










Cyr61 is a genotoxic stress responsive gene 
To further explore the potential roles of Cyr61 in cell cycle progression, we 
investigated the endogenous expression of Cyr61 upon genotoxic stress induction, 
which are known to trigger cellular processes of growth arrest or apoptosis, with p53 
being the major cellular sensor and signal of DNA damage (Amundson et al. 1998). 
As illustrated in section 2.10.2, both p53 wild-type (p53+/+) HepG2 cell line and p53 
null (p53-/-) Hep3B cells line were used in the experiments. As expected, p53 and p21 
proteins significantly accumulated in p53+/+ HepG2 cells over the 48-hour period 
after 5-FU treatment or UV irradiation (Figure 3.40A, upper panel), whereas both 
proteins remained undetectable in p53-/- Hep3B cells (Figure 3.40B, upper panel). 
Remarkably, the endogenous expression of Cyr61, which was barely detectable in 
non-treated HepG2 and Hep3B cells by Western blot, was dramatically increased in 
response to the genotoxic stress in both HCC cells regardless of p53 status (Figure 
3.40A and 3.40B, upper panel). Concomitantly, mRNA expression of Cyr61 was also 
up-regulated in both HepG2 and Hep3B cells upon genotoxic treatment as measured 
by RT-PCR (Figure 3.40A and 3.40B, lower panel). The mRNA expression of Cyr61 
in HepG2 cells quickly peaked at 4h after treatments, compared to a gradually 
increased mRNA expression throughout the 48h period occurred in Hep3B cells, 
though the protein expression of Cyr61 reached a maximal level around 24-48h 






       
 
Figure 3.40 Expression of endogenous Cyr61 was up-regulated in response to 
genotoxic stress regardless of p53 status in HCC cell lines. HepG2 (A) and Hep3B 
(B) cells treated with 5-FU (50μg/ml) or UV irradiation (20J/m2) were harvested at 
indicated time points for lysate extraction and RNA isolation. Cell lysates were 
analyzed by Western blot for the expression of Cyr61, p53 and p21 using specific 
antibodies (upper panel). The transcription level of Cyr61 was measured by semi-
quantitative RT-PCR (lower panel). Band intensities were measured by densitometry, 
and expression levels of Cyr61 for each point relative to the 0h point in each group 
are indicated beneath each band. GAPDH was used to indicate the integrity and 
comparable quantity of RNA samples in RT-PCR. 
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To further confirm the conclusion that Cyr61 is a genotoxic stress inducible 
gene involved in DNA damage response, HCT116 and its derived isogenic p53-/- 
cells were also used for this study as another paired cell lines in parallel to HepG2 and 
Hep3B cells. Cell lysates collected at different time points after 5-FU (50µg/ml) 
treatments were subjected to Western blot using Cyr61 specific antibody. The same 
results as in HepG2 and Hep3B cells were observed, i.e. Cyr61 protein level were 
dramatically up-regulated upon 5-FU treatment in both HCT116 and HCT116 (p53-/-) 







Figure 3.41 Expression of endogenous Cyr61 was up-regulated in response to 
genotoxic stress regardless of p53 status in colon cancer cell lines. HCT116 
(p53+/+) and HCT116 (p53-/-) cells treated with 5-FU (50μg/ml) were harvested at 
indicated time points for lysate extraction. Cell lysates were analyzed by Western blot 
for the expression of Cyr61, p53 and p21 using specific antibodies. β-actin blotting 






3.3.2. Lasp1 is a downstream target of p53  
Chromatin immunoprecipitation (ChIP) is a powerful technique for analyzing 
transcription factor binding site (TFBS) in living cells. This technology was most 
commonly employed to map TFBS in high-throughput manner, such as ChIP-on-
CHIP. Recently, a paired-end ditag method, which extracts 36bp signatures with 18bp 
from the 5’ end and another 18bp from the 3’ end of each cDNA clone, was 
established to concatenate the PETs for efficient sequencing and map the PET 
sequences to the genome to demarcate gene-transcription boundaries (Ng et al. 2005). 
In a more recent study, Lasp1 was found to be a potential p53 target gene identified 
by coupled ChIP with the paired-end ditag technologies (ChIP-PET) (Wei et al. 2006).  
In the current study, having shown the biological functions of Lasp1 in HCC 
growth and metastasis, we further demonstrated the role of p53 in transcriptionally 
regulating Lasp1 using p53 wild-type HepG2 and p53 null Hep3B cells as a model 
cell system. Moreover, in order to exclude any possibility of factors other than p53, 
the colon cancer cell line HCT116 and its derived isogenic p53-/- cell line were also 
included as a parallel cell system, which were obtained from Dr. Bert Vogelstein as a 
gift. 
 
ChIP-PET and ChIP validation 
As shown in Figure 3.42A, three PETs positioning at Chr17: 34278957-
34279301, 34279232-34279970, and 34279673-34280068 were identified from the 
previous ChIP-PET study (Wei et al. 2006). These PETs were mapped to -937~-
593bp, -662~+76bp, and -221~+174bp relative to the transcription start site of Lasp1 




As the original ChIP data were only obtained from HCT116 cells, both 
HCT116 and HepG2 cells carrying wild-type p53 gene were used in a ChIP assay in 
order to further validate the ChIP-PET results. As described in section 2.12, six hours 
after 5-FU treatment, cells were cross-linked with formaldehyde and the chromatin 
extracts containing DNA fragments of average size of 500bp were immuno-
precipitated using anti-p53 antibody. ChIP-qPCR was then performed using p53-
antibody enriched chromatin DNA. Primers were designed to match different regions 
spanning the Lasp1 promoter and part of the transcript, and more specifically to target 
the ChIP-PET overlap region. The ChIP-qPCR primer sequences were listed in Table 
2.11, and their positions relative to the Lasp1 transcription start site (Lasp1 TSS) and 
to the identified PETs (Wei et al., 2006) were illustrated in Figure 3.42A as well. 
Relative occupancy values (fold enrichments) were calculated by determining the 
immuno-precipitation efficiency and normalized to the level observed at a control 
region, which was set at 1.0 as indicated by dashed line in Figure 3.42B. The ChIP-
qPCR results revealed two enrichment regions covered by primer set 3 and 4 (P3 and 
P4), 5 and 6 (P5 and P6) respectively, which spanned -598~-333bp and -92~+96bp 
relative to the Lasp1 transcription start site (TSS). Although the second enrichment 
region spanned by primer set P5 and P6 had a lower enrichment fold than the first 
region, it corresponded well to the second overlap region identified by the previous 
p53 ChIP-PET study (Wei et al. 2006). Thus it is highly possible that the p53 binding 








     
 
Figure 3.42 ChIP-PET and ChIP validation. (A) Illustrations of 3 ChIP-PETs 
located on the Lasp1 promoter region. The PET sequences shown as red rectangles 
are mapped to genome to demarcate the boundaries of DNA fragments. The amplified 
regions of the primer sets (P1~P8) used in ChIP-qPCR are also mapped to the Lasp1 
5’flanking region and part of the Lasp1 transcript. Lasp1 transcription start site 
(Lasp1 TSS) is indicated by the black arrow. (B) Results of ChIP-qPCR. HepG2 and 
HCT116 (p53+/+) cells were treated by 5-FU for 6 hours. ChIP was performed with 
antibody against p53. The p53 binding was tested by using Lasp1 promoter specific 
primer sets P1~P8. Relative occupancy values (fold enrichments) were calculated by 
determining the immuno-precipitation efficiency and normalized to the level observed 





p53 transcriptionally suppresses Lasp1 expression 
Although Chromatin-IP can enrich for TFBS-containing DNA fragments, a 
significant amount of background DNA will still be present in the immuno-
precipitated DNA. With a limited survey of the cloned ChIP DNA fragment pool, it is 
difficult to distinguish between genuine binding sites and noise. Thus, the molecular 
validation is very critical in defining bona fide p53 target genes.  
To test whether p53 can functionally suppress Lasp1 gene expression, we first 
over-expressed p53 gene in p53 null Hep3B cells. The cells were plated in 6-well 
plates for overnight incubation followed by pCMV-p53 (wild-type p53) or pCMV-
p53-R175H (DNA binding domain mutated p53) transfection. Total RNA and lysate 
were collected at different time points (0h, 6h, 10h, 24h, 48h, 72h) for real-time 
quantitative RT-PCR analysis for mRNA expression and Western blot for protein 
expression, respectively. The results of Figure 3.43A showed that the Lasp1 mRNA 
was down-regulated by wild-type p53 but not by mutant p53 in a time-dependent 
manner. The significant change started as early as 6 hours after transfection. As a 
positive control, p21 mRNA was rapidly up-regulated by wild-type p53 but not by 
p53-R175H. The decrease of Lasp1 protein expression was only obviously observed 
in wild-type p53 over-expressed cells after 48 hours of transfection, reaching less than 
half of the original amount at 72 hours (Figure 3.43B, upper panel). After transfection 
with increasing doses of wild-type p53 expression vectors, the down-regulation of 
Lasp1 protein expression was confirmed by Western blot as expected (Figure 3.43C). 
The same set of experiments was performed using HCT116 (p53-/-) cell lines. Similar 
results were obtained as in Hep3B cells, i.e. over-expression of wild-type p53 but not 
mutant p53 down-regulated both Lasp1 mRNA (Figure 3.44A) and protein levels in 










Figure 3.43 p53 but not p53 mutant over-expression down-regulated Lasp1 
expression in Hep3B cells. Hep3B cells transfected with pCMV-p53 or pCMV-p53-
R175H (4µg/well for 6-well plates) were harvested at indicated time points for total 
RNA isolation followed by cDNA synthesis or lysate extraction. (A) The transcription 
level of Lasp1 was measured by real-time quantitative RT-PCR using Lasp1 specific 
primers. After normalized to a housekeeping gene HPRT, Lasp1 expression level was 
presented as the percentage relative to the level at 0h time point, which was arbitrarily 
set at 1.0. The mean ± SD of triplicates are shown for each point. p21 was included 
as a positive control to indicate the functionality of over-expressed p53. (B) Cell 
lysates were analyzed by Western blot for the expression of Lasp1 and p53 using 
specific antibodies. β-actin was used as a control for equal protein loading. (C) Hep3B 
cells transfected with increasing doses of pCMV-p53 or pCMV-p53-R175H (0, 1, 2, 4, 
6µg/well for 6-well plates) were harvested at indicated time points for lysate 
collection. Western blot using Lasp1 and p53 antibodies showed that p53 over-








                    
 
 
Figure 3.44 p53 but not p53 mutant over-expression down-regulated Lasp1 
expression in HCT116 (p53-/-) cells. HCT116 (p53-/-) cells transfected with pCMV-
p53 or pCMV-p53-R175H (4µg/well for 6-well plates) were harvested at indicated 
time points for total RNA isolation followed by cDNA synthesis or lysate extraction. 
(A) The transcription level of Lasp1 was measured by real-time quantitative RT-PCR 
using Lasp1 specific primers. After normalized to a housekeeping gene HPRT, Lasp1 
expression level was presented as the percentage relative to the level at 0h time point, 
which was arbitrarily set at 1.0. The mean ± SD of triplicates are shown for each 
point. p21 was included as a positive control to indicate the functionality of over-
expressed p53. (B) Cell lysates were analyzed by Western blot for the expression of 
Lasp1, p53 and p21 using specific antibodies. β-actin was used as a control for equal 




Treatment of cells with chemotherapeutic drug 5-FU has been shown to 
induce rapid accumulation of p53 (Fritsche et al. 1993; Muller et al. 1998). At 
different time points up to 48 hours, the total RNA and protein lysate from HepG2 
(p53 wild-type) and Hep3B (p53 null) cells treated with 5-FU (50μg/ml) were 
separately collected. In HepG2 cells, a sharp increase was observed in the protein 
expression of p53 and its defined target p21 after 5-FU treatment over the basal 
expression level, while in p53 null Hep3B cells, the p53 and p21 protein level 
remained undetectable (Figure 3.45B). Then the expression of both Lasp1 mRNA and 
protein level was examined by real-time quantitative RT-PCR and Western blot, 
respectively. It was clearly shown that both Lasp1 mRNA and protein levels were 
decreased upon 5-FU treatment in p53 wild-type HepG2 cells but not in p53 null 
Hep3B cells (Figure 3.45A and 3.45B). Since the p53 status is not the only difference 
between HepG2 and Hep3B cells, the same set of experiments was performed in 
HCT116 and its derived isogenic p53-/- cell lines. The similar results were achieved 






















       
 
 
Figure 3.45 Endogenous p53 induced upon 5-FU treatment down-regulated 
Lasp1 expression in HepG2 but not in Hep3B cells. HepG2 and Hep3B cells 
treated with 5-FU (50μg/ml) were harvested at indicated time points for lysate 
extraction and RNA isolation. (A) The transcription level of Lasp1 was measured by 
real-time quantitative RT-PCR using Lasp1 specific primers. After normalized to a 
housekeeping gene HPRT, Lasp1 expression level was presented as the percentage 
relative to the level at 0h time point, which was arbitrarily set at 1.0. The mean ± SD 
of triplicates are shown for each point. p21 was included as a positive control to 
indicate the functionality of p53. (B) Cell lysates were analyzed by Western blot for 
the expression of Lasp1, p53, and p21 using specific antibodies. β-actin was used as a 




                
 
 
Figure 3.46 Endogenous p53 induced upon 5-FU treatment down-regulated 
Lasp1 expression in HCT116 (p53+/+) but not in HCT116 (p53-/-) cells. HCT116 
(p53+/+) and its isogenic p53-null HCT116 (p53-/-) cells treated with 5-FU (50μg/ml) 
were harvested at indicated time points for lysate extraction and RNA isolation. (A) 
The transcription level of Lasp1 was measured by real-time quantitative RT-PCR 
using Lasp1 specific primers. After normalized to a housekeeping gene HPRT, Lasp1 
expression level was presented as the percentage relative to the level at 0h time point, 
which was arbitrarily set at 1.0. The mean ± SD of triplicates are shown for each 
point. p21 was included as a positive control to indicate the functionality of p53. (B) 
Cell lysates were analyzed by Western blot for the expression of Lasp1, p53, and p21 
using specific antibodies. β-actin was used as a control for equal protein loading.  
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To further confirm the role of p53 in transcriptionally regulating Lasp1, we 
transfected p53 specific siRNA into p53 wild-type HepG2 and HCT116 cells to 
knockdown the endogenous p53 expression and examined the change of Lasp1 
mRNA. 24 hours after siRNA transfection, total RNA was extracted and the 
synthesized cDNA was subjected to real-time quantitative RT-PCR. In both HepG2 
(Figure 3.47A) and HCT116 cells (Figure 3.47B) transfected with p53 siRNA, the 
p53 mRNA was down-regulated by its specific siRNA to only 39% (HepG2) and 32% 
(HCT116) compared to the control. Moreover, mRNA expression of its well-known 
downstream target p21 was also suppressed to 55% (HepG2) and 37% (HCT116) 
relative to that in the control siRNA (siControl) transfected cells. Real-time 
quantitative PCR using Lasp1 specific primer set clearly showed that, compared to 
siControl transfected cells, the Lasp1 mRNA expression was up-regulated to 228% in 
HepG2 (Figure 3.47A) and 154% in HCT116 cells (Figure 3.47B) respectively. In 
conclusion, all above experiments demonstrate that Lasp1 expression is negatively 


















        
 
 
Figure 3.47 Knockdown of endogenous p53 by p53 specific siRNA up-regulated 
Lasp1 mRNA in HepG2 and HCT116 (p53+/+) cells. HepG2 (A) or HCT116 
(p53+/+) (B) cells transfected with p53 specific siRNA (white bar) or control siRNA 
(siControl) (black bar) (40nM) were harvested at 24 hours post transfection for RNA 
isolation. Following cDNA synthesis, the mRNA expression level of p53, p21 and 
Lasp1 was analyzed by real-time quantitative RT-PCR. After normalized to a 
housekeeping gene HPRT, gene expression level for all three genes was presented as 
the percentage relative to the level of the siControl transfected cells, which was 
arbitrarily set at 1.0. The mean ± SD of triplicates are shown. p21 was included as a 










pGL3-cloning of Lasp1 promoter region 
To determine an inhibitory effect of p53 on Lasp1 gene transcription, a 
~1.95kb genomic fragment of Lasp1 gene covering -1872bp to +74bp relative to the 
transcription start site was cloned into pGL3-Basic luciferase reporter vector (Figure 
2.5). The ATG translation start codon was excluded from the fragment to ensure the 
correct translation of luciferase reporter gene. The detailed protocol was described in 
section 2.4.3, and the constructed vectors were illustrated in Figure 3.48A. Briefly, the 
insert DNA was isolated by a PCR reaction using HepG2 human genomic DNA as a 
template (Figure 3.48B). The PCR product was first cloned into pCR-BluntII-TOPO 
vector (Figure 2.4) (defined as TOPO-Lasp1-PR) and then sub-cloned into the pGL3-
Basic vector (defined as pGL3-Lasp1-PR). Enzymatic digestion (Figure 3.48C) and 



















Figure 3.48 pGL3-cloning for Lasp1 promoter region. (A) Illustrations of the 
constructed plasmids. TOPO-Blunt II flanking region (green boxes), luciferase gene 
product (luc+, orange box) and the restriction enzyme sites (▲) are indicated. (B) 
PCR amplification of Lasp1 promoter region using HepG2 genomic DNA as a 
template. Lane1: 1kb plus DNA Ladder; Lane2: Lasp1-PR PCR product of about 
1.95kb. (C) Enzyme digestion of the constructed vectors. Lane1: 1kb plus DNA 
ladder; Lane2: TOPO-Lasp1-PR Kpn I + EcoR V digested, 2 fragments (1977bp, 





p53 down-regulates Lasp1 promoter activity 
Genetic reporter systems are widely used to study eukaryotic gene expression 
and cellular physiology. The Dual-Luciferase® Reporter Assay System (Promega) 
provides an efficient means of performing dual-reporter assays, in which the impact 
from different transfection efficiency is removed by sequentially measuring the 
activities of Firefly and Renilla luciferases from a single sample. Hence in this study, 
in order to examine the effect of p53 on Lasp1 promoter activity,  pGL3-Lasp1-PR in 
the presence of different doses of pCMV-p53 or pCMV-p53-R175H was transfected 
into HCT116 (p53-/-) or Hep3B cells in a 96-well plate format. 36 hours after 
transfection, the Lasp1 promoter activities in transfected cells were determined by the 
Dual-Luciferase® Reporter Assay System. The results in Figure 3.49 showed that p53 
but not p53-R175H mutant inhibited the pGL3-Lasp1-PR promoter activity in a dose-
dependent manner in both p53-/- HCT116 (Figure 3.49A) and Hep3B cells (Figure 
3.49C). The pGL3-vector carrying the promoter region of PTPRM2, which was a 
















       
 
 
Figure 3.49 p53 down-regulated Lasp1 promoter activity. The pGL3-Lasp1-PR 
vector was co-transfected with an increasing doses of pCMV-p53 or pCMV-p53-
R175H (0, 2, 10, 25, 50ng) into HCT116 (p53-/-) or Hep3B cells. pGL3-PTPRM2-PR 
was used as positive control. 36 hours after transfection, the Lasp1 promoter activities 
in transfected cells were determined by luciferase assay. After the reporter Firefly 
luciferase activity was normalized to Renilla luciferase activity (F/R ratio), the data 
were presented as the percentage relative to basal promoter activity co-transfected 
with pcDNA3.1 control only (0ng), which was arbitrarily set at 100%. The mean ± 
SD of triplicate wells are shown for each point. (A) Lasp1 promoter activity in 
HCT116 (p53-/-) cells. (B) PTPRM2 promoter activity in HCT116 (p53-/-) cells. (C) 







pGL3-cloning of Lasp1 promoter region deletion constructs 
In order to locate the potential p53 binding motif in Lasp1 promoter, I 
manually searched the promoter sequences from -937bp to +174bp, which covers 3 
PETs identified from the previous p53 ChIP-PET study. Two putative p53 binding 
sites corresponding to the well-defined consensus sequence (PuPuPuC(A/T)(A/T)G 
PyPyPy † PuPuPuC(A/T)(A/T)GPyPyPy, Pu: purine, Py: pyrimidine, †: spacer of 0-
13 nucleotides) (el-Deiry et al. 1992) were found located at each of the two 
enrichment regions defined by ChIP-qPCR, which are  5’-agtCAAGgtc-gcaagtc-
ctcCTAGgtt-3’ (-400bp~-374bp) and 5’-aggCCAGttc-ccca-gctCCAGccg-3’ (-
59bp~-36bp) (Figure 3.50).  
To predict the genuine p53 binding sites, a series of pGL3- constructs with 
truncated Lasp1 promoter region were generated as shown in Figure 3.51A. PCR 
amplification using pGL3-Lasp1-PR as template was performed to generate DNA 
fragment of Lasp1 promoter region with different sizes carrying Kpn I and Hind III 
restriction sites (Figure 3.51B). These PCR products were cloned into pCR®4-
TOPO® vector to generate a series of intermediate constructs (TOPO-Lasp1-PR-
DelA, B, C, D, E, F, G, H, I, J, K). Then, those pCR4-TOPO deletion constructs were 
digested by Kpn I and Hind III and sub-cloned into pGL3-Basic vector to achieve 11 
deletion constructs (pGL3-Lasp1-PR-DelA, B, C, D, E, F, G, H, I, J, K). Enzyme 
digestion (Figure 3.51C) and sequencing confirmed the desired pGL3- deletion 













Figure 3.50 Prediction of potential p53 binding site(s) in Lasp1 promoter. The 
sequences (-937bp~+174bp) which covered 3 PETs identified from the previous p53 
ChIP-PET study were manually searched. Two putative p53 binding sequences were 
in bold and underlined with the strictly conserved C/G highlighted in red. TSS: 











Figure 3.51 pGL3-cloning for Lasp1-PR deletion constructs. (A) Illustrations of 11 
deletion constructs. The length and position of the inserts of the original pGL3-Lasp1-
PR and deletion constructs (A~K) were shown. The two putative p53 binding motifs 
were illustrated as blue and red boxes, respectively. (B) PCR amplification of Lasp1-
PR deletion constructs. Lane1: 1kb plus DNA Ladder; Lane2-12: PCR product of 
Lasp1-PR-DelA~K. (C) Enzyme digestion of the constructed vectors. Lane1: 1kb plus 
DNA Ladder; Lane2: pGL3-Lasp1-PR Kpn I + Hind III digested, 2 fragments 
(2002bp, 4770bp); Lane3-13: pGL3-Lasp1-PR-DelA~K Kpn I + Hind III digested, 2 





The basal promoter activity of all deletion constructs was analyzed by 
luciferase assay in order to locate the region of important transcription regulators in 
Lasp1 promoter by using p53-/- HCT116 and Hep3B cells. As shown in Figure 3.52, 
a significant drop in basal promoter activity was observed in both cells transfected 
with Lasp1-PR-DelI (-97bp) compared to that transfected with Lasp1-PR-DelH (-
255bp), indicating that the most important transcription regulatory sequences are 
located in the small region of -255bp~-97bp relative to Lasp1 transcription start site.  
Next, the luciferase assay for predicting p53-responsive region was performed. 
All deletion constructs, the original full length construct (pGL3-Lasp1-PR) and the 
pGL3-Basic vector were co-transfected with pCMV-p53 or pcDNA3.1 empty vector 
(10ng/well) into HCT116 (p53-/-) or Hep3B cells for luciferase assay. The 
responsiveness to p53 for each deletion construct was presented as the F/R ratio in 
pCMV-p53 co-transfected cells standardized to the F/R ratio observed in control 
vector pcDNA3.1 co-transfected cells, which was arbitrarily set at 100%. The results 
of the response of different constructs to p53 co-transfection shown in Figure 3.53 
identified -97bp~-27bp as the p53-responsive region, where there was a clear 
restoration of the suppression effect by p53 (P < 0.05), indicating that the second 
putative site (-59bp~-36bp) found by manual search (Figure 3.50), which localizes in 







Figure 3.52 Truncation analyses of Lasp1 basal promoter activity. Comparison of 
the Lasp1 promoter activities driven by different lengths of 5’-flanking sequences. 
HCT116 (p53-/-) (A) or Hep3B (B) cells were transfected with pGL3-Lasp1-PR (-
1872bp) or different pGL3-Lasp1-PR deletion constructs pGL3-Lasp1-PR-DelA ~ K, 
which corresponds to -1561 ~ +10bp relative to the Lasp1 transcription start sites. 
Cell lysates were harvested 36h after transfection and the Firefly luciferase activity 






     
Figure 3.53 Localization of the p53-responsive region in Lasp1 promoter. 
HCT116 (p53-/-) (A) or Hep3B (p53-/-) (B) cells were transfected with different 
Lasp1 promoter constructs with pCMV-p53 or pcDNA3.1 empty vector. At 36 hours 
post transfection, cells were harvested and the luciferase activities were determined by 
the Dual-luciferase reporter system. The normalized luciferase activity of each 
construct in the pCMV-p53 transfected cells was compared to that of the pcDNA3.1 
vector, which was expressed as 100%. The different responses to p53 between pGL3-
Lasp1-PR-DelI (-97bp) and pGL3-Lasp1-PR-DelJ (-27bp) were considered as 
statistically significant (*P < 0.05). The pGL3-Basic vector was included to filter out 




In summary, a variety of experimental strategies were manipulated in this part 
of study to explore the potential pathways in linking Cyr61 and Lasp1 in HCC, which 
was illustrated in Figure 3.54. The transcription factor p53 was given a prior 
consideration as it is a well-known central master protein involved in progression of 
almost all cancers.  
Cyr61 was shown to inhibit HCC cell growth, at least in part, by up-regulating 
p53 in p53 wild-type HepG2 cells. HepG2-Cyr61 stable transfectants showed G2/M 
arrest when compared to HepG2-Neo control cells. Furthermore, both transient and 
stable over-expression of Cyr61 in HepG2 cells up-regulated p53 protein level. In 
addition, Cyr61 was shown as a genotoxic stress responsive gene, the expression of 
which was rapidly induced at both mRNA and protein level, regardless of p53 status. 
All these evidences suggested that Cyr61 may behave as an upstream molecule of p53 
in HCC and function in inhibiting HCC growth and metastasis, at least in part, through 
p53-dependent pathways.  
On the other hand, Lasp1 was identified as a potential p53 downstream target 
through a ChIP-PET analysis (Wei et al., 2006). In this current study, both biochemical 
and biological validations for the roles of p53 in transcriptionally suppressing Lasp1 
gene expression were performed. ChIP-qPCR showed that p53 could bind Lasp1 
promoter region in vivo. The transcription factor p53 was also shown to be able to 
negatively regulate Lasp1 expression through a series of experimental investigations, 
such as over-expression of p53 in p53 null cell lines, rapid accumulation of endogenous 
p53 upon 5-FU treatment or knockdown of p53 by p53 specific siRNA in p53 wild-type 
cell lines. Moreover, the role of p53 in repressing Lasp1 promoter activity was 
confirmed by Dual-luciferase reporter assay. All these evidences demonstrated Lasp1 as 






Figure 3.54 Model of pathways involving Cyr61 and Lasp1 in HCC. (A) Structure 
of focal adhesion plaques. Main focal adhesion proteins and F-actin stress fibers (red 
bundles) are shown. (B) Comprehensive Cyr61-Lasp1 pathway in p53 wild-type HCC cell 
lines with added information generated by this study. Cyr61 (green) interacts with integrins 
at ECM (extracellular matrix). Lasp1 (pink) co-localize with zyxin, VASP and paxillin at 
focal adhesion plaque. Cyr61 up-regulates the tumor suppressor p53 (purple hexagon), 
which transcriptionally repress Lasp1 expression. When p53 is mutated, deleted or 














































As the fifth most common cancer worldwide and the third leading cause of 
cancer-related death, hepatocellular carcinoma remains as a big challenge to human 
beings due to lack of early diagnostic markers and effective therapeutic strategies. High 
frequency of recurrence for those resectable tumors due to metastasis also contributes to 
its high fatal rate (Llovet et al. 2003), which poses a major question in understanding 
the mechanisms of hepatocarcinogenesis, especially that of HCC metastasis.  
Gene expression profiling study using HCC clinical tumor samples is a logical 
approach to describe the multiple genetic aberrations and heterogeneous dysregulation 
of oncogenic pathways in HCC development. From our previously published 
microarray data, two metastasis-associated genes, Cyr61 and Lasp1 were identified as 
significant differentially expressed genes in matched HCC tumor and adjacent non-
tumor samples (Neo et al. 2004). In follow-up studies, we report here that Cyr61 and 
Lasp1 may play important roles in growth and metastasis of human hepatocellular 
carcinoma. As a secreted extracellular matrix associated protein, Cyr61 was down-
regulated in both HCC clinical tumors and HCC cell lines. Over-expression of Cyr61 
suppressed HCC cell proliferation through p53 dependent as well as alternative 
pathways. Moreover, Cyr61 exerted inhibitory effects in regulating HCC cell migration 
and invasion by interfering with ECM-integrin signaling pathways. In contrast, the focal 
adhesion scaffolding protein Lasp1 was found to be up-regulated in HCC. Knockdown 
of Lasp1 by siRNA significantly inhibited HCC cell growth. Alterations in Lasp1 
expression in HCC cells inhibited cell migration and invasion ability, possibly through 
influencing F-actin dynamics. More interestingly, Lasp1 is transcriptionally suppressed 
by p53. The current study, therefore, adds information to the existing knowledge on the 
molecular pathogenesis of HCC and provides support for an as yet poorly understood 
role of p53 in relation to the cytoskeleton in cancer.  
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4.1. Cyr61 inhibits the growth and metastasis of HCC 
4.1.1. Cyr61 is down-regulated in HCC 
As the first identified member of the novel CCN family of growth regulators, 
Cyr61 has been shown not only to influence a myriad of cellular functions that 
contribute to many physiological conditions, but also to be actively involved in the 
pathogenesis of various diseases, especially in the development of tumors from diverse 
origins (Brigstock 2003; Planque and Perbal 2003; Perbal 2004). Down-regulation of 
Cyr61 had been observed in prostate cancer (Pilarsky et al. 1998), leiomyoma (Sampath 
et al. 2001), non-small cell lung carcinoma (Tong et al. 2001), and papillary thyroid 
carcinoma (Wasenius et al. 2003). In the previous cDNA microarray analysis, we 
revealed that the expression of Cyr61 was down-regulated in HCC tumor tissues 
compared to matched non-tumor samples (Neo et al. 2004). In this current study, down-
regulation of Cyr61 was consistently shown to occur in both HCC tumor tissues by real-
time quantitative PCR (Figure 3.1) and HCC cell lines by Western blot (Figure 3.3). 
This was in agreement with at least three previous studies (Xu et al. 2001; Chen et al. 
2002a; Wang et al. 2005), but contradicted others which failed to find any difference of 
Cyr61 expression in HCC (Hirasaki et al. 2001) or observed up-regulated Cyr61 in 
HCC compared to non-tumor tissues (Zeng et al. 2004).  Wang et al (2005) had pointed 
out that the usage of a non-quantitative gel-based RT-PCR technique may contribute to 
the negative findings observed by Hirasaki et al (2001). Similarly, the Cyr61 expression 
level was also measured by gel-based RT-PCR by Zeng et al (2004), and the data were 
presented as an average relative yield (mean ± SD) of total 31 HCC tumor tissues 
against that of 31 non-tumor tissues, but the detailed information of difference between 
each paired sample was not provided. 
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It was reported that increased d(CA) microsatellite repeat instability in the 
Cyr61 promoter may account in part for the down-regulation of Cyr61 in HCC (Wang 
et al. 2005). The author also discussed other possible mechanisms, e.g. differential 
promoter methylation as the CG-rich Cyr61 promoter contains at least 49 CGs within a 
region of approximately 1kb. However, the exact mechanism of Cyr61 down-regulation 
has not been fully characterized so far, which may deserve further analysis. It was also 
noticed that the level of Cyr61 mRNA expression in normal human fetal liver tissues, 
which had been known to resemble hepatic neoplasm in many aspects, was extremely 
low as compared to adult normal liver samples (Figure 3.2). This finding suggests that 
Cyr61 expression may be under certain extent of suppression in newly regenerating 
hepatocytes.  
 
4.1.2. Cyr61 may inhibit HCC cell growth, at least in part, through up-
regulating p53 and inducing G2/M arrest. 
Abnormal expression of Cyr61 has been reported in various cancers. Moreover, 
the multiple roles of Cyr61 in the progression of a number of tumors have been broadly 
explored. However, although several previous studies reported the expression of Cyr61 
in HCC, the potential roles of Cyr61 in the development of HCC have not been fully 
understood as yet. In this study, we further investigated the biological functions of 
Cyr61 in HCC cells and for the first time demonstrated that Cyr61 may function as a 
tumor suppressor in hepatocellular carcinoma.  
Our functional study indicates that down-regulation of Cyr61 in HCC may 
represent a mechanism by which tumor cells can gain growth advantages. Over-
expression of Cyr61 in HCC cells significantly suppressed the cell proliferation rate 
both in monolayer and the anchorage independent colony formation of HepG2 cells in 
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soft agar, which is an important indicator of malignant transformation. The anchorage-
independent growth ability was also tested using Hep3B cells. However, it is hard to 
score any difference as they cannot form sufficiently large colonies even after culturing 
for 3 weeks (data not shown).  
As the progression of cell growth is tightly controlled through cell cycle at a 
series of checkpoints, we performed cell cycle analysis using HepG2-Cyr61 stable cell 
lines in this study, which usually generate more consistent results by removing the 
variability of different transient transfection efficiency. The results suggest that Cyr61 
may act as a tumor suppressor gene in HCC by inhibiting tumor cell growth through 
G2/M arrest induction. Interestingly, it had also been reported that Cyr61 suppressed 
the growth of non-small cell lung cancer cells by inducing G1 arrest, and it inhibited the 
growth of endometrial cancer cells by promoting apoptosis (Tong et al. 2001; Chien et 
al. 2004). Taken together, these observations imply that Cyr61 may function as a tumor 
suppressor through various mechanisms depending on the tissue of origin and cellular 
context, most likely by binding to diverse integrin receptors that are differentially 
expressed on various tumor cells.  
In addition, consistent with two early reports on lung cancer study (Tong et al. 
2001; Tong et al. 2004), the p53 and p21 proteins were found being up-regulated in 
both stably and transiently transfected HepG2 cells with over-expressed Cyr61 in this 
study. The mRNA level of two G2/M marker gene, 14-3-3σ and GADD45, which are 
well-characterized p53 downstream targets (Hermeking et al. 1997; Wang et al. 1999), 
were also found up-regulated upon Cyr61 over-expression (Figure 3.39). As Tong et al 
suggested that Cyr61 is a tumor suppressor in non-small-cell lung cancer and may 
suppress the growth of these cells via the β-catenin-c-myc-p53 pathway (Tong et al. 
2004), we propose that the induction of G2/M arrest by Cyr61 in HCC cells might be, at 
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least in part, mediated through activating p53 and subsequently up-regulating its 
downstream target genes implicated in G2/M arrest.  
However, p53 dependent pathway is by no means the only mechanism which 
Cyr61 can act upon to interfere with HCC cellular proliferation, since its growth 
inhibitory effects were similarly observed in both p53 null Hep3B cells and p53 
mutated Huh-7 cells (Figure 3.6). This was indirectly supported by a novel finding in 
this study that endogenous expression of Cyr61 was induced in both p53+/+ HepG2 and 
p53-/- Hep3B cells in response to genotoxic stress at both transcriptional and protein 
levels (Figure 3.40). To the best of our knowledge, this is the first description of Cyr61 
as a gene involved in DNA damage response upon genotoxic stress, though it is already 
known as an immediate-early gene induced by a variety of growth factors and other 
stimuli (O'Brien et al. 1990). The question of whether the induction of Cyr61 upon 
genotoxic stress directly contributes to the activation of p53 in p53+/+ HepG2 (Figure 
3.40) or HCT116 cells (Figure 3.41) is at the moment unclear as there are several 
independent pathways known to activate p53 (Appella and Anderson 2001). We plan to 
explore the relationship between Cyr61 and these pathways in our future work. 
Although the molecular mechanism underlying the growth inhibitory effects of Cyr61 
in HCC cells is not fully understood yet, the immediate induction of Cyr61 in response 
to genotoxic stress suggests an influential role of this gene in regulating cellular growth 
and survival, which may be critical to hepatocarcinogenesis. As a potential tumor 
suppressor in HCC, Cyr61 may suppress the growth of HCC cells via both p53-
dependent and alternative pathways.   
Cyr61 is a secreted protein associated with the ECM and cell surfaces to exert 
diverse biological functions. We have consistently found that Cyr61 is localized at the 
secretory pathway in HCC cells as illustrated by the cellular localization study of the 
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GFP fusion proteins under confocal microscope, and the secreted Cyr61 was detected in 
the culture supernatants of transfected HCC cells (Figure 3.15). These results indicate 
that Cyr61 is secreted out of the cells where it functions as an extracellular signaling 
molecule in HCC development.  
 
4.1.3. Cyr61 regulates HCC cell adhesion and mobility through interfering with 
ECM-Integrin signaling pathways. 
In our study, both transient and stable over-expression of Cyr61 in HCC cells 
efficiently inhibited cell migration and invasion abilities as compared to controls. 
Enhanced adhesion to ECM proteins observed in Cyr61 over-expressed HCC cells 
probably in part contributed to their reduced migratory and invasive activities. 
Adhesion to extracellular matrix molecules through integrin receptors is a fundamental 
requirement for cell movement. Interestingly, the maximal rate of cell migration occurs 
at intermediate levels of adhesiveness, which allow traction at the cell front while 
detaching at the rear, resulting in net forward movement (Ridley et al. 2003). Therefore, 
at high levels of adhesiveness, as occurred in HepG2 and Hep3B cells transfected with 
Cyr61, cells cannot break contact properly and become less mobile.     
Cyr61 may regulate cell adhesion and mobility through interfering with ECM-
integrin signaling pathways, which are actively engaged in diverse cellular functions 
including cell movement (Hood and Cheresh 2002; Carragher and Frame 2004). Cyr61 
is a known ligand for several integrins, such as αIIbβ3, αvβ5, αvβ3 and α6β1 
(Jedsadayanmata et al. 1999; Grzeszkiewicz et al. 2001; Grzeszkiewicz et al. 2002; 
Schober et al. 2002; Menendez et al. 2005), some of which were found up-regulated in 
hepatocarcinoma cells and involved in hepatocarcinogenesis (Carloni et al. 2001; 
Nejjari et al. 2002). It was discovered in the current study that the cell adhesion abilities 
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to fibronectin and vitronectin respectively in HepG2 and Hep3B cells were most 
significantly enhanced upon Cyr61 over-expression (Figure 3.12). As both αvβ3 and 
αIIbβ3 were known as receptors for fibronectin and vitronectin (Stamatoglou and 
Hughes 1994), and CCN2 was reported to bind directly to fibronectin through the C-
terminal heparin binding cystine knot domain (Chen et al. 2004; Hoshijima et al. 2006; 
Leask and Abraham 2006), it is highly possible that, analogous to CCN2, Cyr61 can 
also function as a scaffolding protein to link fibronectin/vitronectin and integrin and 
strengthen their associations. 
Cyr61 may also manipulate ECM-integrin interactions by directly up-regulating 
the expression of some integrin receptors, including β1, α3, α5 and αvβ3 (Chen et al. 
2001b; Xie et al. 2004; Menendez et al. 2005). The fact that the adhesiveness to 
fibronectin was extremely weak in HepG2 cells may be explained by the finding that 
the expression of the fibronectin-binding integrin α5β1 in transformed cell lines was 
often markedly reduced during tumorigenesis. Re-expression of integrin α5β1 in cell 
lines showed decreased proliferation and loss of the transformed phenotype (Varner et 
al. 1995; Hood and Cheresh 2002). Thus, the cell surface integrin α5β1 may be up-
regulated upon over-expression of Cyr61 and lead to prominent enhancement in HCC 
cell adhesion ability to fibronectin. Similarly in Hep3B cells, the increased adhesion 
ability to vitronectin upon Cyr61 over-expression may be explained partly by the up-
regulation of the major vitronectin receptor–integrin αvβ3, as observed in U343 glioma 
cells (Xie et al. 2004).   
Besides its receptor, fibronectin has also been found down-regulated in a variety 
of tumors and oncogene-transformed cells, and its over-expression resulted in reversion 
of transformed cells to an untransformed normal morphology (Oliver et al., 1983; 
Akamatsu et al., 1996; Brenner et al., 2000). Fibronectin is not a passive adhesion 
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molecule but an active participant in the cell adhesive process that triggers signal 
transductions, for example, engagement of integrins by fibronectin activated Rho-
ROCK signaling and led to focal adhesions and stress fiber formation, which 
subsequently suppressed cell migration/invasion (Akiyama 1996; Clark et al. 1998; 
Spence et al. 2006). It is likely that over-expression of Cyr61 may exert inhibitory 
signals for HCC cell migration by initially enhancing the ECM-integrin interactions. 
More comprehensive studies on the interactions between Cyr61, integrins and multiple 
ECM proteins in HCC cells and downstream signal pathways involved in the processes 
are under further investigations.  
 
4.1.4. Cyr61 may have disparate roles in HCC itself depending on the 
differentiation status. 
Increasing evidences confirmed that CCN proteins can indeed act either as 
oncogenes or tumor suppressors, depending upon the type of cancers considered. 
Divergent pro-proliferative and anti-proliferative effects of Cyr61 were suggested to 
involve a balance between β-catenin induced stimulation of p53 via c-myc and integrin 
linked kinase (ILK) inhibition of p53 (Brigstock et al. 2005). An interesting observation 
from this study was that, based on Cyr61 protein expression analysis, the current panel 
of 14 HCC cell lines can be partitioned into 2 distinct groups of expressors and non-
expressors (Figure 3.3). It was noticed that the three cell lines (HA22T, Mahlavu and 
SK-Hep1) which had high expression of Cyr61 are all poorly-differentiated HCC cell 
lines, whereas almost all Cyr61 negative cell lines are well-differentiated (Lin et al. 
1998; Seki et al. 1999; Hu et al. 2003b; Yang et al. 2005) . In addition, several studies 
in the global gene expression profiles of HCC by microarray indicated that HCC can be 
divided into divergent subtypes (Lee and Thorgeirsson 2002; Lee et al. 2006). Hence, 
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this intriguing finding from our study suggests that Cyr61 may have distinct expression 
level and elicit disparate biological roles in HCC itself depending on the cellular origin 
and the differentiation stage. Hence, whether Cyr61 has different functions in a more 
aggressive HCC cell line such as Sk-Hep1 deserves our further investigations.  
In addition, Cyr61 is a well-known angiogenic factor (Lau and Lam 1999). 
Angiogenesis is an essential step, not only in the growth of primary tumors but also in 
the formation of metastases (Fidler and Ellis 1994). Angiogenesis facilitates metastasis 
formation by providing a mechanism to increase the possibility of tumor cells entering 
the blood circulation and provide nutrients and oxygen for growth at the metastatic site. 
The establishment of metastatic lesions depends on the activation of multiple 
angiogenic pathways at both primary and metastatic sites (Takeda et al. 2002). HCC is 
a typical hypervascular tumor, with largely different angiogenesis capacities between 
different subtypes of HCC (Sakamoto et al. 1993; Sun and Tang 2004). As emphasized 
above, Cyr61 only exists in low-differentiated, highly aggressive HCC cell lines but not 
in high-differentiated, less aggressive HCC cell lines, indicating that the angiogenic 
factor Cyr61 may have important role in HCC metastasis at a later stage of liver cancer 
progression by restoring its expression.  
A recent interesting report showed that human Cyr61 is a transcriptional target 
of TGF-β signaling in cancer cells (Bartholin et al. 2007). Therefore, the potential 
disparate roles of Cyr61 in HCC may also be substantiated by the well-known dual 
nature of TGF-β as tumor suppressor versus tumor promoter (Bachman and Park 2005). 
Specifically in hepatocytes, TGF-β was suggested to have a dual role as it induces 
proliferation arrest but provides a crucial function in promoting late malignant events in 
collaboration with activated Ha-Ras (Gotzmann et al. 2002), which may possibly be 
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explained by the proposed tumor promoting role of the TGF-β downstream effector 
Cyr61 in a more malignant HCC. 
 
4.2. Lasp1 promotes the growth and metastasis of HCC 
4.2.1. Lasp1 is up-regulated in HCC 
As a gene initially identified from a cDNA library of human metastatic lymph 
node during breast cancer progression, Lasp1 (LIM and SH3 protein) was found to be 
over-expressed in both breast cancer and ovarian cancer tissues (Tomasetto et al. 1995; 
Grunewald et al. 2006; Grunewald et al. 2007). However, unlike Cyr61, which were 
shown to be involved in a wide range of tumors, not much information is known 
regarding the associations of Lasp1 with cancer. Our study revealed for the first time 
that Lasp1 was up-regulated in hepatocellular carcinoma. Real-time quantitative PCR 
confirmed the over-expression of Lasp1 in HCC tumor tissues used in previous cDNA 
microarray study (Figure 3.16) and the Western blot analysis indicated that Lasp1 had 
high expression levels in most HCC cell lines tested (Figure 3.18).  
 
4.2.2. Possible mechanisms for Lasp1 up-regulation in HCC 
Although the mechanism of up-regulation of Lasp1 in HCC is unclear, the 
known information on the genetic or epigenetic regulation of Lasp1 provides us with 
clues in understanding this aspect.  
Lasp1 gene was mapped to chromosome 17q12-21, a region including several 
well-characterized genes involved in breast cancer progression and prognosis, for 
example, the proto-oncogene c-erbB-2 (Fukushige et al. 1986). Interestingly, this region 
was also reported to be amplified sporadically in HCC tumor and several HCC cell lines, 
such as Sk-Hep1 and Li7 (Marchio et al. 1997; Zondervan et al. 2000; Chen et al. 
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2002b; Yasui et al. 2002; Okamoto et al. 2003). Thus, one possible reason for Lasp1 
over-expression in HCC may reside in gene amplification by chromosome gain. 
However, this may not be the primary consideration as the amplification of c-erbB-2 
was reported as an uncommon event in HCC (Prange and Schirmacher 2001; Xian et al. 
2005).  
Lasp1 is a known transcriptional target of the morphogen Sonic Hedgehog 
(Ingram et al. 2002) and IGF-1R pathway (Loughran et al. 2005). There is evidence 
showing the frequent activation of Hedgehog pathway in HCC (Huang et al. 2006) and 
the role of deregulated IGF-1R signaling in hepatocarcinogenesis (Scharf et al. 2001; 
Alexia et al. 2004), suggesting that the Sonic Hedgehog pathway and/or IGF-1 
signaling may be altered to some degree in HCC leading to the up-regulation of Lasp1. 
Thus, it would be also interesting for us to investigate whether these deregulated 
signaling pathways act through Lasp1 to promote hepatocarcinogenesis.  
Moreover, the transcriptional repression of Lasp1 by the tumor suppressor p53 
demonstrated in this current study may contribute to the explanation of the observed 
increase of Lasp1 mRNA in HCC as well. As introduced in Chapter 1 that the 
sequential loss of p53 function through mutation and/or deletion and/or inhibition by 
virus in hepato-carcinogenesis was frequently detected (Feitelson et al. 2002; 
Thorgeirsson and Grisham 2002; Hussain et al. 2007), Lasp1 mRNA may be up-







4.2.3. Lasp1 may promote HCC cell growth through multiple pathways 
associated with cytoskeleton 
In the current study, after showing the over-expression of Lasp1 in both HCC 
clinical tumors and HCC cell lines, we further investigated the functional roles of Lasp1 
in growth and metastasis of human HCC. This is the first evidence that besides breast 
cancer and ovarian cancer, Lasp1 may also be associated with other cancer types, such 
as liver cancer. A series of functional assays were performed to explore the potential 
roles of Lasp1 in HCC cell growth. Depletion of Lasp1 by specific siRNA inhibited cell 
proliferation in monolayer and anchorage-independent growth in soft agar. Whereas, 
over-expression of Lasp1 in both high and low Lasp1 expressing HCC cell lines 
significantly enhanced cell proliferation rate. These results suggest that Lasp1 may 
trigger cellular signaling pathways leading to cell survival, cell proliferation or 
inhibiting apoptosis.  
Although Lasp1 was defined as a focal adhesion adaptor protein,  the specific 
mechanisms are poorly understood (Chew et al. 1998; Keicher et al. 2004). Lasp1 could 
interact with several focal adhesion molecules, including the F-actin binding protein 
zyxin, LPP, VASP and F-actin itself. Several previous studies have reported the 
potential pathways in which Lasp1 may participate and regulate cancer cell growth and 
survival. For instance, Lin et al. (2004) reported that Lasp1 directly contributed to 
H2O2- and cisplatin-induced apoptosis in a phosphorylation-dependent manner. It was 
postulated that those apoptotic agents may prevent Lasp1 localization to focal adhesions 
through phosphorylation of Lasp1 on Tyr-171 by Abl only in apoptotic cells and thus 
disrupt survival signals from these structures (Lin et al. 2004). It was also reported that 
Lasp1 silencing in breast cancer and ovarian cancer cells led to reduced cell cycle 
progression and an induced G2/M phase accumulation. This was accompanied by 
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change of cellular localization of zyxin in these cancer cell lines plus up-regulation or 
down-regulation of several proteins, such as pyruvate kinase, enolase-1, glucose 
dehydrogenase, 14-3-3 and heat-shock protein HSP27 in ovarian cancer cells 
(Grunewald et al. 2006; Grunewald et al. 2007). It was proposed by Grunewald et al 
(2007) that part of zyxin enters the nucleus, binds to the tumor suppressor h-warts, leads 
to G2/M cell cycle arrest and inhibits cell proliferation as observed after Lasp1 
silencing. Pyruvate kinase, enolase-1 and glucose dehydrogenase are part of the 
glycolytic metabolism and their regulation correlates well with the cell cycle arrest in 
G2/M. In addition, over-expression of 14-3-3, which are well-known inhibitors of 
G2/M progression (Pietromonaco et al. 1996; Hermeking et al. 1997; Peng et al. 1997; 
Alvarez et al. 2002), might also lead to cell cycle arrest in cell culture models (Tzivion 
et al. 2006) and therefore contribute to the observed G2/M arrest in ovarian cancer cells 
lacking Lasp1.  
By considering findings from our current study, it is likely that in HCC cell lines 
such as HepG2 and Hep3B, Lasp1 siRNA knockdown triggers a similar inhibitory 
pathway as in ovarian cancer cells. However, in Lasp1 over-expressed HCC cells, 
where zyxin also shows diffused distribution in the cells (Figure 3.33), the cell 
proliferation rate is promoted rather than suppressed, which implies that Lasp1 may 
have important function in regulating HCC cell growth through interfering with 
multiple cellular pathways triggered by its various binding partners. Our confocal 
microscopy analysis suggests that Lasp1 may also bind to the integrin associating 
protein – paxillin, leading to further interactions between Lasp1 and the multiple 
integrin signaling pathways. In addition to regulating cell adhesion to the ECM, 
integrins also relay molecular cues regarding the cellular environment that influence 
cell shape, survival, proliferation, gene transcription and migration. Upon binding to its 
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ligands, integrins cluster and activate tyrosine protein kinases, such as focal adhesion 
kinase (FAK), where paxillin supports a platform for it. Activated FAK can trigger 
signaling pathways, such as Ras-Raf-MEK-MAPK pathway and PI3K-Akt pathway, 
leading to altered cell proliferation rate and survival (Mitra and Schlaepfer 2006). Thus, 
Lasp1 may also regulate HCC cell growth through its potential binding partner, paxillin. 
To demonstrate this hypothesis, the potential direct association between Lasp1 and 
paxillin, as well as the related downstream pathways deserve our further 
characterizations. 
In conclusion, though the mechanism underlying the Lasp1 regulation on HCC 
cell growth is largely unexplored, the results from this current study suggest that, 
similar to the down-regulation of Cyr61 in HCC, up-regulation of Lasp1 also represents 
a strategy of tumor cells to gain growth advantages. More experimental evidences, such 
as cell cycle analysis, may facilitate our understanding in the proposed mechanisms 
discussed above, by which Lasp1 may participate in influencing HCC cell growth. 
 
 
4.2.4. Lasp1 regulates HCC cell mobility through influencing F-actin dynamics 
at focal adhesion sites.  
Cell migration and the controlled assembly and disassembly of focal adhesions 
are highly integrated multi-step processes and central features in the molecular 
pathology of cancer (Ridley et al. 2003). Focal adhesion plaque contains diverse 
molecules such as adapter proteins, protein kinases and proteins that propagate signals 
arising from the activation of integrins following their engagement with ECM proteins 
as well as regulate the rate and organization of actin polymerization and focal adhesion 
turnover in protrusion (Turner 2000b; Grunewald et al. 2006). Unlike the secreted 
extracellular matrix protein Cyr61, which inhibits HCC cell migration and invasion 
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partly through enhancing the cell adhesion activity to ECM proteins, Lasp1 does not 
play a role in affecting cell adhesion but exert important functions in influencing F-actin 
dynamics as a focal adhesion adaptor protein.  
In our study, silencing of Lasp1 by siRNA in HCC cell lines inhibited cell 
migration and invasion ability. Depletion of Lasp1 by siRNA in breast and ovarian 
cancer cells was reported to change zyxin localization, which was suspected to be the 
mechanism of Lasp1 siRNA treatment in suppressing the cell migration and invasion 
ability (Grunewald et al. 2006; Grunewald et al. 2007). Interestingly, both our analysis 
and several previous studies showed that further over-expression of Lasp1 in cancer cell 
lines also inhibited cell migration and invasion activities (Lin et al. 2004; Grunewald et 
al. 2006; Grunewald et al. 2007). It was discussed by Grunewald et al (2006) that the 
amplification of Lasp1 in cancer cells already overexpressing this scaffolding protein 
led to disrupted pathways and changes in the cytoskeleton structure that influence cell 
migration. Nonetheless, how exactly Lasp1 over-expression in cancer cells influences 
the cytoskeleton dynamics still remains obscure. In the current study, we showed that 
further over-expression of Lasp1 in HCC cell lines may disrupt the signal pathways 
leading to F-actin polymerization presumably through affecting the localization of 
several focal adhesion proteins, including zyxin, VASP and paxillin. All of these three 
Lasp1 associating proteins are known to influence actin filament dynamics as well as 
influence multiple signaling pathways (Beckerle 1997; Krause et al. 2003; Keicher et al. 
2004; Spence et al. 2006).  
As a member belonging to one subfamily of LIM proteins, zyxin is localized 
primarily at focal adhesion plaques and plays a central role in actin filament 
polymerization in mammalian cells (Beckerle 1997). Silencing of zyxin in HeLa cells 
resulted in significantly reduced actin stress fibers (Griffith et al. 2005). In genetically 
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zyxin-deficient fibroblasts, focal adhesions are depleted from Mena and VASP, and 
cells lacking zyxin display deficits in actin cytoskeleton remodelling (Hoffman et al. 
2006). From our immuno-fluorescence experiments, we observed a diffused cellular 
localization of zyxin co-localized with over-expressed GFP-tagged Lasp1 without 
obvious protein loss as identified by Western blot analysis, indicating the important 
roles of Lasp1 in binding and recruiting zyxin to focal contacts. The decreased cell 
motility after Lasp1-GFP over-expression can thus be explained by the sequestration of 
zyxin by Lasp1, otherwise it acts as a scaffolding protein that facilitates the formation 
of molecular complexes to promote site-specific actin assembly required for cell 
movement.  
Another interesting finding revealed that HepG2 cells had no detectable zyxin 
protein by Western blot analysis (Figure 3.36). As described in Chapter 1, zyxin mainly 
exists in mature focal contact (Mitra et al. 2005). However, the question of whether 
HepG2 cells do not require the formation of mature focal contact where zyxin may play 
a role when cultured in vitro, or there is an intrinsic mechanism to down-regulate zyxin 
expression in HepG2 cells and in turn inhibit the formation of more mature focal 
adhesion, is still unclear and needs further characterizations. Our observations showing 
that Lasp1 did play a role in regulating the migration and invasion ability of HepG2 
cells, indicate that Lasp1-mediated localization of zyxin may not be a mere or 
indispensable function in which Lasp1 may participate. 
As a member of a zyxin-related subfamily of LIM domain containing proteins, 
paxillin is also localized primarily at focal adhesion plaques. Despite being relatively 
small (599 amino acids), paxillin contains many protein-binding modules that allow it 
to become one of the prototypical adaptor proteins involved in integrin signaling by 
recruiting many signaling proteins to the plasma membrane (Turner 2000a). It provides 
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a platform for FAK, which is also known to activate Rho-family of GTPases 
(RhoA/Rac/Cdc42) directing local actin assembly into stress fibers, lamellipodia or 
filopodia and thus regulates cell migration (Mitra et al. 2005). Besides those protein 
kinases, paxillin has been demonstrated to interact with many proteins that are 
implicated in effecting changes in organization of the actin cytoskeleton, which are 
necessary for cell motility associated with embryonic development, wound repair and 
tumor metastasis, as reviewed by Turner (2000b). In this current study, Lasp1 was for 
the first time shown to be co-localized with paxillin and able to change its localization 
most probably due to a direct or indirect binding. As paxillin is a multi-functional 
adaptor protein which could integrate signaling of cell growth and mobility, this 
suggests potential novel cellular functions of Lasp1.  
Ena/VASP proteins are a conserved family of actin regulatory proteins. One 
potential link between VASP proteins and actin dynamics involves their ability to bind 
to the actin monomer-binding protein profilin. Profilin promotes the formation of ATP-
actin, and actin monomers bound to profilin can be added to the free barbed-ends, but 
not pointed-ends of the actin filaments. Ena/VASP proteins function to recruit profilin-
actin complexes to sites of actin assembly, promote actin filament nucleation, bundling 
and elongation by antagonizing the activity of capping proteins (Kwiatkowski et al. 
2003). Recruitment of Ena/VASP proteins to mitochondria or to the surface of Listeria 
that cannot activate Arp2/3 causes no detectable F-actin assembly (Bear et al. 2000; 
Skoble et al. 2000). All the above evidences may provide a sound explanation for the 
observation from our immunofluorescence study that the sequestration of zyxin, 
paxillin and VASP by over-expressed Lasp1-GFP is concomitant with less F-actin 
bundles formed in Hep3B and Huh-7 cells.  
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Upon over-expression of Lasp1, HCC cells shows decreased cell invasion 
ability, which is also substantiated by the morphology change from elongated shape 
with pseudopodia/lamellipodia (mesenchymal-like) to oval shape (epithelial-like). The 
formation and elongation of pseudopodia/lamellipodia structure are critical for cell 
migration and invasion process. Lasp1, as well as its co-localized binding partner Krp1, 
were reported to have a role in elongation of pseudopodia structures which are required 
for v-Fos-transformed rat fibroblast (FBR) cells to invade (Spence et al. 2006). Thus, 
the inhibited formation of F-actin stress fibers and changed cell morphology in Lasp1-
GFP over-expressed HCC cell lines may partly represent a reversion of the pathway 
model similar to that of the transformation of 208F fibroblast cells to FBR cells by v-fos 
as proposed by Spence et al (2006). In this new model, further over-expression of 
Lasp1 in HCC cells somehow disrupted the interaction of Lasp1 with Krp1 and in turn 
inhibited the formation of focal adhesion and elongation of stress fibers that would 
otherwise support cell invasion.   
The confocal microscopic analysis from both previous reports on Lasp1 
depletion and our current study on Lasp1 over-expression suggests that Lasp1 function 
within a certain optimal concentration. There is possibly an intrinsic regulation system 
in maintaining Lasp1 expression to this optimal saturated level, upon which either 
increasing or decreasing it will reduce the cell mobility and inhibit cancer metastasis. 








4.3. The tumor suppressor p53 may inhibit tumor metastasis via novel 
mechanism in negatively regulating metastasis-promoting genes 
A legion of p53-responsive genes and genome-wide p53 binding sites has been 
identified by various means, including differential display, SAGE, microarray and the 
more recent ChIP-PET strategy. For example, in the recent genome-wide ChIP-PET 
study that we referred to (Wei et al. 2006), at least 542 binding loci of p53 with high 
confidence and 98 previously unidentified p53 target genes were discovered. However, 
whether all of these will prove to be bona fide target genes of p53 is unknown, and, to 
some extent, the criteria that we used to apply to verify the authenticity of a direct p53-
target gene themselves are not sufficiently reliable. We now realize that identification of 
p53-binding sites within gene promoter sequences might not reflect p53 responsiveness, 
and the p53 responsiveness might be mediated by sequences other than the defined p53-
binding sites. Therefore, it is valuable to identify and validate biologically important 
genes transcriptionally regulated by p53 through multiple methodologies, which can 
help us to understand p53 gene regulatory network. On the other hand, elucidating the 
roles of those characterized p53 target genes with previously unknown functions is also 
fascinating as it confers p53 with novel biological significance.  
 
4.3.1. Role of p53 in transcriptionally suppressing gene expression 
There is now compelling evidence that the transcriptional activity of tumor 
suppressor p53 is required for its growth suppressing and tumor suppressing activities. 
Most of these studies have focused on the trans-activation function of p53 because of 
the strong association between trans-activation and tumor suppression. However, p53 is 
known to be able to repress transcription from various viral and cellular promoters 
(Ginsberg et al. 1991; Kley et al. 1992; Seto et al. 1992; Jackson et al. 1993; Mack et al. 
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1993). Emerging evidences suggest that the transcriptional repression by p53 also plays 
important roles for its ability to promote apoptosis. Examples including Bcl-2, survivin, 
MAP4, PIK3CA, which are transcriptionally repressed by p53, were shown to inhibit 
p53-dependent apoptosis (Wang et al. 1993; Chiou et al. 1994; Murphy et al. 1996; 
Hoffman et al. 2002; Mirza et al. 2002; Singh et al. 2002).  However, the underlying 
mechanisms and the functional consequence of this suppression are largely unexplored. 
Thus, by showing that p53 is able to transcriptionally suppress the expression of Lasp1, 
our study adds critical information to the existing pool of p53 negatively regulated 
genes as well as expands the roles of p53 via its transcriptional repression function.  
 
4.3.2. Role of p53 in regulating cytoskeleton and tumor metastasis 
Recently, increasing lines of evidences suggest that p53 also functions in 
regulating cell migration, invasion, and cancer metastasis through targeting genes 
functionally linked to cytoskeletons. As mentioned earlier, several tumor metastasis 
suppressor genes, such as Maspin, KAI1/CD82 have been demonstrated to be bona fide 
p53 targets which can be transcriptionally activated by p53 (Mashimo et al. 1998; Zou 
et al. 2000; Liu and Zhang 2006). These findings underscore the role of p53 in the 
negative regulation of cell invasion and metastasis. The emerging p53 function may 
provide a mechanistic explanation for the increased metastatic susceptibility of tumors 
harboring p53 mutations. From this point of view, our finding that p53 transcriptionally 
represses a novel metastasis-related protein Lasp1 has great significance as it not only 
strengthens the association of p53 with cytoskeleton but also propose a hypothesis to 
the mechanisms of the p53-mediated suppression of tumor metastasis, that is, p53 
inhibits hepatocarcinogenesis and liver cancer metastasis by transcriptionally suppress 
the expression of metastasis promoting genes, such as Lasp1.  
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4.3.3. p53 may repress gene expression through direct binding to a p53 response 
element 
Besides directly binding to specific DNA sequences, the transcription factor p53 
is also shown to interact with co-activators or co-repressors under various conditions. A 
number of studies have investigated the mechanism of p53-mediated repression and 
found that although the wild-type p53 almost always up-regulates the expression of 
genes containing a p53-binding site, it tends to down-regulate expression of a myriad of 
genes without the classical p53 binding motif, such as c-fos, c-jun, Rb, Bcl-2 and hsc70 
(Donehower and Bradley 1993; Jackson et al. 1993; Zambetti and Levine 1993; 
Miyashita et al. 1994), where p53 exerts its function by engaging in complexes with 
other proteins (Espinosa and Emerson 2001) or by acting as a transcriptional co-
activator or co-repressor (Levine 1997). For instance, p53 represses the AFP gene by 
inhibiting the promoter binding of hepatic nuclear factor 3 (HNF-3), a transcription 
factor that activates AFP transcription (Lee et al. 2006).  
Alternatively, a model in which the existence of a p53-binding motif in the 
promoter of some genes is indispensable for the p53-mediated transcriptional repression 
of these particular genes was also established, as exemplified by one study indicating 
that a p53 binding site at the survivin promoter is required for its transcriptional 
repression by p53 (Hoffman et al. 2002). At the end of this study, the p53 response 
element in Lasp1 promoter was confirmed by luciferase assay using truncated 
constructs (Figure 3.53), indicating that p53 inhibits Lasp1 transcription by a direct 
binding to this binding site though it violate the rule of the strict p53 concensus binding 
sequence defined by el-Deiry et al (1992). However, it complies well with the 
experimentally verified model of p53 binding motif (Figure 4.1) as suggested by a 
recent comprehensive study of p53 response element sequence (Ma et al. 2007). Further 
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confirmation experiments, such as luciferase assay using construct with internal 
deletion of the predicted binding site only and gel shift assay, are required to be 







Figure 4.1 Comparison of the identified p53 response element in Lasp1 promoter 
with a pooled representation of p53 binding consensus sequences.  The p53 logo 
compiled from 100 experimentally verified p53 response elements defined by Ma et al. 
(2007) is shown in the top panel, while the identified p53 response element in Lasp1 
promoter (-59bp to -36bp) is shown in the bottom panel. A (Green), T (Red), G 










4.4. Build a comprehensive signaling pathway in HCC involving Cyr61 and 
Lasp1 
Focal adhesion plaques form a structural link between the ECM and the actin 
cytoskeleton, and are also the important sites of signal transduction. The trans-
membrane molecules of the integrin superfamily are the primary proteins at focal 
adhesion plaques and function to integrate the extracellular matrix into the actin 
filaments. This connection also requires many actin-attachment proteins and other 
cytoplasmic adhesion proteins. Thus, proteins at focal contacts form multiple 
interactions and signal transduction pathways, which not only influence cell adhesion, 
spreading, and migration, but also convey signals into the nucleus to regulate gene 
transcription, cell proliferation, differentiation and apoptosis (Wang and Gilmore 2003).  
Both Cyr61 and Lasp1 studied in this work are proteins located at the focal 
adhesion pathway and play active roles in the formation of focal adhesion and trigger 
pathways into the cell interior, integrating multiple functions in cell proliferation, 
adhesion, migration and invasion in HCC cell lines. From this view of whole cell 
signaling transduction networks, the pathways in which Cyr61 or Lasp1 are involved in 
HCC cells in one way or another connected together or have crosstalk with each other. 
A diagram illustrating an overview for the regulation and consequences of these cellular 
pathways involving Cyr61 and Lasp1 in HCC cells is presented in Figure 4.2.  
In this figure of overview, the tumor suppressor p53 is a central master protein 
in linking Cyr61 and Lasp1 in HCC cells. Cyr61 could up-regulate p53 expression in 
p53 positive HepG2 cells and cause G2/M arrest most probably due to the effect of p53. 
Coincidently, Lasp1 was identified as a novel p53 target gene which could be 
transcriptionally suppressed by p53. Hence, in HCC cells carrying wild-type p53, given 
that other unclear contributing molecules are functional, Cyr61 should be able to down-
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regulate Lasp1 through up-regulating p53 level. The pathway could be sketched as 
Cyr61→p53┤Lasp1. It is known that only Huh-1, Huh-6, HepG2 and Sk-Hep1 cells 
harbor wild-type p53 among 14 HCC cell lines used in this current study (Cagatay and 
Ozturk 2002). However, as the mutant p53 known to be carried by the rest cell lines 
except Hep3B (p53 null) may still be partially functional, whether the observed inverse 
correlation of the Cyr61 and Lasp1 expression in most HCC cell lines relates to the p53 
status needs our further characterizations. Taken together, this finding strengthens the 
point that Cyr61 may function as a tumor suppressor in liver cancer metastasis by 
inhibiting cell migration and invasion ability partly through down-regulating the 
expression level of Lasp1, which has high potential in causing metastasis of HCC.  
Both Cyr61 and Lasp1 are functionally linked to integrins in HCC. Cyr61 is a 
well-known ligand to several types of integrins. Inhibition of cell migration and 
invasion by over-expression of Cyr61 in HCC cells may be due to the enhanced cell 
adhesion to ECM mediated by Cyr61-integrin interactions, which in turn trigger 
multiple pathways in regulating actin cytoskeleton dynamics leading to modified cell 
migration and invasion activities. Lasp1, on the other hand, functions as an F-actin 
binding adaptor protein. It may also associate with integrin through its various direct or 
indirect binding partners. Thus we may conclude that Lasp1 is perhaps located at one or 
more of Cyr61-integrin triggered focal adhesion associated pathways or pathways 





























Figure 4.2 Cyr61 and Lasp1 integrate signals to influence various cellular 
functions in HCC cells.  Cyr61 up-regulates p53, which induces cell cycle arrest 
through activating the expression of its well-characterized downstream target genes 
(p21, 14-3-3σ, GADD45…) as well as regulates cell migration and invasion via 
repressing the expression of the newly-identified target gene Lasp1. Cyr61 interacts 
with extracellular matrix (ECM) and various integrins, strengthening the cell adhesion 
ability to ECM and in turn regulating cell migration and invasion ability. On the other 
hand, Lasp1 indirectly associate with integrin through its multiple binding partners 
localized at focal adhesion plaque. These interactions regulate focal adhesion 
mediated pathways, e.g. the RhoA/Rac1/Cdc42 pathway to influence cell 
migration/invasion, the Ras-Raf-MAPK or PI3K-Akt pathway to influence gene 










4.5. Significance of the study in HCC 
4.5.1. Cyr61 may be used as a diagnostic and prognostic marker for HCC 
As the mortality rate of HCC ranks high among all malignancies due to high 
rate of recurrence or metastasis even after curative resection, the early diagnosis of 
HCC is of the utmost importance. Since its discovery, the serum AFP remains as the 
most widely used tumor marker in detecting patients with hepatocellular carcinoma, and 
has been proven to have capability of prefiguring the prognosis. Nonetheless, some 
reports have indicated that it has a limited utility in both efficiently and specifically 
diagnosing HCC for its high false-positive and false-negative rates, for example, 
markedly increased AFP levels are also detected in patients with acute exacerbation of 
viral hepatitis but without HCC (Soresi et al. 2003; Bae et al. 2005). Therefore, there is 
urgent need to identify new early markers for HCC as a valuable supplement or even 
substitute for the serum AFP.  
As we discussed earlier, the current panel of 14 HCC cell lines can be 
partitioned into 2 distinct groups of expressors and non-expressors. Interestingly, there 
is a remarkable inverse correlation with α-fetoprotein (AFP) expression patterns 
reported by Lee and Thorgeirsson (2002) i.e. Cyr61 negative cell lines (e.g. HepG2, 
Hep3B, Huh-7) correspond to the high AFP group defined by Lee and Thorgeirsson, 
while the Cyr61 expressing lines (e.g. SNU449, Sk-Hep1) are within the second 
subgroup cluster which are AFP negative. Furthermore, in both normal fetal liver and 
adult liver tissues (Figure 3.2), Cyr61 expression also had an inverse relationship with 
that of AFP, which is well-known as being primarily produced by the fetal liver and 
detected in the serum of about 50-70% of HCC patients (Lee and Thorgeirsson 2002). 
These intriguing findings suggest that Cyr61 may have distinct expression level in HCC 
 
Discussion 201
depending on differentiation stage and may be used as a novel potential diagnostic 
marker for AFP negative liver tumors.  
In a recent study, a strong correlation of the expression of Cyr61 with the 
clinical features of lung cancer has been disclosed. More interestingly, levels of Cyr61 
are tightly related to pivotal clinical and prognostic features of non-small-cell lung 
cancer (NSCLC), as the patients with high-expression of Cyr61 showed a significantly 
extended mean survival time in comparison with other patients with low level of Cyr61 
(Chen et al. 2007). This finding also substantiates the earlier conclusion drawn by the 
same research group that Cyr61 is a tumor suppressor in NSCLC (Tong et al. 2001). As 
our current study applied in HCC shows similar results of down-regulated Cyr61 
expression and pathway involving up-regulation of p53 as in NSCLC, it is conceivable 
that Cyr61 may be used as a novel biomarker for the clinical features and prognosis of 
HCC patients as well.  
 
4.5.2. Lasp1 may be used as a metastasis and prognostic marker for HCC 
The ability to predict HCC patients at higher risk of recurrence or tumor 
metastasis with a poor prognosis would help to guide surgical and chemotherapeutic 
treatment according to individual risks. Attempts have been made to define a multitude 
of metastasis and prognostic markers for HCC patients with potential clinical 
significance, such as PTEN, p16, p27, MMP-2, serum VEGF, and osteopontin (Honda 
et al. 1998; Ito et al. 1999; Sugo et al. 1999; Niu et al. 2000; Hu et al. 2003a; Matsuda 
et al. 2003; Pan et al. 2003; Cui et al. 2004). Nevertheless, the conclusions from these 
independent studies are often conflicting due to differing methodologies applied in 
these studies (Mann et al. 2007). Even though many prognostic markers for HCC have 
been put forward, the well-characterized candidates for HCC prognosis and the 
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underlying mechanisms still remain rather limited. Thus, it is of great importance and 
necessity to validate these potential markers in large cohorts of patients, as well as to 
identify novel metastatic and prognostic markers for HCC.  
A large number of studies have examined the prognostic role of p53 in HCC. 
Among them, several analyses showed that p53 mutation is associated with shorter 
interval of recurrence or decreased overall survival (Hayashi et al. 1995; Honda et al. 
1998; Sugo et al. 1999; Park et al. 2001). In our study, Lasp1 is shown to have an 
important role in inhibiting the migration and invasion ability of HCC cells. In addition, 
by considering its previously characterized role in metastatic breast cancer and ovarian 
cancer, as well as the novel findings from the current study that Lasp1 is a p53 target 
which could be suppressed by p53, it is reasonable to propose that Lasp1 may be a 
novel metastatic and prognostic marker for HCC or even possibly for other tumors as it 
is localized at the crossroads of p53 regulated pathway network and the focal adhesion 
signaling in controlling cell motility. 
 
4.5.3. Cyr61 and Lasp1 may be used as potential therapeutic targets for HCC 
Curative treatments for HCC such as resection, liver transplantation and 
percutaneous ablations induce clinical remissions in a high proportion of patients and 
are expected to improve the overall survival. However, these treatments can only be 
applied to a small portion of HCC patients excluding cases such as cirrhotic tumors or 
big multi-nodules. Besides curative therapy, palliative treatments like embolisation or 
chemoembolisation, arterial or systemic chemotherapy, radiation, and immunotherapy, 
in some cases, can obtain good response and even improve survival of patients (Llovet 
et al. 2003). Despite the many treatment options, the prognosis of HCC remains dismal. 
A majority (70-85%) of patients with advanced or unresectable disease is excluded 
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from curative treatments. Even for those patients who undergo resection, the recurrence 
rates can be as high as 50% at 2 years (Yamamoto et al. 1996; Poon et al. 1999). Hence, 
prevention of metastatic recurrence after HCC resection is one of the major goals for 
the further improvement of prognosis of HCC patients.  
Identification of key molecular targets and pathways involved in 
hepatocarcinogenesis has significant therapeutic implications. In this current study, both 
Cyr61 and Lasp1 were demonstrated to play important roles in regulating the growth 
and metastasis of HCC based on in vitro assays, though the roles of Cyr61 and Lasp1 in 
HCC will need to be strengthened by conducting in vivo study in the future. Cyr61 acts 
as a potential tumor suppressor in HCC in inhibiting cell proliferation, migration and 
invasion. Cyr61 is a protein secreted to ECM where it interacts with its binding partners 
and triggers multiple signaling pathways to regulate cell growth and motility. 
Neutralizing antibodies and purified recombinant proteins are often applied in 
biomedical research to abrogate or restore the functions of some membrane and 
extracellular proteins, as exemplified by an early study on Cyr61 in which recombinant 
Cyr61 protein produced in the baculovirus expression system was proven to be able to 
regulate cell proliferation, migration, and adhesion in NIH 3T3 cells and HUVECs 
(Kireeva et al. 1996). The identification of the roles of Cyr61 in HCC from this current 
study and the functionality of recombinant Cyr61 proteins provide a theoretical basis 
for its potential application as a therapeutic target. On the other hand, Lasp1 seems to 
play an important role in controlling the metastatic potential of HCC as well. As 
suggested by our study, it is critical for the HCC cells to maintain an optimal cellular 
level of Lasp1 to acquire their maximal potential of movement. Therefore, Lasp1 may 





emergence of these well-characterized molecular targets provides the rationale and 
opportunity for novel therapeutic strategies which will be applied in HCC. 
 
4.6. Conclusions 
Hepatocellular carcinoma (HCC) is one of the most deadly cancers with poor 
prognosis associated with tumor invasion and metastasis. In this current study, we 
report that two metastasis related genes – Cyr61 and Lasp1, may play important roles 
in growth and metastasis of human HCC. This is the first time that abnormal 
expression of Lasp1 in HCC is demonstrated and its role in growth and metastasis is 
revealed. In addition, by demonstrating Lasp1 as a bona fide p53 target, this study 
provides new insights into the role that p53 may play in tumor metastasis. The above 
characterization of the roles of Cyr61 and Lasp1 in HCC will shed more light on the 
complex mechanisms underlying the tumorigenesis of HCC as well as suggest two 
interesting genes which are potential therapeutic targets and/or diagnostic markers to 
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Buffers and Solutions for Cell Culture 
 
FBS (Fetal Bovine Serum) 
500ml of FBS (Invitrogen) was thawed at 37°C water bath and heat inactivated at 56°C for 30 
minutes. Aliquot in 50ml falcon tubes and store at -20°C 
 
DMEM Culture Medium (DMEM/10% FBS) 
DMEM (Invitrogen)                   450ml (90%) 
FBS (heat inactivated) 50ml (10%) 
Total Volume 500ml 
Filter to sterilize and store at 4°C. 
 
DMEM/G418 Culture Medium 
DMEM Culture Medium                   492ml 
G418 (50mg/ml stock from Invitrogen) 8ml (800μg/ml working concentration) 
Total Volume 500ml 
Filter to sterilize and store at 4°C. 
 
Serum-free Medium (DMEM/0.5% FBS) 
DMEM (Invitrogen)                               497.5ml (99.5%) 
FBS 2.5ml (0.5%) 
Total Volume 500ml 
Filter to sterilize and store at 4°C 
 
2 × DMEM Medium 
Dissolve 1 bag (for 1L 1 × DMEM Medium) of DMEM powder (high glucose) (Gibco, Invitrogen) 
in <400mL Mini-Q H2O, adjust pH (just measure), add 100mL FBS, top-up to 500mL. Filter to 
sterilize and store at 4°C 
 
FM (Freezing Medium)  
DMEM  45ml (45%) 
FBS 45ml (45%) 
DMSO 10ml (10%) 
Total Volume 100ml 
Filter to sterilize and store at 4°C. 
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Dissolve in ~800ml Mini-Q H2O and adjust pH to 7.4 with HCl, make up the final volume to 1L, 
autoclave and store at 4°C 
 
PBS with Ca++, Mg++ 




Re-constitute 5-FU powder (Sigma) in DMSO to make a 50mg/ml stock and store at -20°C. 
Dilute in DMEM/10%FBS to a working concentration of 50μg/ml (or 375μM) before use 
 
 
Buffers and Solutions for Cloning 
 
Luria Bertani Broth (LB Broth) 
 Powder (for 1L) Final Concentration (w/v) 
Tryptone 10g 1% 
Yeast Extract                                      5g 0.5% 
NaCl 10g 1% 
Dissolve in Mini-Q H2O and make up the final volume to 1L, autoclave and store at 4°C 
 
Luria Bertani Agar (LB Agar) 
 Powder (for 400ml) Final Concentration (w/v) 
Tryptone 4g 1% 
Yeast Extract                                      2g 0.5% 
NaCl 4g 1% 
Agarose 6g 1.5% 
Make up the final volume to 400ml (for about 20 plates) with Mini-Q H2O. Autoclave the solution 
and cool down at room temperature to about 55°C, add appropriate antibiotics before pour plate.   
 
Ampicillin 
Stock concentration: 200mg/ml in Mini-Q H2O, filter to sterilize. Working concentration: 
100μg/ml 
 
Appendix I: Buffers and Solutions 232
Kanamycin 
Stock concentration: 50mg/ml in Mini-Q H2O, filter to sterilize. Working concentration: 50μg/ml 
 
 
Buffers and Solutions for Agarose Electrophoresis, SDS-PAGE and Western Blot 
 
TBE Buffer (Tris-Borate-EDTA) (10×) 
Tris base 108g 
Boric acid 55g 
EDTA 9.3g 
Make up the final volume to 1000ml with Mini-Q H2O, autoclave and store at room temperature 
 
Agarose gel (1% or 1.5%) 
Dissolve 1.0g (for 1% gel) or 1.5g (for 1.5% gel) DNase-free agarose (Bio-Rad) in 100ml 1 × 
TBE, boil, allow to cool and add 5μl of 10mg/ml ethidium bromide, pour into the casting frame, 
allow the gel to harden in about 20 minutes 
 
NP-40 Cell Lysis Buffer 
 Stock Volume (for 100ml) 
50mM Tris-HCl (pH7.8) 1M Tris-HCl (pH7.8) 5ml 
150mM NaCl                                     5M NaCl                        3ml 
1% Nonidet P-40 Nonidet P-40 (100%) 1ml 
Top-up with Mini-Q H2O, store at 4ºC. Add complete mini (final concentration: 1 ×) and PMSF 
(final concentration: 1mM) freshly before use 
 
PMSF Stock (200×) 
PMSF was dissolved in isopropanol at a concentration of 200mM and stored at -20ºC 
 
Complete Mini Stock (7×) 
1 tablet (Roche) was dissolved in 1.5mL ddH2O to make a 7 × stock and stored at -20ºC 
 
2 × SDS-PAGE Sample Buffer 
 Stock Volume (for 100ml) 
50mM Tris-HCl (pH6.8) 1M Tris-HCl (pH6.8) 12.5ml 
20% Glycerol                                     100% Glycerol                        20ml 
4% β-mercaptoethanol β-mercaptoethanol 4ml 
0.4% Bromophenol Blue (w/v) Bromophenol Blue (Powder) 0.4g 
4% SDS (w/v) SDS (Powder) 4g 
Top-up with Mini-Q H2O, aliquoted and stored at -20°C 
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10 × Tris-Glycine SDS-PAGE Running Buffer 
 Powder (for 1L) Final Concentration (w/v) 
Tris base 30.2g 25mM (× 10) 
Glycine                                               144g 192mM (× 10) 
Top-up to 1000 ml with Mini-Q H2O, store at -20°C, add 10% SDS to 1 × buffer to 0.1% final 
concentration 
 
10 × Transfer Buffer 
 Powder (for 1L) Final Concentration (w/v) 
Tris base 58.2g 48mM (× 10) 
Glycine                                               29.3g 39mM (× 10) 
Top up to 1000 ml with Mini-Q H2O. To make 1 liter 1 × buffer, add 100 ml 10 × buffer, 3.75 ml 
10% SDS and 200 ml methanol, top up to 1000 ml with Mini-Q H2O 
 
TBST Buffer 
 Stock Volume (for 1L) 
20mM Tris-HCl (pH7.6)  1M Tris-HCl, pH7.6 20ml 
150mM NaCl                                     5M NaCl 30ml 
0.1% Tween-20 100% Tween-20 1ml 
Top up to 1000 ml with Mini-Q H2O 
 
Blocking Buffer 
5% non-fat milk in 1 × TBST buffer, store at 4°C 
 
 
Buffers and Solutions for Flow Cytometry Analysis 
 
RNase A stock 
RNase A (Sigma) was dissolved in DNase/RNase free H2O (Invitrogen) to make a 1mg/ml stock, 
aliquot and store at 4°C, 10 × dilution in DNase/RNase free H2O to 100μg/ml working 
concentration before use 
 
PI (propidium iodide) stock 
PI (Sigma) was dissolved in DNase/RNase free H2O (Invitrogen) to make a 2mg/ml stock, aliquot 
and store at 4°C in dark, 40 × dilution in DNase/RNase free H2O to 50μg/ml working 




Appendix I: Buffers and Solutions 234
Buffers and Solutions for Soft Agar Assay 
 
Soft Agar Stock  
Prepare 2% stock agar solution in Mini-Q H2O, autoclave, aliquot and store at room temperature 
 
INT (p-iodonitrotetrazolium) Stock 
INT (Sigma) was dissolved in DMSO to make a 10mg/ml stock, store at 4°C, dilute into 1mg/ml 




Buffers and Solutions for Chromatin Immunoprecipitation (ChIP) 
 
TBSE Buffer 
 Stock Volume (for 1L) 
20mM Tris-HCl (pH7.5) 1M Tris-HCl (pH7.5)     20ml 
150mM NaCl                                     5M NaCl                        30ml 
1mM EDTA                                       0.5M EDTA                   2ml 
Top up to 1000 ml with autoclaved Mini-Q H2O, store at 4°C 
 
FA Cell Lysis Buffer 
 Stock Volume (for 1L) 
10mM Tris-HCl (pH8.0)                    1M Tris-HCl (pH8.0)      10ml 
0.25% Triton-X100                            20% Triton-X100          12.5ml 
10mM EDTA                                     0.5M EDTA                   20ml 
0.1M NaCl                                         5M NaCl                        20ml 
Top up to 1000 ml with autoclaved Mini-Q H2O, store at 4°C 
 
1%SDS FA Lysis Buffer 
 Stock Volume (for 1L) 
50mM HEPES-KOH (pH7.5)            1M HEPES-KOH         50ml 
150mM NaCl                                     5M NaCl                      30ml 
2mM EDTA                                       0.5M EDTA                   4ml 
1% Triton-X100                                 20% Triton-X100        50ml 
0.1% NaDOC                                     10% NaDOC                10ml 
1%SDS                                               10% SDS                      100ml 
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0.1%SDS FA Lysis Buffer 
 Stock Volume (for 1L) 
50mM HEPES-KOH (pH7.5)            1M HEPES-KOH         50ml 
150mM NaCl                                     5M NaCl                      30ml 
2mM EDTA                                       0.5M EDTA                   4ml 
1% Triton-X100                                 20% Triton-X100        50ml 
0.1% NaDOC                                     10% NaDOC                10ml 
0.1%SDS                                            10% SDS                      10ml 
Top up to 1000 ml with autoclaved Mini-Q H2O, store at 4°C 
 
ChIP Elution Buffer 
 Stock Volume (for 50mL) 
50mM Tris-HCl (pH7.5)                    1M Tris-HCl (pH8.0)      2.5ml 
10mM EDTA                                     0.5M EDTA                  1ml 
1%SDS                                               10% SDS                       5ml 
autoclaved MiniQ-H2O                       41.5ml 
 
NP-40/LiCl Buffer 
 Stock Volume (for 1L) 
10mM Tris-HCl (pH8.0)                    1M Tris-HCl (pH8.0)      10 ml 
0.25M LiCl                                         4M LiCl                          62.5ml 
1mM EDTA                                       0.5M EDTA                  2ml 
0.5%NP-40                                         10% NP-40                     50ml 
0.5% NaDOC                                     10% NaDOC                  50ml 
autoclaved MiniQ-H2O                       825.5ml 
 
TE buffer 
 Stock Volume (for 50mL) 
10mM Tris-HCl (pH8.0)                    1M Tris-HCl (pH8.0)      0.5 ml 
1mM EDTA                                      0.5M EDTA                  100μl 
autoclaved MiniQ-H2O                       49.4ml 
 
Glycine Stock 
2.5M Glycine dissolved in Mini-Q H2O. Freeze at -20°C 
 
Pronase 
20mg/ml Pronase stock in TBSE. Freeze at -20°C 
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Buffers and Solutions for Immunofluoresence 
 
PFA (paraformaldehyde, 4% in PBS) (freshly prepared) 
Dissolve 0.4g paraformaldehyde in ~8ml PBS, warm at 56°C waterbath. Add 10N NaCl dropwise 
until solution clears. Make up to 10ml with PBS 
 
Triton-X100 (0.1% in PBS) 
Add 1ml Triton-X100 (Bio-Rad) to 99ml PBS to prepare 1% stock. 10 × dilution with PBS to 
make 0.1% Triton-X100 before use 
 
BSA (bovine serum albumin, 5% in PBS) (freshly prepared) 
Dissolve 0.5g BSA in 10ml PBS before use 
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International Journal Papers 
Feng P, Wang B (co-first author), Ren EC. 2008. Cyr61/CCN1 is a tumor suppressor 
in human hepatocellular carcinoma and involved in DNA damage response. Int J 
Biochem Cell Biol. 40: 98-109. (doi: 10.1016/j.biocel.2007.06.020) 
 
Wang B, Feng P, Xiao ZW, Ren EC. Identification of Lasp1 as a novel p53 target 





Feng P, Wang B, Neo SY, Ren EC. 2005. Down-regulation of dermatopontin (DPT) 
in hepatocellular carcinoma (HCC) might promote liver cancer development. 
Presented at the 7th World Congress on Gastrointestinal Cancer. (Poster). Barcelona, 
Spain, 15-18 June, 2005 
 
Wang B, Feng P, Ren EC. 2006. Identification of the role of a novel cell cycle 
regulatory gene D123 in hepato-carcinogenesis. Presented at the 19th Meeting of the 
European Association for Cancer Research (EACR-19) (Poster). Budapest, Hungary, 
1-4 July, 2006 
 
 
 
 
